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The number of cancer survivors is growing
As populations age, each year more individuals are diagnosed with cancer worldwide.1,2 
In the Netherlands the number of new cancer cases per year has almost doubled from 
57 thousand in 1990 to 110 thousand in 2017.3 Fortunately, survival rates for most cancer 
types have also increased, due to earlier diagnosis and improved cancer treatments.4 
As a result, a growing number of individuals live years beyond a cancer diagnosis and 
may ultimately survive the disease. In the Netherlands, there were almost 800 thousand 
cancer survivors in 2017, which is expected to exceed a million by 2025.4,5 Using the 
original definition of the American National Coalition of Cancer Survivorship (NCCS), 
all individuals who were ever diagnosed with cancer are included as ‘cancer survivors’.6 
However, ‘cancer survivors’ and ‘cancer patients’ are used interchangeably in this thesis.
Cancer survivors face many long-term issues
Cancer survivors often struggle to continue life after cancer treatment due to physical 
and psychological effects that persist for extended periods of time, or that develop later 
in post-treatment life.7 Long-term and late effects frequently reported by cancer survivors 
include - but are not limited to - fatigue, pain, sleep problems, cognitive limitations, sexual 
dysfunction, anxiety and depression.7,8 These symptoms subsequently translate into 
challenges such as difficulties in performing daily activities, maintaining social relationships 
and returning to work, which greatly affect the quality of life of many cancer survivors.7,9 
Hence, survivors report a need for information and support to be able to deal with the 
many issues related to survivorship.10-12
Survivorship care is new and complex
In the past decade there has been an increasing awareness of the growing population of 
cancer survivors that need appropriate care to manage the issues related to survivorship. 
At the same time, this growing population puts an increasing pressure on health care 
resources.13,14 Therefore, efforts have been made to develop guidelines and models 
to improve care for cancer survivors while dealing with these challenges.15 In general, 
survivorship care starts right after cancer treatment and is provided to individuals that 
are cancer-free or able to manage chronic or intermittent disease (Fig 1).16 However, for 
those with disease progression or a recurrence, it is emphasized that survivorship care 
and palliative care should be integrated across the cancer care continuum that flows from 
diagnosis into end-of-life-care.16,17
Several models of care have been proposed that aim to incorporate survivorship care 
into the cancer care trajectory, ranging from one-time consultations by a provider from 




Although evidence is lacking for any of these survivorship care models18, the ‘shared care 
model’ has been widely endorsed as proposed by the American Institute of Medicine 
(IOM) and supported by the American Society of Clinical Oncology (ASCO)’.16 According 
to this model, cancer survivors are transferred from the oncologist to the primary care 
physician for the continuation of long-term care, mostly starting from one to two years 
after diagnosis.15 However, most practices outside of the United States, including the 
Netherlands, use a more traditional model in which cancer survivors continue to receive 
first-line follow-up care, by either their oncologist or oncology nurse, up to five years after 
diagnosis or longer.19
‘Survivorship care plans’ are widely recommended
A central component of the shared care model that was recommended by the IOM in 2006, 
is a ‘survivorship care plan’ (SCP).16 According to the IOM, all cancer patients completing 
primary treatment should be provided with an SCP containing a comprehensive care 
summary including a record of all care received and important disease characteristics, a 
follow-up care plan including written information on the known and potential late effects 
of the treatments received, and recommendations for health promotion.16 A central goal 
of the SCP is to transfer cancer survivors from cancer treatment to primary care. Therefore, 



















Figure 1: The Cancer Care Trajectory, adapted from the Institute of Medicine, 2006
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care physician. Following the IOM, several paper and web-based SCP templates have 
been developed20-22 and the recommendation has been widely adopted outside of the 
United States. The Dutch Health Counsel has recommended SCPs for all cancer survivors 
in the Netherlands since 2007.23
The implementation of survivorship care plans is slow
Ever since the first recommendation in 2006, the implementation and dissemination of 
SCPs has been slow and inconsistent. In the United States, it was estimated that less than 
a quarter of survivorship care programs provided SCPs in 2011, and less than one out 
of eight patients received one.24 Since SCPs were implemented as a care standard by 
the American Commission on Cancer (CoC) in 2015, the proportion of cancer survivors 
receiving SCPs in affiliated programs slowly increased to 20% in that year.25 In Europe, the 
implementation and receipt of SCPs has not been reported, but the lower endorsement 
of survivorship care programs in Europe compared to the United States26 suggests an 
even lower compliance to SCP guidelines. The main barriers to SCP provision include the 
limited availability of templates or (electronic) systems to create SCPs and lack of time to 
provide them.24,27 The time needed for an oncologist or oncology nurse to create and 
provide an SCP was estimated to range from 1 to 4 hours.28-30
Evidence for the effectiveness of survivorship care plans is limited
As the IOM’s recommendation was not evidence-based back in 2006, SCPs have 
been the center of survivorship research since first recommended. Qualitative studies 
and observational surveys yielded promising results: survivors found that SCPs were 
empowering and reassuring, they were more satisfied with care and communication 
between health care providers, and were more motivated to change their lifestyle.31,32 
Moreover, primary care physicians felt increasingly comfortable in providing continued 
follow-up care to survivors.32 However, contrary to initial hopes and expectations, 
randomized controlled trials (RCTs) failed to identify beneficial effects of SCPs in various 
patient populations, including breast33,34, gynecological28,35,36, colorectal29 and prostate37 
cancer. Hence, the evidence-base for SCPs is still inconclusive. The one RCT that evaluated 
SCPs in the Netherlands is the ROGY Care Trial.
The ROGY Care Trial evaluates the impact of automatically generated sur-
vivorship care plans
Between 2011 and 2016 the ROGY Care Trial was conducted to assess the effectiveness 
of automatically generated SCPs on patient and health care provider reported outcomes 
in ovarian and endometrial cancer.38 The ROGY Care Trial was the first pragmatic cluster 
randomized controlled trial that evaluated the effectiveness of SCPs. The pragmatic 
component allowed individual practices to decide who was providing the SCP (i.e. 




SCP, both maximizing the generalizability to ‘real life’ clinical practice. The cluster design 
prevents contamination between the trial arms by randomizing hospitals instead of 
individual patients.38 In total, 12 hospitals in the south of the Netherlands were randomized 
to providing ‘SCP care’ or ‘care as usual’. In the SCP Care arm, SCPs were automatically 
generated, which minimized the time needed to create and provide the SCP. SCPs were 
generated by simply clicking a button in the web-based Registration system Oncological 
GYnecology (ROGY). The SCP contained a treatment summary including information on 
diagnostic tests, type of cancer, stage, grade, treatment, and contact details of the hospital 
and specialists, and a tailored follow-up care plan, including detailed information on the 
most common short- and long-term effects of the treatments received and information 
about additional support. The oncology providers were instructed to deliver the SCP to 
the patient in print-form and to at least discuss the most important components, such 
as the diagnosis, treatments received, and most important side-effects. The effectiveness 
of the SCP was evaluated in patients, oncology providers and primary care physicians.38
The ROGY Care Trial included ovarian and endometrial cancer patients
The ROGY Care Trial included women that were recently diagnosed with ovarian or 
endometrial cancer and were treated with curable intent. Ovarian and endometrial cancer 
are the two most common gynecological cancer types and, respectively, the fourth and 
seventh most common cancer types for women worldwide.39 In the Netherlands about 
2,000 women were diagnosed with endometrial cancer and 1,300 with ovarian cancer in 
2017.40 Ovarian cancer is the deadliest gynecological cancer, with only 38% of patients 
surviving 5 years after their diagnosis, while this is 80% for endometrial cancer patients.40 
Endometrial cancer is mostly diagnosed at earlier cancer stages (stage I or II) and treated 
with surgical removal of the uterus, fallopian tube and/or ovary (staging). For aggressive 
tumors, adjuvant radiotherapy or chemotherapy is considered. At higher stages (stage 
III or IV) of endometrial cancer, additional surgery (staging and/or debulking) and/or 
adjuvant radiotherapy or chemotherapy is needed.41 Similarly, low stage ovarian cancer (I 
or IIA) can be treated with surgery (staging) only, but ovarian cancer is mostly diagnosed 
at higher cancer stages (IIB, III or IV) and requires a combination of surgery (staging 
and debulking) and chemotherapy.42 Common issues resulting from gynecological cancer 
treatment include infertility, pain, post-menopausal symptoms, sexual dysfunction, bowel 
and bladder dysfunction, peripheral neuropathy and fatigue.43-45 In the Netherlands both 
ovarian and endometrial cancer patients receive first-line follow-up care until 5 years after 
diagnosis.19
Prior results from the ROGY Care Trial are not conclusive
In the ROGY Care Trial, SCPs were received by 74% of the endometrial cancer patients 
in the SCP Care arm. In this group SCPs increased the perceived amount of information 
received, but not the satisfaction with the information and care received. Instead, SCPs 
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14
increased concerns about the illness, emotional impact, the  symptoms experienced and 
cancer-related contact with the primary care physician (PCP).35 However, SCPs seemed 
helpful for endometrial cancer patients who did not use the internet to look up medical 
information, comprising two-thirds of the sample.46 Oncology providers were generally 
satisfied with the SCP but encountered difficulties in finding the time to provide and 
discuss it.47 Only one third of the patients’ PCPs received a copy of the SCP, and those who 
received one reported a desire for a more concise version.48 Prior publications from the 
ROGY Care Trial only evaluated the impact of SCPs in endometrial cancer and not yet in 
ovarian cancer. Therefore, definite conclusions about the effectiveness of SCPs on patient 
reported outcomes could not be drawn. It also remained unclear why some patients did 
and others did not receive an SCP, and whether threatening illness perceptions due to the 
SCP are either harmful or beneficial for the patient. On the one hand, threatening illness 
perceptions due to the SCP may reflect a more realistic perspective of the disease, which 
helps to accept future consequences of the disease. On the other hand, SCPs may cause 
persistent psychological distress by giving rise to more threatening illness perceptions.49 
In view of the poorer prognosis in ovarian cancer, the information provided in the SCP 
may be perceived as even more threatening by ovarian cancer patients compared to 
endometrial cancer patients. 
Models for ‘survivorship care planning’ are undefined
In this thesis, ‘survivorship care plan’ (SCP) refers to the actual document containing written 
information that is provided to the patient. ‘Survivorship care planning’ as a broader 
term refers to the process of information provision in survivorship care, comprising what 
type of information is provided and when, how and by whom it is provided.50 There 
is no “one-size-fits-all” approach for survivorship care planning, and implementation 
typically depends on the individual practice, the availability of resources and the survivor 
population. Hence, an major challenge of survivorship care planning is that the entire 
process has to meet the needs of multiple stakeholders, including the patient, his or her 
caregivers, and health care providers. Factors contributing to successful survivorship care 
planning remain undefined.51,52 
Aims and outline of this thesis
The central goal of this thesis was to understand the impact information provision has on 
(gynecological) cancer survivors and use our findings to inform future survivorship care 
planning. The three overall aims were:
1. To assess the impact of survivorship care plans (SCPs) on patient-reported outcomes 
among ovarian and endometrial cancer survivors in daily clinical practice;
2. To understand the role  illness perceptions play in the impact of SCPs;
3. To assess the need for information and care among (gynecological) cancer 




A conceptual framework was developed to guide the outline of this thesis, and to describe 
the  effects of SCPs on patient reported outcomes and the mediating and moderating 
factors influencing the effects (Figure 2). This framework was based on existing behavioral 
and methodological models, including Leventhals’ Self-Regulation Model of Illness53, 
Miller’s behavioral style scale54 and Caroll’s implementation fidelity framework55.
Part I: the impact of survivorship care plans
First, according to implementation research, we must assess the degree in which the 
intervention was delivered as intended (i.e. ‘implementation fidelity’) before we can 
evaluate the effectiveness of the intervention.55,56 Therefore, the aim of Chapter 2 is to 
evaluate the degree of SCP receipt in the intervention arm of the ROGY Care Trial and 
the factors associated with SCP receipt. The main effects of SCPs on patient reported 
outcomes in ovarian cancer, including satisfaction with information provision and care, 
health care use and illness perceptions are described in Chapter 3 and mirror a previous 
publication from the ROGY Care Trial in endometrial cancer.35 Further considering that 
individuals respond differently to health information according to their information coping 
style, as reported by Miller (1987), Chapter 4 aims to assess whether the impact of SCPs on 
the main outcomes in the ROGY Care Trial was moderated by information coping styles. 
Miller identified two main information coping styles: information seeking (‘monitoring’) 
and information avoiding (‘blunting’).54,57
Figure 2: Conceptual framework of the effects of survivorship care plans and information and care 
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Part II: the role of illness perceptions
According to Leventhal’s Self-Regulation Model of Illness (1980), individuals that are 
confronted with a health threat - such as a cancer diagnosis - develop cognitive and 
emotional representations of the illness, which through coping responses have an effect 
on emotional and health outcomes.53 SCPs may intervene in the pathway illustrated by 
Leventhal, by increasing threatening illness perceptions. Therefore, the aim of Chapter 
5 is to assess the indirect effects of SCPs on health-related quality of life, anxiety and 
depression through illness perceptions. In order to further investigate whether ‘realistic’ 
information as presented in an SCP is beneficial for cancer survivors, we seek to assess 
the benefits of  ‘realistic’, ‘optimistic’ or ‘pessimistic’ illness perceptions with regard to an 
individual ’s prognosis. This cross-sectional analysis of the PROFILES registry including 
various cancer diagnoses is presented in Chapter 6.
Part III: Information and care needs
In order to define optimized models for survivorship care planning, we aim to assess 
the information and care needs of cancer survivors across the cancer care continuum. 
Chapter 7 concerns survivorship care planning in the year following treatment of 
gynecological cancer, and describes the perspectives of patients, caregivers and health 
care providers from an American Academic Medical Center. The aim of Chapter 8 is to 
identify subgroups of cancer survivors with distinct patterns of health care needs and 
factors associated with these patterns, in an American sample of survivors with various 
non-metastasized cancer types. Chapter 9 concerns patients with recurrent endometrial 
or ovarian cancer and describes the differences in satisfaction with information and care 






1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an 
update. Cancer Epidemiology and Prevention Biomarkers. 2016;25(1):16-27.
2. Hay CM, Courtney-Brooks M, Lefkowits C, Hagan TL, Edwards RP, Donovan HS. Symptom 
management in women with recurrent ovarian cancer: Do patients and clinicians agree on what 
symptoms are most important? Gynecologic oncology. 2016;143(2):367-370.
3. Netherlands Cancer Registry (NCR). Incidentie alle tumoren. Cijfers over Kanker 2018; www.
cijfersoverkanker.nl.
4. KWF. Kanker in Nederland tot 2020, Trends en Prognoses. 2011.
5. Netherlands Cancer Registry (NCR). Prevalentie alle tumoren. Cijfers over Kanker 2018; www.
cijfersoverkanker.nl.
6. National Coalition for Cancer Survivorship (NCCS). NCCS Mission. 2018; https://www.canceradvocacy.
org/about-us/our-mission/.
7. Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It’s not over when it’s over: long-
term symptoms in cancer survivors—a systematic review. The International Journal of Psychiatry in 
Medicine. 2010;40(2):163-181.
8. Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of 
cancer. Cancer. 2008;112(S11):2577-2592.
9. Wu H-S, Harden JK. Symptom burden and quality of life in survivorship: a review of the literature. 
Cancer nursing. 2015;38(1):E29-E54.
10. Geller BM, Vacek PM, Flynn BS, Lord K, Cranmer D. What are cancer survivors’ needs and how well 
are they being met? The Journal of family practice. Oct 2014;63(10):E7-16.
11. Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the unmet supportive care 
needs of people with cancer? A systematic review. Supportive Care in Cancer. 2009;17(8):1117-1128.
12. Kent EE, Arora NK, Rowland JH, et al. Health information needs and health-related quality of 
life in a diverse population of long-term cancer survivors. Patient education and counseling. 
2012;89(2):345-352.
13. Aaronson NK, Mattioli V, Minton O, et al. Beyond treatment–psychosocial and behavioural issues in 
cancer survivorship research and practice. European Journal of Cancer Supplements. 2014;12(1):54-64.
14. Nekhlyudov L, Ganz PA, Arora NK, Rowland JH. Going Beyond Being Lost in Transition: A Decade of 
Progress in Cancer Survivorship. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology. Jun 20 2017;35(18):1978-1981.
15. Oeffinger KC, McCabe MS. Models for delivering survivorship care. Journal of Clinical Oncology. 
2006;24(32):5117-5124.
16. Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Translation. 
Committee on Cancer Survivorship: Improving Quality Care and Quality of Life, National Cancer 
Policy Board. Washington, DC: National Academies Press; 2006.
17. Hui D, Bruera E. Integrating palliative care into the trajectory of cancer care. Nature Reviews Clinical 
Oncology. 2016;13(3):159-171.
18. Recklitis CJ, Syrjala KL. Provision of integrated psychosocial services for cancer survivors post-
treatment. The Lancet Oncology. 2017;18(1):e39-e50.
19. Oncoline. Herstel na Kanker, Landelijke Richtlijn, versie 1.0. www.oncoline.nl: Oncoline; 2011.
20. Oncolink. Oncolife Survivorship Care Plen. Livestrong Care Plan 2018; http://www.livestrongcareplan.
org/.
21. Oncology ASoC. ASCO Cancer Treatment and Survivorship Care Plans. Survivorship 2018; 
 https://www.cancer.net/survivorship/follow-care-after-cancer-treatment/
asco-cancer-treatment-and-survivorship-care-plans.
22. Survivorship NCfC. Examples of Cancer Care Plans. 2018; https://www.canceradvocacy.org/
resources/planning-your-care/examples-of-cancer-care-plans/.
23. Netherlands HCot. Follow-up in oncology. Identify objectives, substantiate actions. The Hague: Health 
Council of the Netherlands;2007.
Chapter 1
18
24. Birken SA, Mayer DK, Weiner BJ. Survivorship care plans: prevalence and barriers to use. Journal 
of cancer education : the official journal of the American Association for Cancer Education. Jun 
2013;28(2):290-296.
25. Miller NS. The Commission on Cancer’s survivorship care plan standard: Implementation is underway. 
American Society of Clinical Oncology; 2017.
26. Rowland JH, Kent EE, Forsythe LP, et al. Cancer survivorship research in Europe and the United 
States: where have we been, where are we going, and what can we learn from each other? Cancer. 
2013;119(S11):2094-2108.
27. Dulko D, Pace CM, Dittus KL, et al. Barriers and facilitators to implementing cancer survivorship care 
plans. Oncology nursing forum. Nov 2013;40(6):575-580.
28. Brothers BM, Easley A, Salani R, Andersen BL. Do survivorship care plans impact patients’ evaluations 
of care? A randomized evaluation with gynecologic oncology patients. Gynecologic oncology. 
2013;129(3):554-558.
29. Jefford M, Gough K, Drosdowsky A, et al. A randomized controlled trial of a nurse-led supportive 
care package (SurvivorCare) for survivors of colorectal cancer. The oncologist. 2016;21(8):1014-1023.
30. Spain PD, Oeffinger KC, Candela J, McCabe M, Ma X, Tonorezos ES. Response to a treatment 
summary and care plan among adult survivors of pediatric and young adult cancer. Journal of 
oncology practice. 2012;8(3):196-202.
31. Mayer DK, Birken SA, Check DK, Chen RC. Summing it up: an integrative review of studies of cancer 
survivorship care plans (2006-2013). Cancer. Apr 1 2015;121(7):978-996.
32. Salz T, Oeffinger KC, McCabe MS, Layne TM, Bach PB. Survivorship care plans in research and 
practice. CA: a cancer journal for clinicians. 2012;62(2):101-117.
33. Boekhout AH, Maunsell E, Pond GR, et al. A survivorship care plan for breast cancer survivors: 
extended results of a randomized clinical trial. Journal of Cancer Survivorship. 2015;9(4):683-691.
34. Grunfeld E, Julian JA, Pond G, et al. Evaluating survivorship care plans: results of a randomized, 
clinical trial of patients with breast cancer. Journal of Clinical Oncology. 2011;29(36):4755-4762.
35. Nicolaije KA, Ezendam NP, Vos MC, et al. Impact of an Automatically Generated Cancer Survivorship 
Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a 
Pragmatic, Cluster Randomized Trial. Journal of Clinical Oncology. 2015;33(31):3550-3559.
36. de Rooij BH, Ezendam NPM, Nicolaije KAH, et al. Effects of Survivorship Care Plans on patient 
reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial. Gynecologic 
oncology. May 2017;145(2):319-328.
37. Emery JD, Jefford M, King M, et al. ProCare Trial: a phase II randomized controlled trial of shared care 
for follow-up of men with prostate cancer. BJU international. 2017;119(3):381-389.
38. van de Poll-Franse LV, Nicolaije KA, Vos MC, et al. The impact of a cancer Survivorship Care Plan 
on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study 
protocol for a pragmatic cluster randomized controlled trial. Trials. 2011;12:256.
39. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A cancer journal for clinicians. 2015.
40. IKNL. Prevalentie | Vrouwelijke geslachtsorganen. Cijfers over kanker 2018; www.cijfersoverkanker.nl. 
Accessed 03-04-2018.
41. Oncoline. Initiële behandeling. Endometriumcarcinoom 2018; 
 https://www.oncoline.nl/endometriumcarcinoom.
42. Oncoline. Behandeling. Epitheliaal Ovariumcarcinoom 2018; 
 https://www.oncoline.nl/ovariumcarcinoom 
43. Ferrell B, Smith S, Cullinane C, Melancon C. Symptom concerns of women with ovarian cancer. 
Journal of pain and symptom management. Jun 2003;25(6):528-538.
44. Bradley S, Rose S, Lutgendorf S, Costanzo E, Anderson B. Quality of life and mental health in cervical 
and endometrial cancer survivors. Gynecologic oncology. 2006;100(3):479-486.
45. Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual concerns reported by 
gynecological cancer survivors. Gynecologic oncology. 2012;124(3):477-489.
46. Nicolaije KA, Ezendam NP, Pijnenborg JM, et al. Paper-Based Survivorship Care Plans May be Less 
Helpful for Cancer Patients Who Search for Disease-Related Information on the Internet: Results of 





47. Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, van de Poll-Franse LV, Kruitwagen RF. Oncology 
providers’ evaluation of the use of an automatically generated cancer survivorship care plan: 
longitudinal results from the ROGY Care trial. Journal of cancer survivorship : research and practice. 
Jun 2014;8(2):248-259.
48. Ezendam NP, Nicolaije KA, Kruitwagen RF, et al. Survivorship Care Plans to inform the primary care 
physician: results from the ROGY care pragmatic cluster randomized controlled trial. Journal of 
cancer survivorship : research and practice. Dec 2014;8(4):595-602.
49. van de Poll-Franse LV, Nicolaije KA, Ezendam NP. The impact of cancer survivorship care plans on 
patient and health care provider outcomes: a current perspective. Acta Oncologica. 2017;56(2):134-138.
50. Burbage D. Survivorship Care Planning. Supportive Cancer Care: Springer; 2016:97-109.
51. Stricker CT, Jacobs LA, Risendal B, et al. Survivorship care planning after the institute of medicine 
recommendations: how are we faring? Journal of cancer survivorship : research and practice. Dec 
2011;5(4):358-370.
52. Parry C, Kent EE, Forsythe LP, Alfano CM, Rowland JH. Can’t see the forest for the care plan: a call to 
revisit the context of care planning. Journal of Clinical Oncology. 2013;31(21):2651-2653.
53. Leventhal H, Meyer D, Nerenz D. The common sense representation of illness danger. Contributions 
to medical psychology. 1980;2:7-30.
54. Miller SM. Monitoring and blunting: validation of a questionnaire to assess styles of information 
seeking under threat. Journal of personality and social psychology. 1987;52(2):345.
55. Carroll C, Patterson M, Wood S, Booth A, Rick J, Balain S. A conceptual framework for implementation 
fidelity. Implementation science : IS. 2007;2(1):40.
56. Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of health innovations: 
a systematic review of structural, organizational, provider, patient, and innovation level measures. 
Implementation science : IS. 2013;8:22.
57. Miller SM. Monitoring versus blunting styles of coping with cancer influence the information patients 
want and need about their disease. Implications for cancer screening and management. Cancer. 
1995;76(2):167-177.





Factors influencing implementation of a Survivorship Care 
Plan – a quantitative process evaluation of the ROGY care 
trial







L.V. van de Poll-Franse




Purpose: to investigate the factors that influence implementation of Survivorship Care 
Plans (SCPs) in the intervention arm of the ROGY care trial by 1) assessing the level of SCP 
receipt in the ROGY care trial and 2) identifying patient- and provider-level factors that 
influence SCP receipt.
Methods: Between 2011 and 2015, a pragmatic cluster randomized-controlled-trial was 
conducted on the effects of automatically generated SCPs. Endometrial (N=117) and 
ovarian (N=61) cancer patients were allocated to ‘SCP care’, as provided by their SCP 
care providers (N=10). Associations between SCP receipt (self-reported SCP receipt and 
actually generated SCPs), patient-factors (socio-demographic-, clinical-, and personality 
factors) and care provider factors (profession, a-priori motivation regarding SCP provision) 
were tested in univariate analysis. The odds ratios of factors influencing self-reported SCP 
receipt were estimated with a multivariate regression model.
Results: Of all patients in the SCP care arm (N=178), SCPs were generated by the care 
provider for 90% of the patients and 70% of the patients reported that they had received 
an SCP. Patients with older age, ovarian cancer, type D (distressed) personality, and 
patients that completed the questionnaire a longer period of time after the SCP consult 
were more likely to report no SCP receipt.
Conclusions: SCP receipt was influenced by patient- but not care-provider factors.
Implications for cancer survivors: Certain patient groups were less likely to report SCP 
receipt. Whether all patients are in need of an SCP requires further investigation. If they 
do, more efforts need to be made towards the implementation of SCPs.




In 2006, the American Institute of Medicine (IOM) and the Dutch Health Council 
advocated Survivorship Care Plans (SCPs) as a standard of care for all cancer patients.1,2 
An SCP is a formal document that is handed to the patient and includes a record of 
all care received, important disease characteristics of the patient, short- and long term 
effects of the treatments received and information for supportive care services.1 SCPs aim 
to promote cancer survivors’ follow-up care and outcomes.1 However, since the IOM’s 
recommendations, implementation and dissemination of SCPs in clinical practice have 
been low and inconsistent.3-6
Our recently published study of the pragmatic cluster-randomized ROGY care trial7 was 
accompanied by an editorial declaring the need for more attention for implementation 
of SCPs.8 The ROGY Care study contributes to the small number of clinical trials that have 
evaluated the effects of SCPs on patient reported outcomes.9-11 Published SCP trials could 
not draw definite conclusions on SCP effectiveness and highlighted the complexity of 
SCP implementation.7,9-11 It is therefore recognized that, alongside investigations of the 
effectiveness of SCPs, we need to understand how SCPs were implemented and compare 
implementation strategies between SCP trials.8,12 The pragmatic nature of the ROGY 
care trial provides the unique opportunity to evaluate implementation of SCPs in clinical 
practice.
Evaluations of intervention implementation often include a measure of fidelity - that is, 
the degree to which an intervention was delivered as intended.13 The implementation 
fidelity of SCPs (i.e. the content of the SCP, the coverage of patients that receive SCPs 
and the frequency of SCP receipt) is expected to have an impact on survivors’ outcomes.8 
Subsequently, poor implementation fidelity of SCP care in clinical trials would diminish the 
observed effects of SCPs, leading to an underestimation of true SCP effectiveness.13
Little is known about the factors that influence implementation of SCPs. Current evidence 
is predominantly based on qualitative studies that focus on system- and organizational 
level factors that influence SCP implementation, including organizational resources, 
adequate (electronic) systems, templates and training for SCP use.3,14-19 A few observational 
studies have revealed that patients with lower age, non-white race, higher income, 
higher educational level, better than fair health status, and patients that participated 
in a trial, more often reported receipt of an SCP.4,19-21 However, generalizability of these 
observational studies is limited due to patient selection bias. Furthermore, in these studies 
only self-reported receipt of SCPs by patients was available.4,19-21 To our knowledge, 
no SCP effectiveness randomized controlled trials have yet examined the factors that 
influence implementation of SCPs.
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The ROGY care trial provides longitudinal quantitative data on a wide range of patient-level 
and provider-level factors, along with both objective and self-reported implementation 
outcomes of SCPs in routine Dutch clinical practice. Patient-level factors include 
demographic, clinical and personality characteristics, and provider-level factors include 
demographic characteristics, profession and opinions regarding SCPs.  Understanding 
factors that promote or inhibit successful implementation of SCPs in the ROGY care trial 
can support future implementation of SCPs.8,12
The aim of the current study is to investigate factors that influence implementation of 
SCPs in the ROGY care trial by 1) assessing the level of SCP receipt and 2) identifying 
patient- and provider-level factors that influence SCP receipt.
METHODS
Design
Between April 2011 and October 2015, the pragmatic cluster-randomized ROGY Care 
Trial was conducted to evaluate the impact of an automatically generated SCP on 
gynecological cancer patient and health care provider reported outcomes. In the South 
of the Netherlands, 12 hospitals were randomized to either ‘usual care’ or ‘SCP care’. After 
initial diagnosis, all endometrial and ovarian cancer patients were invited to participate in 
the study. Patients were invited with a letter, informed consent form, and questionnaire, 
sent to the patient by their own gynecologist.22,23 Follow-up questionnaires were sent 
directly to the patient at 6, 12, 18 and 24 months after diagnosis. Patients, but not care 
providers, were blinded to trial assignment. The ROGY care trial was centrally approved 
by a Medical Research Ethics Committee, as well as by each participating center.22 The trial 
design has been described in detail elsewhere.22 The present study describes the results 
of implementation fidelity in the intervention arm.
Patients and care providers
Participants include 117 newly diagnosed endometrial and 61 ovarian cancer patients that 
were in the intervention arm of the ROGY care trial and completed the first questionnaire, 
and their 10 SCP care providers (i.e., gynecologists, gynecologic oncologists, oncology 
nurses) in the 6 hospitals of the intervention arm. A follow-up questionnaire was sent to 
the patients 12 months after diagnosis. Follow-up questionnaires were returned by 68% 
(N=79) of the endometrial and 57% (N=35) of the ovarian cancer patients. Patient exclusion 
criteria (i.e., undergoing palliative care or unable to complete a Dutch questionnaire)22 
were minimal to maximize generalizability.24  All care providers of the intervention arm 
(N=10) completed a questionnaire before the start of the trial.25
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Implementation of SCP care
In the hospitals that were allocated to ‘SCP care’, all care providers attended an instruction 
evening. The care providers were instructed to provide an SCP to patients after diagnosis 
and to provide an updated SCP during follow-up visits if applicable (i.e. when there were 
changes in the cancer, treatment, or oncology provider). In addition, care providers were 
instructed to send a copy of the SCP to the patient’s primary care physician.26 Practical 
guidelines were given on the components of the SCP that should minimally be discussed 
with each patient during the SCP consult (i.e. diagnosis, prognosis, treatment(s), most 
important side-effects) and how often the SCP should be discussed (shortly after diagnosis 
and during follow-up visits after 6, 8, 12, 18 and 24 months). Care providers in the SCP 
care arm were instructed to provide the first SCP at the consultation where the results of 
histopathology and (adjuvant) treatment plan were discussed, mostly 7-14 days after the 
operation or biopsy.  Because of the pragmatic approach, care providers in the SCP care 
hospitals were free to choose whether the gynecologist/gynecologic oncologist, and/or 
oncology nurse provided the SCP, fitting their clinical practice.22 No other care providers 
(i.e. medical oncologists or radiotherapists) were involved in the trial because they do not 
use the registration system through which SCPs were generated.
SCPs could be automatically generated through the web-based ‘Registrationsystem 
Oncological Gynecology’ (ROGY), which is used by all participating oncology providers 
in both arms since 2006. For each patient, a detailed registration is made in a uniform 
way, including tumor stage and grade, treatment, comorbidity, complications, follow-up, 
and information about the involved specialists (e.g., gynecologist/gynecologic oncologist, 
medical oncologist, radiotherapist). For the ROGY care trial, an application was built in 
ROGY that enables automatic generation of an SCP combining patient and disease data 
from ROGY. Care providers could generate an SCP by pressing a button in ROGY. This 
button was only visible for the care providers in the intervention arm.
Survivorship care plan
The SCP was based on the Dutch translation of IOM’s SCP template,27 adjusted to the 
local situation28 by a group of gynecologists/gynecologic oncologists, oncology nurses, 
a radiotherapist, medical oncologist, primary care physician, and patients.22 Texts of the 
SCP were based on pilot-tested patient education material from the Dutch Cancer Society. 
In addition, the SCP was pilot-tested on patients with a low/intermediate educational level 
to ensure that the SCP was understandable.
The SCP consisted of a tailored treatment summary including information on diagnostic 
tests, type of cancer, stage, grade, treatment (type, date and specialist), and contact 
details of the hospital and specialists. The treatment summary contained explanatory 
notes of the clinical information provided and visual representations of affected organs 
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and cancer stage. In addition, the SCP contained a tailored follow-up care plan, including 
detailed information on the most common short- and long-term effects of the treatments 
received, effects on social and sexual life, possible signs of recurrence and secondary 




Receipt of SCPs was assessed by the number of patients for whom SCPs were generated, 
the number of patients that reported having received an SCP, the number of patients for 
whom follow-up SCP(s) were generated and the number of patients that reported having 
received a follow-up SCP. The number of patients of whom (first and follow-up) SCPs were 
generated was obtained from ROGY. ROGY recorded whether the SCP was generated for 
the patient by a care provider.  Whether the patients actually received the SCP was based 
on self-report, by asking ‘did you receive a survivorship care plan?’. No further explanation 
about the SCP was given in the questionnaire to avoid feelings of disadvantage in the 
control arm. Follow-up SCP receipt was assessed by follow-up questionnaires (‘how often 
did you receive a survivorship care plan?’), on 6 and 12 months after diagnosis. Patients 
that reported (first or follow-up) SCP receipt while no SCP was generated in ROGY were 
allocated to ‘reported no (first or follow-up) SCP receipt’, because it was not possible to 
receive an SCP when not generated.
Patient factors
Age, socio-economic status (SES) and clinical data, such as cancer type, cancer stage 
and date of diagnosis, were obtained from the Netherlands Cancer Registry (NCR). 
The NCR routinely collects data on newly diagnosed cancer patients in all hospitals in 
the Netherlands.29 SES was based on postal code of the residence area of the patient, 
combining aggregated individual fiscal data on the economic value of the home and 
household incomes.30 SES was categorized into low, medium or high.
Shortly after diagnosis, a first questionnaire was sent to the patient to assess partner status, 
the number of comorbidities and Type D personality. Partner status was dichotomized 
(having a partner vs. not having a partner). The number of comorbidities was assessed 
by the adapted Self-administered Comorbidity Questionnaire (SCQ).31 Type D (distressed) 
personality is defined as the joint tendency towards negative affectivity (e.g. worry, 
irritability, gloom) and social inhibition and has previously been associated with lower 
perceived receipt of information in cancer patients.32 Type D personality was assessed by 
the type-D scale (DS14).33
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In a follow-up questionnaire 12 months after diagnosis, health literacy was measured by 
one item of the 5-point Chew’s scoring scale ( ‘How confident are you by filling out medical 
forms?’).34 Low health literacy was defined as being somewhat, a little or not at all confident 
filling out medical forms, medium health literacy was defined as being quite confident 
filling out medical forms and high health literacy was defined as being very confident 
filling out medical forms.34 Furthermore, the time between SCP consult and completion of 
questionnaire was calculated by the difference in weeks between first treatment received 
(obtained from the NCR) and the date of filling out the first questionnaire.
SCP care provider factors
The primary oncology provider (i.e. gynecologist or gynecologic oncologist) that was in 
charge of the SCP care of the patient, was registered in ROGY. In 3 out of 6 hospitals in the 
intervention arm, the provision and discussion of the SCP was delegated to an oncology-
nurse. Age, sex and motivation of the care providers regarding SCP provision and opinion 
about SCP benefit were measured by a questionnaire among all care providers before the 
start of the trial.25 Motivation regarding SCP provision (‘How motivated are you to start 
using the SCP?‘) and opinion about SCP benefit (‘To what extent do you expect the SCP 
to affect the patient positively?’) were measured on a 10-point scale (strongly disagree – 
strongly agree).
Statistical analysis
Statistical analyses were conducted using Statistical Analysis System (SAS) version 9.4. 
(SAS Institute, Cary, NC, 1999). Means with standard deviations (SD) were used to describe 
normally distributed continuous variables, medians and interquartile ranges (25th-75th) to 
describe not normally distributed variables and frequencies (N) with percentages (%) 
to describe categorical variables. All patient- and care provider level factors influencing 
SCP receipt were assessed in univariate analysis, using independent samples t-tests 
for normally distributed continuous variables, Mann-Whitney U Test for not normally 
distributed continuous variables and Chi2-tests for categorical variables. For categorical 
variables with an expected count less than five, Fisher’s exact tests were used. In the 
main analysis, the dependent variable was SCP receipt as reported by the patient. In 
additional analyses, dependent variables were generated SCPs, reported receipt of 
follow-up SCPs and generated follow-up SCPs. Independent variables were patient- or 
provider -level factors. Independent variables with a significance level greater than 0.05 
were entered into a multivariable logistic regression model using a forward selection 
method. For each selected independent variable, the odds of SCP receipt as reported 
by the patient was estimated (SCP received versus no SCP received). A significance level 





Of all 178 patients in the intervention arm of the trial, an SCP was generated for 90% of 
the patients (N=161). From the patients for whom an SCP was generated, 70% (N=125) 
reported receipt of an SCP (figure 1). 
Patient and SCP care provider factors related to SCP receipt
In univariate analysis, patients who reported first SCP receipt were significantly younger (65 
years versus 70 years, p<0.01) and less often had Type D personality (15% vs. 31%, p=0.02) 
compared to patients that reported no first SCP receipt (table 1). In endometrial cancer 
patients, first SCPs were more often received by patients with an advanced FIGO stage 
(table 1). No SCP care provider factors were associated with first SCP receipt (table 2).
Multivariate analysis showed that older age, having ovarian cancer vs endometrial 
cancer, having Type D personality versus no type D personality and completion of the 
questionnaire a shorter period of time after the SCP consult were all independently 
associated with a lower chance of reported first SCP receipt (table 3).
Reported receipt of follow-up SCPs was associated with hospital (p<0.01) and having an 
oncology nurse as SCP provider compared to a gynecologist/oncologic gynecologists 
(31% vs. 10%, p<0.01) (not tabulated).  No patient factors were associated with receipt of 
follow-up SCPs. Follow-up SCPs were reported as received by 21% (N=27) of the patients 
(data not shown). 
Additional analyses showed that first SCPs were more often generated for endometrial 
compared to ovarian cancer patients (95% vs. 82%, p<0.01). Follow-up SCPs were also 
more often generated for endometrial compared to ovarian cancer patients (24% vs. 11%, 
p=0.04) and more often for ovarian cancer patients who had surgery only compared to 
ovarian cancer patients who also had chemotherapy (40% vs. 9%, p=0.04) (not tabulated).
In addition, 36 patients (20%) for whom a first SCP was generated (Ntotal=161) did not 
report receiving an SCP. These patients were significantly older compared to patients who 
reported first SCP receipt (71 [SD 8.0] versus 65 [SD 10], p<0.01) (not tabulated).






 Randomized hospitals (n=12) 
Hospitals allocated to SCP care (n=6) Hospitals allocated to usual care (n=6) 
Patients receiving questionnaire  (n=245) 
Endometrial cancer (n=154) 
Ovarian cancer (n=91) 
 
Patients receiving questionnaire (n=299) 
Endometrial cancer (n=142) 
Ovarian cancer (n=157) 
Patients completing questionnaire (n=180) 
Endometrial cancer (n=119) 
Ovarian cancer (n=61) 
 
Patients completing questionnaire (n=216) 
Endometrial cancer (n=102) 
Ovarian cancer (n=114) 
 
SCP was generated for 
patients (n=161) 
Endometrial cancer (n=111) 
Ovarian cancer (n=50) 
 
 
SCP was not generated for 
patients (n=17) 
Endometrial cancer (n=6) 
Ovarian cancer (n=11) 
 
Patients included in analysis (n=178) 
Endometrial cancer (n=117) 
Ovarian cancer (n=61) 
Patients reported SCP 
receipt (n=125) 
Endometrial cancer (n=85) 
Ovarian cancer (n=40) 
 
 
Patients reported no SCP 
receipt (n=53) 
Endometrial cancer (n=32) 
Ovarian cancer (n=21) 
 
 
SCP was generated but 
patients did not report SCP 
receipt (n=36) 
Endometrial cancer (n=26) 
Ovarian cancer (n=10) 
 
 
Not included in analysis because no SCP care condition 
Not included in analysis (n=2) 
Figure 1: Flow diagram of patients included in analysis and (first) SCP receipt in the ROGY care trial
Chapter 2
32








Age, mean (SD) 64.7 (10.2) 70.4 (8.6) <0.01
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Weeks between SCP con-
sult and questionnaire, 
median(25th-75th) 10.7 (7.0-14.6) 11.2 (7.0-15.9) 0.43
a Low = being somewhat, a little or not at all confident filling out medical forms; medium = being quite confident filling out 
medical forms; high = being very confident filling out medical forms. Health literacy was unknown for n=68.Note 1P-values 
are based on independent samples t-tests for continuous variables and Chi2-tests/ Fisher’s exact tests for categorical vari-
ables. 2All percentages stated are column percentages.
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SCP Care provider, N (%)
Gynecologist/ OG





Age SCP provider, Mean (SD) 43.5 (5.0) 43.2 (5.2) 0.75







Motivation regarding SCP 
provision, mean (SD)
Range 0-10 8.1 (0.7) 8.0 (0.7) 0.94
Opinion about SCP benefit,
mean (SD)
range 0-10 7.4 (1.1) 7.4 (1.1) 0.90
Note 1P-values are based on independent samples t-tests for continuous variables and Chi2-tests/ Fisher’s exact tests for 
categorical variables.
Table 3: odds ratio’s (OR) of first SCP receipt versus no first SCP receipt
SCP received versus not received
(N=146)
OR 95% CI P-value
Age, per 10 years 0.35 0.20-0.57 <0.01
Cancer type,
   Endometrial




   Yes
  No
0.28












Time between SCP consult and 
questionnaire, per week 0.95 0.90-1.00 0.04
Note: Candidate variables for multivariate regression were all patient factors (age, cancer type, FIGO stage, treatment type, 
socio-economic status, health literacy, Type D personality, number of comorbidities and number of weeks between SCP 
consult and questionnaire) and SCP Care provider factors (hospital, SCP Care provider, age, gender, motivation regarding 
SCP provision and opinion about SCP benefit). Candidate variables with a significance level higher than 0.05 were entered 
into a multivariate regression model using a forward selection method.  Selected variables were entered into a separate 




In this study of endometrial and ovarian cancer survivors in the intervention arm of 
the ROGY care trial, first SCPs were generated for 90% of the patients and reported as 
received by 70% of the patients. Follow-up SCPs were reported as received by 21% of the 
patients. Patient factors, including being older, having ovarian cancer and having a Type 
D personality were independently associated with a lower chance of perceived receipt of 
first SCPs, while having an oncology nurse as care provider was associated with higher 
perceived receipt of follow-up SCPs.
To our knowledge, this is the first study that examines patient and care provider factors 
associated with SCP receipt in a trial. The self-reported SCP receipt in our trial is substantially 
higher compared to the coverage ranging between 24% and 58% in observational 
studies.35 This is probably related to the ease with which the SCP could be automatically 
generated through ROGY by clicking a button. However, due to the pragmatic nature of 
the trial, 100 percent dissemination of SCP receipt was not attained.
Interestingly, we found that a considerable group of patients reported no SCP receipt 
while an SCP was generated. These patients were older on average compared to patients 
who did report receiving an SCP. There are two possible explanations for this finding: SCP 
receipt may have been underreported by older patients due to a recall bias; or during 
consultation SCP care providers decided more often not to hand over the SCP to older 
patients. In line with our findings, younger age has previously been associated with higher 
self-reported SCP receipt in observational studies.20,21 This has formerly been explained by 
a higher need for instructions for follow-up care in younger cancer patients.20 In addition, 
recall bias may explain lower self-reported SCP receipt in older patients.
Cancer type has also previously been associated with differences in SCP receipt. In two 
observational studies, patients with more common types of cancer, including breast-, 
prostate-, lung- and colorectal- cancer reported SCP receipt more often compared 
to patients with less common types of cancer such as melanoma and gynecological 
cancers.20,21 It is possible that this is related to the fact that SCP templates are less 
available for less common types of cancer.3,36 SCP receipt in endometrial and ovarian 
cancer patients specifically has not previously been investigated. Brothers and coworkers’ 
SCP trial in gynecological cancer patients did not examine how many SCPs were actually 
received in the intervention arm.9 Our study showed that SCPs were more often generated 
for, and more often reported as received by, endometrial cancer patients compared to 
ovarian cancer patients. Maybe, SCP care providers perceive more barriers to providing 
information to cancer patients with worse prognosis. This is in accordance with literature 
showing that health care providers are often reluctant to provide information on late 
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effects in order to prevent disproportionate fear in the patient.37  Further, ovarian cancer 
patients less often received follow-up SCPs when they had chemotherapy compared to 
surgery only. This could be explained by the fact that during chemotherapy, treatment 
of the patient is scheduled for follow-up visits at the medical oncologist instead of the 
gynecologist/oncologic gynecologist.25 Medical oncologists were not involved in our trial 
and therefore did not provide SCPs.
Besides younger age and cancer type, other studies found that higher SES is associated 
with higher perceived SCP receipt.20,21 In addition, higher health literacy has been 
associated with higher perceived information provision.38 Although we did not find 
statistically significant differences, our data suggest positive trends between SES and 
perceived SCP receipt, and health literacy and perceived SCP receipt.
To date, no patient personality factors have been studied in relation to SCP receipt. Our 
study shows that patients with a Type D personality (a combination of negative affect and 
social inhibition), were more likely to report no SCP receipt. Patients with this personality 
type have the tendency to experience increased negative emotions and tend not to share 
these emotions because of fear of rejection or disapproval.33 In this study, 19% of the 
patients had a Type D personality, which is comparable to 21% in the general population.33 
Other studies have shown that cancer patients with a Type D personality are less likely to 
report receipt of both oral and written information.32 SCP receipt in patients with a Type 
D personality may have been underreported. This may be due to negative emotions they 
experience towards medical information,32 or because SCP care providers may be more 
reluctant to provide SCPs for patients that are more inhibited and less likely to ask for 
information. Future research should explore whether information needs are lower among 
patients with a Type D personality and consequently whether lower provision of SCPs for 
patients with a Type D personality is desired.
A  minority of the patients in our study received a follow-up SCP. We found that follow-up 
SCP receipt, but not first SCP receipt, was higher in hospitals where SCP care was 
delegated to an oncology nurse. This was mainly due to the presence of one oncology 
nurse that provided SCP care for a large number of the patients in our analysis. Therefore, 
the generalizability of this finding is questionable. Moreover, we could not adjust for 
the patients’ need of an updated SCP (i.e. when there were changes in the cancer, 
treatment, or care provider), which could have biased our results. However, previous 
studies also suggest that oncology nurses promote successful implementation of SCPs.18,39 
Consistently, prior results from the ROGY care trial showed that oncology providers in our 
study (i.e. gynecologists, gynecologic oncologists and oncology nurses) prefer oncology 
nurses to provide SCPs in their practice.25 Therefore, for improved implementation of 
follow-up SCPs, delegation of SCP care to an oncology nurse is recommended. However, 
Chapter 2
36
oncology nurses did not provide first SCPs more often compared to gynecologists/
oncologic gynecologists in our study. Another suggestion to improve implementation 
of follow-up SCPs may be that the follow-up SCPs’ content is tailored to the information 
needs of the patient during follow-up. In our trial, follow-up SCPs only differed from 
first SCPs when there were substantial differences in the treatment or care provider.  If 
other information is provided in a follow-up SCP than the first SCP, care providers would 
probably be more prone to provide follow-up SCPs. Further, it would probably be helpful 
for the care provider if  a reminder is sent when a follow-up SCP needs to be delivered.
A strength of the current study is the trial design, in which a large number of patient- 
and SCP care provider factors were measured along with longitudinal objective and 
subjective measures of SCP receipt. In addition to self-reported receipt of SCPs that has 
been examined in previous literature, we were able to examine whether an SCP was 
generated or not. This revealed new insights into, for instance, a possible recall bias of 
reported SCP receipt related to older age, and more certainty about factors influencing 
actual SCP receipt including cancer type and Type D personality.
In order to maximize the generalizability of our trial results, the ROGY care trial is 
characterized by a pragmatic approach; exclusion criteria for patient inclusion were limited 
and oncology providers were free to choose how the SCP provision was integrated in 
clinical practice.  Despite the pragmatic nature of the trial, however, adherence to SCP 
provision by the care providers was probably higher than we would expect in clinical 
practice outside a trial setting.3,36 For instance, SCP care providers in our trial frequently 
received reminders for patient inclusion and providing an SCP if not done so yet. This 
is reflected by a relatively long period between SCP provision and completion of the 
questionnaire by the patient. Our findings may therefore not be fully generalizable to 
everyday routine clinical practice.
Limitations of our study include the uncertainty of our measure of SCP receipt; although 
we were able to objectively examine whether an SCP was generated through ROGY, we 
are not sure whether the SCP was handed over to the patient. Therefore, we have to 
rely on self-report of the patient. However, our results suggest that the self-reported 
assessment of SCP receipt may have been affected by recall bias in older patients. Besides 
that, independent from age, patients who completed the questionnaire a longer period of 
time after the SCP consult were more likely to report no SCP receipt. A delay in completion 
of the questionnaire was either caused by a longer time needed for the gynecologist to 
include a patient in the study and sending the questionnaire, or by the patient taking a 
longer time before filling out the questionnaire after receiving the questionnaire. Either 
way, this may indicate a recall bias of self-reported SCP receipt. Future studies should 
therefore aim to include a more reliable measure of SCP receipt in the study, for instance 
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by sending a questionnaire shortly after SCP receipt in order to prevent recall bias. 
Alternatively, SCP receipt could be recorded by the care provider, but this may result in 
over-report of SCP receipt due to a social desirability bias.
The level of implementation fidelity of SCPs in the ROGY care trial is expected to have 
an influence on the observed effectiveness of SCPs. When no 100 percent coverage of 
SCP receipt in the intervention arm is attained, a comparison between the intervention 
and control arm (intention to treat analysis) may result in an underestimation of SCP 
effectiveness on patient reported outcomes. Therefore, a per protocol analysis could 
provide a more accurate estimation, by only comparing patients who reported SCP 
receipt to all patients in the usual care arm.7 The current study shows, however, that SCP 
receipt may have been underreported due to recall bias. Subsequently, only patients 
who accurately remembered SCP receipt (i.e. because of younger age or more extensive 
discussion of SCP by the care provider) were included, which may result in an overestimation 
of SCP effectiveness.  Therefore, both types of analysis require careful interpretation. It 
remains debatable whether a per protocol analysis based on actually generated SCPs 
instead of self-reported SCP receipt would better reflect SCPs effectiveness in the ROGY 
care trial.
Our findings can support future implementation of SCPs in clinical practice if widespread 
implementation is decided upon, or future clinical trial research. Disparities in SCP care 
could be reduced by paying particular attention to older patients and patients with ovarian 
cancer, who appear to less often receive SCPs. In addition, SCP care providers should 
pay particular attention to patients with a Type D personality, as they experience more 
negative emotions towards medical information and are not likely to ask for information 
themselves. However, the question arises whether all patients are in need of information 
as provided in an SCP. For instance, whether patients with a distressed personality benefit 
from SCP receipt instead of unnecessarily accumulating psychosocial distress, requires 
further investigation.7 Possibly, more personalized SCPs (i.e. modules fitting individual 
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Objective: The aim of this study was to assess the long-term impact of an automatically 
generated Survivorship Care Plan (SCP) on patient reported outcomes in ovarian cancer 
in routine clinical practice. Outcome measures included satisfaction with information 
provision and care, illness perceptions and health care utilization.
Methods: In this pragmatic cluster randomized trial, twelve hospitals in the South of the 
Netherlands were randomized to ‘SCP care’ or ‘usual care’. All newly diagnosed ovarian 
cancer patients in the ‘SCP care’ arm received an SCP that was automatically generated 
by the oncology provider, by clicking a button in the web-based Registrationsystem 
Oncological GYnecology (ROGY). Ovarian cancer patients (N=174, mean age 63.3, 
SD=11.4; all stages)  completed questionnaires directly after initial treatment and after 6, 
12 and 24 months. 
Results: First questionnaires were returned from 61 (67%) ovarian cancer patients in the 
‘SCP care’ arm and 113 (72%) patients in the ‘usual care’ arm. In the ‘SCP care’ arm, 66% 
(N=41) of the patients reported receipt of an SCP. No overall differences were observed 
between the trial arms on satisfaction with information provision, satisfaction with care 
or health care utilization. Regarding illness perceptions, patients in the ‘SCP care’ arm 
had lower beliefs that the treatment would help to cure their disease (overall, 6.7 vs. 7.5, 
p<0.01). 
Conclusions: SCPs did not increase satisfaction with information provision or care in 
ovarian cancer patients. Our trial results suggest that patients may not benefit from an 
SCP.




The number of cancer patients that live with or beyond cancer is increasing worldwide, 
due to earlier detection, rapid improvement of treatments and ageing.1 Consequently, 
a growing number of cancer survivors face physical and psychological challenges in 
life after treatment.2 The provision of Survivorship Care Plans (SCPs), yielding patient-
tailored information for cancer survivors to deal with these challenges, has been widely 
recommended for all cancer survivors.3 However, evidence for informed implementation 
of SCPs in routine clinical practice is limited.4,5
Three randomized controlled trials (RCTs) did not find an effect of SCPs on short or long-
term satisfaction with care, quality of life or distress.6-9 The ROGY care trial was the first 
RCT with a pragmatic cluster randomized design, which maximizes external validity and 
prevents contamination between trial arms.10 Prior results from the ROGY care trial showed 
that in endometrial cancer patients, automatically generated SCPs increased the perceived 
amount of information received but did not improve satisfaction with information provision 
or care, up to one year after diagnosis.11 In contrast to the other RCTs, the ROGY care trial 
found an effect on other outcomes: SCPs increased worry, emotional impact, experienced 
symptoms and contact with the primary care physician about their disease.11 Based on 
current evidence, no definite conclusions can be drawn on the benefit of SCPs. Moreover, 
potential negative consequences should be considered. The ROGY care trial was designed 
and powered to separately evaluate the impact of SCPs in endometrial and ovarian cancer 
patients in order to take into account the potential moderation effect of different treatment 
regimens and prognosis between these two types of cancer. 
In contrast to endometrial cancer, ovarian cancer is often detected at an advanced stage, 
resulting in a poor prognosis.12 Current 5-year survival of ovarian cancer patients is only 
38-46% in developed countries.12,13 Subsequently, information provided in an SCP (i.e. 
patients’ cancer stage and grade, patients’ treatments and long-term and late effects 
of the treatments) is often unfavorable and may be perceived as threatening. The 
initial hypotheses of the ROGY care trial was that SCPs would have a positive effect on 
patient reported outcomes. However, earlier findings from the ROGY care trial related 
to patients with endometrial cancer suggest that SCPs may also increase threatening 
illness perceptions. We now expect that SCPs worsen illness perceptions in ovarian cancer 
patients likewise the outcomes in endometrial cancer patients. 
The current study aims to assess the impact of automatically generated SCPs in the ROGY 
care trial on patient-reported outcomes in ovarian cancer patients up to two years after 
diagnosis, including satisfaction with information provision and care, illness perceptions 





The pragmatic cluster randomized ROGY care trial among 221 endometrial and 174 
ovarian cancer patients was conducted to assess the longitudinal impact of automatically 
generated SCPs on patient and health care provider reported outcomes. In the south of 
the Netherlands, twelve hospitals were randomly allocated to either ‘usual care’ or ‘SCP 
care’. The trial was centrally approved by a Medical Research Ethics Committee, as well as 
by each participating center.10 Accordingly, the current study describes the results of the 
impact of SCPs on patient reported outcomes in ovarian cancer patients. The impact of 
SCPs on health care provider reported outcomes has been described previously.14 
Participants and recruitment
All patients newly diagnosed with ovarian cancer as a primary tumor between April 2011 
and March 2014 were invited to participate. Patients were excluded if they had borderline 
ovarian cancer, were undergoing palliative care or were unable to complete a Dutch 
questionnaire.10 All eligible patients in both trial arms were included in the study shortly 
after initial treatment. Patients were invited to take part by means of a letter, accompanied 
with an informed consent form and a questionnaire, provided to the patient by their own 
gynecologist.10,15 After consent, follow-up questionnaires were sent directly to the patients’ 
home address at 6, 12, 18 and 24 months after treatment (Figure 1). Questionnaires 
collected at 18 months after diagnosis did not include questions on any of the outcomes 
in the current study and was therefore not included in the current analysis.
Randomization and blinding
To avoid potential contamination between the trial arms, a cluster-randomized design 
with randomization on hospital-level was chosen. Hospitals were included if they used 
the registration system ROGY, which was needed to generate SCPs. To prevent imbalance 
between the trial arms, stratified randomization was used according to whether a hospital 
has a Gynecologic Oncology Center, and the annual number of endometrial and ovarian 
cancer patients diagnosed in each hospital. Randomization was performed via a table of 
random numbers, by an independent researcher blinded to the identity of the hospitals. 
Patients, but not oncology providers or researchers assessing the outcomes, were blinded 
to trial assignment.16 
SCP care versus usual care
In the hospitals that were allocated to ‘usual care’, standard care was provided in 
accordance to the Dutch follow-up guidelines. These guidelines include: verbal and 
written information about the period after treatment and follow-up, about signs of 
recurrence, and hospital contact details. In most hospitals, verbal information and the 
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generic brochures of the Dutch Cancer Society were provided.17 None of the hospitals 
provided SCPs as developed for this study.
In the hospitals that were allocated to ‘SCP care’, all oncology providers (gynecologist/
gynecologic oncologist and oncology nurses, N=24) attended an instruction evening 
devoted to when and how SCPs should be provided. They were instructed to provide 
an SCP to patients at the consultation where the results of histopathology and (adjuvant) 
treatment plan were discussed, mostly 7-14 days after surgery. If applicable (i.e. if there 
were any changes in the cancer, treatment or oncology provider), an updated version 
of the SCP could optionally be discussed in a follow-up consultation.18 In addition, 
Patients receiving questionnaire   (n=91) 
Patients completing questionnaire (n=61) 
Refused participation (n=30) 
Patients wanting to stop after 1 questionnaire (n=10) 
Patients receiving questionnaire   (n=157) 
Patients completing questionnaire (n=113) 
Refused participation (n=44) 







Hospitals receiving allocated intervention  
6 months: 
Patients receiving a questionnaire  
Patients completing the questionnaire  
Refused participation (n=3), Deceased (n=4) 
12 months: 
Patients receiving a questionnaire  
Patients completing the questionnaire  
Refused participation (n=7), Deceased (n=5) 
24 months: 
Patients receiving a questionnaire  
Patients completing the questionnaire (n=29) 







Hospitals receiving usual care during follow-up 
6 months: 
Patients receiving a questionnaire  
Patients completing the questionnaire  
Refused participation (n=7), Deceased (n=4) 
12 months: 
Patients receiving a questionnaire  
Patients completing the questionnaire  
Refused participation (n=13), Deceased (n=8) 
24 months: 
Patients receiving a questionnaire  
Patients completing the questionnaire  (n=46) 






After treatment  (n=61) 
6 months follow-up   (n=44) 
12 months follow-up  (n=35) 
24 months follow-up (n=29) 
Hospitals allocated to intervention (n=6) 





After treatment  (n=113) 
6 months follow-up   (n=79) 
12 months follow-up  (n=65) 
24 months follow-up (n=46) 
Hospitals allocated to usual care (n=6) 
Received allocated usual care  (n=6) 
Analysis 
Randomized hospitals (n=12) Enrollment 
Enrollment of patients 
Allocation 
Figure 1: CONSORT Flow diagram of ovarian cancer patient enrollment
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care providers were instructed to send a copy of the SCP to the patient’s primary care 
physician.19 In the Netherlands, follow-up care is provided by an oncology provider up to 
5 years after diagnosis (www.oncoline.nl). Therefore, the SCP was not meant to transition 
the patient from oncology care to primary care, but to inform the patient about the 
treatments, long-term and late effects of the treatments and support services. Practical 
guidelines were given on the components of the SCP that should minimally be discussed 
with each patient during the consultation (i.e. diagnosis, prognosis, treatment(s), most 
important side-effects). Because of the pragmatic approach of the trial, care providers in 
the ‘SCP care’ arm were free to choose whether the gynecologist/gynecologic oncologist, 
or oncology nurse provided the SCP fitting their clinical practice.10
Survivorship care plan
The SCP was based on the Dutch translation of the American Institute of Medicine (IOM) 
SCP template,20 adjusted to the local situation21 by a group of gynecologists/gynecologic 
oncologists, oncology nurses, a radiotherapist, medical oncologist, primary care physician, 
and patients.10 Texts of the SCP were based on pilot-tested patient education material 
from the Dutch Cancer Society. In addition, the SCP was pilot-tested on patients with a 
low/intermediate educational level to ensure that the SCP was understandable.
The SCP consisted of a tailored treatment summary including information on diagnostic 
tests, type of cancer, stage, grade and treatments received (type of treatment, date 
and medical specialist) and contact details of the hospital and medical specialists. The 
treatment summary contained explanatory notes of the clinical information provided and 
visual representations of affected organs and cancer stage of the patient. In addition, 
the SCP contained a tailored follow-up care plan, including detailed information on the 
most common short- and long-term effects of the treatments received, effects on social 
and sexual life, possible signs of recurrence and secondary tumors, and information on 
rehabilitation, psychosocial support, and supportive care services.10 To make sure that 
patients were aware of receiving an SCP, the front page clearly stated “Survivorship Care 
Plan”.
Measures
Age, socio-economic status (SES) and clinical data, such as cancer type, cancer stage 
and date of diagnosis, were obtained from the Netherlands Cancer Registry (NCR). 
The NCR routinely collects data on newly diagnosed cancer patients in all hospitals in 
the Netherlands.22 SES was based on postal code of the residence area of the patient, 
combining aggregated individual fiscal data on the economic value of the home and 
household incomes.23 SES was categorized into low, medium or high. Data obtained from 
the NCR were available for both participants and non-participants in the trial. Among 
the participants of the trial, additional socio-demographic information (i.e. marital status, 
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employment status and comorbidities) was assessed in the first questionnaire. Marital status 
(‘married/living together’ versus ‘divorced/widowed/never married’) and employment 
status (‘having a paid job’ versus ‘not having a paid job’) were dichotomized. Comorbidity 
was assessed by the adapted Self-administered Comorbidity Questionnaire (SCQ), and 
categorized into no comorbidities, one comorbidity or more than one comorbidities.24 
Information provision was assessed with the EORTC-QLQINFO25.25 Scales included four 
multi-item subscales (information about the disease, medical tests, treatment and other 
care services) and four single-item scales (information about different places of care, 
things you can do to help yourself get well, satisfaction with the information, helpfulness 
of the information). All scales indicated a score between 0 (low perceived information 
provision) and 100 (high perceived information provision). Internal consistency of the scales 
(Cronbach’s alphas 0.75-0.90) were good. Test-retest reliability (intraclass correlations 
0.71-0.91) were good.25
Satisfaction with care was assessed with the EORTC INPATSAT32.26 Scales included two 
multi-item scales (doctor’s interpersonal skills and nurses’ interpersonal skills) and two 
singe-items scales (exchange of information between caregivers and general satisfaction 
with care). All scales indicated a score between 0 (low perceived quality of care) and 100 
(high perceived quality of care). Internal consistency of the scales (Cronbach’s alphas 0.93-
0.94) were good. Test-retest reliability (intraclass correlations 0.66-0.85) were good.26
Illness perception was assessed with the Brief Illness Perception Questionnaire (B-IPQ).27 
Scales included eight single-time scales regarding cognitive illness representations (how 
much illness affects life, how long illness will continue, how much patient has control over 
illness, how much treatment helps to cure illness, how many symptoms are experienced), 
emotional representations (how concerned patient is about illness, how much patient is 
affected emotionally) and comprehensiveness (how well patient understands illness). All 
scales indicated a score between 0 (low endorsement) and 10 (high endorsement). Test-
retest reliability (Pearson correlations 0.42-0.75) was good.27
Health care utilization was assessed by the number of visits that were made to a medical 
specialist or primary care physician in relation to cancer in the past 6 months. 
Actual receipt of an SCP was assessed in the first questionnaire (“Did you receive a 
Survivorship Care Plan?”), in both trial arms. In addition, patients were asked how many 
times they received the SCP at 6, 12 and 24 months after treatment. If patients in the 
‘SCP care’ arm reported SCP receipt but no SCP was generated in ROGY, they were not 





Statistical analyses were conducted using Statistical Analysis System (SAS) version 9.4. (SAS 
Institute, Cary, NC, 1999). Differences in characteristics of patients between the trial arms, 
between participants and non-participants of the trial, and between participants that 
completed participation and participants lost to follow-up were compared using t-tests 
for normally distributed continuous variables, Mann-Whitney U-tests for not-normally 
distributed variables and chi-square tests for categorical variables.
Linear multilevel regression analysis was performed to assess the effect of SCPs on 
patient reported outcomes, allowing for adjustment of inter-dependency between 
repeated measures within patients28 and correction for data missing at random.29,30 A 
random intercept on the patient-level was included in the model to adjust for the inter-
dependency between repeated measures. Based on likelihood ratio tests, neither a 
random intercept on the hospital-level (ICCs<0.16) to account for the cluster-design, nor 
a random-slope on the patient-level (ICCs<0.14) to account for potential dependency 
between the intervention and outcome variable, improved the model for any of the 
outcome variables and were therefore not included in the model.  All a priori-selected 
covariates were entered into the model (i.e. age, time since diagnosis, marital status, 
socio-economic status, employment, comorbidities, stage, and treatment). Dependent 
variables were the information provision and care-, illness perceptions-, and health care 
utilization- scales.  Additionally, we assessed whether the effect of SCPs differed for 
each time-point separately by adding a time-reference variable and an interaction term 
between trial arm and the time-reference variable to the overall model.28 
Intention-to-treat analysis (ITT) compared all patients in the ‘SCP care’ (N=61) arm to all 
patients in the ‘usual care’ arm (N=113). Per-protocol (PP) analysis compared patients in 
the ‘SCP care’ arm who reported having received an SCP at any time during follow-up and 
where an SCP had been generated (N=40), to all patients in the usual care arm (N=113). 
The ROGY care trial was powered to detect a clinically meaningful difference of 0.5 SD for 
SCP care versus usual care on the overall primary outcomes (satisfaction with information 
provision and satisfaction with care). A total of 150 patients were targeted (75 per trial 
arm) to attain 80% power, assuming an intra-class correlation (ICC) between the hospitals 
of 0.005.10
RESULTS
No differences were observed in socio-demographic or clinical baseline characteristics 
between the trial arms (Table 1) or between participants and non-participants of the trial 
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(Table 2). However, patients that were lost to follow-up during the trial had a significantly 
higher FIGO-stage (patients with stage IV, 25% vs. 8%, p=0.03) (Table 2). 
Questionnaires were sent to 91 patients in the SCP care arm and 157 patients in the 
usual care arm. Questionnaires were returned after treatment by 61 patients (67%) in 
the SCP care arm and 113 patients (72%) in the usual care arm. Follow-up questionnaires 
were  received after 6 months (48% SCP care; 51% usual care), 12 months (38% SCP care; 
42% usual care) and 24 months (32% SCP care; 29% usual care) (Figure 1). Post-hoc 
power analysis show that for detecting  a clinically meaningful difference of 0.5 SD on the 
outcomes, statistical power was sufficient for overall ITT analysis (96%) and for separate 
ITT analysis after diagnosis (88%), but lower for separate ITT analysis after 6 (75%), 18 
(66%) and 24 (55%) months. For PP analysis, statistical power was sufficient for overall 
analysis of all time-points (89%), but low for analysis of separate time-points (77%, 63%, 
52%, 44% respectively). 
In the SCP care arm, 40 patients (66%) reported in the first questionnaire that they had 
received an SCP and 10 patients (16%) reported that they had received an updated 
follow-up SCP at 6, 12 or 24 months. In the usual care arm, 21 patients (18%) reported that 
they had received an SCP, and no patients reported receipt of an updated follow-up SCP. 












Age at diagnosis 
   Mean (SD) 63.3 (11.4) 63.3 (11.3) 63.3 (11.4) 0.97
Age at time of first questionnaire 
   Mean (SD) 64.1 (10.8) 63.6 (11.2) 64.3 (10.7) 0.67
SES, n (%)
   Low 31 (18) 13 (21) 18 (16) 0.43
   Intermediate 74 (42) 22 (36) 52 (46)
   High 70 (40) 26 (43) 44 (39)
Months since diagnosis
   Median (IQR) 2.8 (1.6-4.1) 3.0 (1.8-4.2) 2.4 (1.6-4.1) 0.31
   <1 34 (19) 8 (13) 26 (23) 0.15
   1-2 57 (33) 18 (30) 39 (34)
   2-3 25 (14) 8 (13) 17 (15)
   >3 59 (34) 27 (44) 32 (28)
Comorbidity1
   None 2 (2) 2 (4) 0 (0) 0.14
   1 57 (33) 21 (34) 36 (32)
   2 or more 115 (66) 38 (62) 77 (68)
Marital status2
   Partner 131 (75) 48 (79) 83 (73) 0.39














   Yes 51 (29) 20 (33) 31 (27) 0.44
   No 124 (71) 41 (67) 83 (73)
FIGO-stage, n (%)
   I 52 (30) 21 (34) 31 (28) 0.63
   II 16 (9) 7 (11) 9 (8)
   III 74 (43) 23 (38) 51 (46)
   IV 30 (17) 10 (16) 20 (18)
Treatment, n (%)
   Surgery 158 (91) 54 (88) 104 (93) 0.33
   Chemotherapy 136 (79) 44 (72) 92 (82) 0.13
Hospital, n (%)
   1 16 (9) 16 (26)
   2 8 (5) 8 (13)
   3 5 (3) 5 (8)
   4 25 (14) 25 (41)
   5 3 (2) 3 (5)
   6 4 (2) 4 (7)
   7 37 (21) 37 (33)
   8 30 (17) 30 (26)
   9 25 (14) 25 (22)
   10 5 (3) 5 (4)
   11 4 (2) 4 (4)
   12 13 (7) 13 (11)
Hospitals
# endometrial and ovarian
cancer patients per year
   ≤50 4 (33) 2 (33) 2 (33)
   >50 8 (67) 4 (67) 4 (67)
Gynecologic Oncology 
Center (Tertiary Referral 
Hospital)
   Yes 2 (17) 1 (17) 1 (17)
   No 10 (83) 5 (83) 5 (83)
Note: *P-values report comparisons between the intervention arm and the usual care arm, according to t-tests, Wilcox-
on-Mann-Whitney test and chi-square tests. Means (M) with standard deviations (SD) were used to describe normally dis-
tributed continuous variables, medians with interquartile range (IQR) to describe not-normally distributed continuous vari-
ables, and frequencies with percentages to describe categorical variables. 1Comorbidities included heart disease, high blood 
pressure, lung disease, diabetes, ulcer or stomach disease, kidney disease, liver disease, blood disease, cancer, depression, 
pain and swelling in joints other than the back, osteoporosis and  fractures.2Marital status included: partner = married/living 
together; no partner = divorced/widowed/never married.  The numbers may not always add up to 100, because percentages 
have been rounded off to whole numbers.
Table 1: Continued
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Table 2: socio-demographic and clinical variables according to (non-)participation, complete par-














Age at diagnosis 
   Mean (SD) 63.3 (11.4) 65.1 (12.6) 0.27 62.2 (9.9) 64.2 (12.3) 0.25
Age at time of first 
questionnaire
   Mean (SD) 64.1 (10.8) unknown 62.4 (9.9) 64.7 (12.0) 0.08
SES, n (%)
   Low 31 (18) 16 (23) 0.34 15 (22) 15 (16) 0.67
   Intermediate 74 (42) 32 (46) 25 (37) 35 (38)
   High 70 (40) 21 (30) 28 (41) 41 (45)
Marital status1
   Partner 131 (75) unknown 57 (76) 74 (74) 0.76
   No partner 44 (25) unknown 18 (24) 26 (26)
Employed
   Yes 51 (29) unknown 22 (29) 29 (29) 0.96
   No 124 (71) unknown 53 (71) 71 (71)
FIGO-stage, n (%)
   I 52 (30) 20 (28) 0.70 27 (36) 25 (26) 0.03
   II 16 (9) 4 (5) 8 (11) 8 (8)
   III 74 (43) 35 (48) 34 (45) 40 (41)
   IV 30 (17) 14 (19) 6 (8) 24 (25)
Treatment, n (%)
   Surgery 158 (91) 64 (88) 0.38 72 (96) 87 (89) 0.08
   Chemotherapy 136 (79) 53 (73) 0.31 55 (73) 80 (81) 0.19
Comorbidity2
   None 2 (2) unknown 19 (26) 30 (30) 0.82
   1 57 (33) unknown 21 (28) 27 (27)
   2 or more 115 (66) unknown 34 (46) 43 (43)
Hospital, n (%)
   1 16 (9) 2 (3) 0.33 16 (21) 21 (21) 0.69
   2 8 (5) 3 (4) 9 (12) 7 (7)
   3 5 (3) 2 (3) 14 (19) 16 (16)
   4 25 (14) 15 (21) 11 (15) 14 (14)
   5 3 (2) 4 (5) 3 (4) 5 (5)
   6 4 (2) 4 (5) 4 (5) 1 (1)
   7 37 (21) 10 (14) 1 (1) 4 (4)
   8 30 (17) 12 (16) 10 (13) 15 (15)
   9 25 (14) 7 (10) 1 (1) 2 (2)
   10 5 (3) 3 (4) 1 (1) 3 (3)
   11 4 (2) 3 (4) 3 (4) 10 (10)
   12 13 (7) 8 (11) 2 (3) 2 (2)
Note: P-values report comparisons between participants and non-participants, and between patients that completed par-
ticipation and patients lost to follow-up, according to t-tests and Chi-square tests. Means (M) with standard deviations (SD) 
were used to describe normally distributed continuous variables and frequencies with percentages to describe categorical 
variables. Patients with complete participation completed baseline questionnaire and all follow-up questionnaires at 6, 12 
and 24 months after diagnosis; patients lost to follow-up were patients that did not complete all follow-up questionnaires. 
1Marital status included: partner = married/living together; no partner = divorced/widowed/never married. . 2Comorbidities 
included heart disease, high blood pressure, lung disease, diabetes, ulcer or stomach disease, kidney disease, liver disease, 
blood disease, cancer, depression, pain and swelling in joints other than the back, osteoporosis and  fractures.The numbers 
may not always add up to 100, because percentages have been rounded off to whole numbers.
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ITT analysis (N=174) showed no significant differences in satisfaction with information 
provision or satisfaction with care between patients in the SCP care arm and patients in 
the usual care arm overall. At 6 and 24 months after diagnosis, patients in the SCP care 
arm reported lower perceived information on other services (6 months: M=29.8, SD=23 
vs. M=38.1, SD=25, P=0.02; 24 months: M=27.4, SD=23 vs. M=34.5, SD=20, P=0.03), 
but effect sizes were small (r=0.2). In the PP analysis (N=153), this difference remained 
only significant after 24 months (M=27.0, SD=23 vs. M=34.5, SD=20, P=0.048, r=0.2). 
Further, in ITT analysis only after 24 months, patients in the SCP care arm reported lower 
satisfaction with the interpersonal skills of the nurses (M=67.8, SD=22 vs. M=83.1, SD=14, 
P=0.04, r=0.4), but this difference was not significant in the PP analysis (M=63.3, SD=21 vs. 
M=83.1, SD=14, P=0.06, r=0.5) (Table 3). 
In the ITT analysis overall, after diagnosis and after 6 and 12 months, patients in the 
SCP care arm reported lower beliefs that the treatment would help to cure the illness 
compared to patients in the usual care arm (overall: M=6.9, SE=0.2 vs. 7.5, SE=0.3, p<0.01, 
r=0.2; after diagnosis, M=7.2, SD=2.3; vs. M=7.8, SD=1.8, P=0.03, r=0.1; after 6 months, 
M=6.7, SD=2.9 vs. M=7.2, SD=2.4, P=0.04, r=0.1; after 12 months: M=6.4, SD=2.7 vs. 
M=7.2, SD=2.5, P<0.01, r=0.2) (Table 3, Figure 2). In PP analysis this finding was only 
significant overall (M=7.5, SE=0.2 vs. M=6.9, SE=0.3, P<0.01, r=0.2) and after 12 months 
(M=6.6, SD=2.6 vs. M=7.2, SD=2.5, P<0.01, r=0.1;Table 3). 
In ITT analysis, patients in the ‘SCP care’ arm reported less visits to the medical specialist 
in the 6 months after treatment (M=4.9, SD=3.5 vs. M=7.6, SD=9.4, P=0.04, r=0.2 Table 
3). In additional analysis, we also adjusted for time between first questionnaire and 
last treatment, to adjust for possible systematic differences in the timing of treatments 
between the hospitals which could explain the number of visits to the medical specialist, 
but results were similar (data not shown). 
There were no interactions between trial arms and patients lost to follow-up for any of 
the outcomes, indicating that the effect of SCP care did not differ for patients who were 
lost to follow-up. There were also no interactions between the trial arms and time for any 
of the outcomes, indicating that the effect of SCP care did not differ over the time points.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the present trial among ovarian cancer patients, SCPs had no beneficial effect on 
satisfaction with information provision and care. Instead, receiving an SCP caused less 
trust that the treatment would help to cure the disease. These current results are in line 
with earlier findings from the ROGY care trial among endometrial cancer patients.11 
Prior findings from our trial among endometrial cancer patients showed no effect of SCPs 
on satisfaction with information provision and care, but patients were more concerned 
about their illness, more affected emotionally and they experienced more symptoms.11 
In the current study among ovarian cancer patients, no effect of SCPs was found on 
concerns, emotional impact or symptoms experienced. This may be due to existing 
information provision that in most cases already explains about the poor prognosis 
and extensive treatment regimens generally needed for ovarian cancer. From oncology 
practice, we know that in endometrial cancer, treatments are often less extensive and 
therefore generally less information is provided. On the other hand, ovarian cancer 
patients who received an SCP had less trust that the treatment would help to cure the 
disease. This may be explained by the fact that ovarian cancer generally has a poor 
prognosis, and information provided in the SCP (i.e. on chance of recurrence) may not 
support the patients’ belief that she will be cured. This is negative yet realistic information 
that the patient otherwise would mostly not receive, as oncology providers are often 
reluctant to provide such information in order to prevent the patient from negative 
psychosocial effects.31 We should take in mind that for patients with an advanced cancer 
stage and poor prognosis, an SCP provides unfavorable information and may need to be 
accompanied with more extensive discussion with an oncology provider. Earlier RCTs did 
not focus on patient populations with advanced stages.6-8,32
At this point, we are not sure whether less trust in the treatment is either harmful or 
beneficial for the patient. If patients incorrectly experience less trust in the treatment, the 
SCP may unnecessarily accumulate psychosocial distress. However, if less trust is according 
prospect, patients may be more prepared for potential negative long-term consequences 
of the disease, such as side effects or a recurrence.  Further research is needed to assess 
the impact of less treatment trust on long-term quality of life, anxiety and depressive 
symptoms. However, it is important to keep in mind that effect sizes of illness perceptions 
are small; they did not reach the minimal clinically important difference threshold of 0.5 
SD and may therefore be considered not clinically relevant.
In contrast to earlier findings of our trial which showed an increased amount of cancer 
related contact with the primary care physician in endometrial cancer patients who 
received an SCP, we found that ovarian cancer patients receiving an SCP reported less 
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contact with the medical specialist in the six months after diagnosis. Possibly, ovarian 
cancer patients receiving an SCP have lower needs of contact with their medical specialist 
because questions or concerns regarding the illness are already covered in the SCP. 
Another explanation of this finding may be that the patients in the SCP care arm less 
often received chemotherapy and had therefore less contact with the medical specialist. 
Further, our results are based on self-reported health care use; exact registrations of 
hospital visits would be more reliable and may show different results. For instance, 
patients in the SCP care arm completed the first questionnaire a longer period of time 
after diagnosis compared to patients in the usual care arm. The lower self-reported health 
care use in the SCP care arm at 6 months after diagnosis may therefore be explained by 
time since treatment completion. However, we adjusted for this in our analysis and results 
remained similar. 
Strikingly, we found that patients in the usual care arm reported a higher receipt of 
information on other services at 6 and 24 months after diagnosis, and higher satisfaction 
with the interpersonal skills of the nurses. These findings may be explained by the 
pragmatic approach of our trial; we did not control the existing information provision or 
care in the usual care arm. It is therefore possible that in the usual care hospitals certain 
aspects of information provision were perceived better compared to the intervention 
hospitals. Further, 18% of the patients in the usual care arm reported receipt of an SCP, 
although SCP provision was impossible in these hospitals.10 Probably, these patients have 
perceived other information provision as an SCP. 
An advantage of our pragmatic design is that oncology providers were free to choose 
how SCP provision was implemented, reflecting real-life clinical practice. Inevitably, this 
resulted in variance across the hospitals with respect to how the SCP was provided, 
ranging from extensively discussing the SCP with the patient to just handing one without 
discussion. Our trial did not aim to assess the impact of an SCP that is extensively 
discussed with the patient. Therefore we did not measure the extent to which the SCP 
was discussed with each patient. However, as shown in a recent trial among breast cancer 
patients, combining an SCP with a behavioral intervention using motivational interviewing 
techniques may actually be beneficial for patients.32 Possibly, this would be even more 
beneficial in patients with advanced cancer stages as they generally have higher supportive 
care needs.33 Future research is needed to assess the impact of an SCP combined with a 
behavioral intervention in larger samples and various cancer types. 
Among the few RCTs that assessed the impact of SCPs on patient reported outcomes.6-8,32 
the ROGY care trial was the first with a pragmatic cluster randomized design, which 
maximizes external validity and prevents contamination between trial arms.10 Another 
unique feature of the trial was that SCPs could be automatically generated through the 
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online registration system ROGY, which minimizes the time needed for SCP provision and 
allows for provision of updated follow-up SCPs. However, only 16% of the patients in this 
study reported receipt of an updated SCP. This shows that SCPs were not always updated 
by the oncology provider when there was a recurrence, changes in treatment or oncology 
provider. This is probably due to difficulties with finding time to discuss the SCP.14
A limitation of our study is the small number of patients in our SCP care arm. This was 
mainly due to one large intervention hospital which, in contrast to endometrial cancer 
patients, did not include ovarian cancer patients in the trial. Nevertheless, our overall 
analysis had sufficient power to detect a minimum effect size of 0.5. However, effect sizes 
in our analyses turned out to be much smaller, meaning that the power of our analysis 
was too small to detect those small effects. Future studies aiming to detect an effect of 
SCPs on the outcomes used in the current analyses, should use a larger sample size. 
However, one may argue that detecting an effect with an effect size smaller than 0.5 is 
not clinically relevant. 
In this study, a substantial number of patients were lost to follow-up during our two-
year trial. Because of the relatively low survival in ovarian cancer, lost to follow-up was 
for a large part caused by death or ill-health. This resulted in a selection of patients in 
our follow-up analysis, who had lower cancer stages. However, the effect of the SCP was 
similar for patients lost to follow-up and patients who completed participation in our trial. 
Further, as shown in a process evaluation of our trial18 SCPs were generated (i.e. the 
oncology provider clicked the SCP button in the ROGY system) for 82% of the ovarian 
cancer patients. However, we found that only 66% of the ovarian cancer patients in the 
SCP care arm actually reported SCP receipt. Thus, for 16% of the patients we are not sure 
what happened: the oncology provider did not hand over the SCP to the patient, or the 
patient might have forgotten her receipt of an SCP. Among endometrial cancer patients, 
the number of patients that reported receipt of an SCP was higher (74%), probably 
because most of the oncology care was provided by an oncology provider that provided 
the SCP in our trial (i.e. gynecologist, gynecologic oncologist or oncology nurse), while in 
ovarian cancer patients oncology care is for a large part provided by medical oncologists 
who were not instructed to provide SCPs. 
Due to the pragmatic nature of the trial, not all trial participants received an SCP, reflecting 
real-life clinical practice. A process evaluation of our trial18 showed that certain patients 
less often received an SCP (i.e. older patients and patients with a distressed personality). 
Current results may therefore not be fully generalizable to the full patient population. 
Possibly, SCPs have a higher impact on threatening illness perceptions in patients with 
a distressed personality, as they tend to experience more negative emotions without 
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sharing these emotions with others.18 Unfortunately, we could not assess if there was a 
selection bias in patient recruitment in the SCP care arm compared to the usual care arm, 
as no data was available on proportions of patients recruited versus not recruited. We did 
not find statistical differences in baseline characteristics between the trail arms, but our 
trial was not powered to detect differences in the categorical baseline variables. Possibly, 
patients in the SCP care arm were somewhat healthier compared to patients in the usual 
care arm (i.e. lower FIGO stage and less often received chemotherapy), which may have 
underestimated true effects of the SCPs to some extent. For instance, the impact of 
SCPs on illness perceptions may be worsened in unhealthier patients. However, we do 
not assume that we would find an effect on satisfaction with information provision or 
satisfaction with care, as no trend is observed in current results. 
In order to assess the impact of SCPs in a situation where all patients would receive one, 
we conducted a per protocol analyses in addition to an intention to treat analyses. To 
make sure of this, we only compared the patients in the SCP care arm that reported SCP 
receipt, to all patients in the usual care arm. However, results did not differ much between 
intention to treat and per protocol analyses. 
In conclusion, the present study confirms earlier findings from the ROGY care trial that 
SCPs did not increase satisfaction with information provision or care. Instead, SCPs led 
to a lower trust in the treatment among ovarian cancer patients which might reflect a 
more realistic perspective on the treatments effects, while among endometrial cancer 
patients the SCPs seemed to unnecessarily cause higher concerns, emotional impact and 
symptom awareness. Our trial results suggest that patients may not benefit from an SCP 
as was proposed by the IOM. However, the benefit of an SCP combined with a behavioral 
intervention needs to be further explored. 




1. Rowland JH, Kent EE, Forsythe LP, et al. Cancer survivorship research in Europe and the United 
States: where have we been, where are we going, and what can we learn from each other? Cancer. 
2013;119(S11):2094-2108.
2. Aaronson NK, Mattioli V, Minton O, et al. Beyond treatment–psychosocial and behavioural issues in 
cancer survivorship research and practice. European Journal of Cancer Supplements. 2014;12(1):54-64.
3. Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Translation. 
Committee on Cancer Survivorship: Improving Quality Care and Quality of Life, National Cancer 
Policy Board. Washington, DC: National Academies Press; 2006.
4. Mayer DK, Birken SA, Check DK, Chen RC. Summing it up: an integrative review of studies of cancer 
survivorship care plans (2006-2013). Cancer. Apr 1 2015;121(7):978-996.
5. Klemanski DL, Browning KK, Kue J. Survivorship care plan preferences of cancer survivors and 
health care providers: a systematic review and quality appraisal of the evidence. Journal of Cancer 
Survivorship. 2016;10(1):71-86.
6. Grunfeld E, Julian JA, Pond G, et al. Evaluating survivorship care plans: results of a randomized, 
clinical trial of patients with breast cancer. Journal of Clinical Oncology. 2011;29(36):4755-4762.
7. Hershman DL, Greenlee H, Awad D, et al. Randomized controlled trial of a clinic-based survivorship 
intervention following adjuvant therapy in breast cancer survivors. Breast cancer research and 
treatment. 2013;138(3):795-806.
8. Brothers BM, Easley A, Salani R, Andersen BL. Do survivorship care plans impact patients’ evaluations 
of care? A randomized evaluation with gynecologic oncology patients. Gynecologic oncology. 
2013;129(3):554-558.
9. Boekhout AH, Maunsell E, Pond GR, et al. A survivorship care plan for breast cancer survivors: 
extended results of a randomized clinical trial. Journal of Cancer Survivorship. 2015;9(4):683-691.
10. van de Poll-Franse LV, Nicolaije KA, Vos MC, et al. The impact of a cancer Survivorship Care Plan 
on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study 
protocol for a pragmatic cluster randomized controlled trial. Trials. 2011;12:256.
11. Nicolaije KA, Ezendam NP, Vos MC, et al. Impact of an Automatically Generated Cancer Survivorship 
Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a 
Pragmatic, Cluster Randomized Trial. Journal of Clinical Oncology. 2015;33(31):3550-3559.
12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A cancer journal for clinicians. 2015.
13. Netherlands CR. Netherlands Cancer Registry. 5-year survival of ovarian cancer patients diagnosed 
between 2008 and 2012. URL www.cijfersoverkanker.nl [accessed 1/4/2016]. 2014.
14. Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, van de Poll-Franse LV, Kruitwagen RF. Oncology 
providers’ evaluation of the use of an automatically generated cancer survivorship care plan: 
longitudinal results from the ROGY Care trial. Journal of cancer survivorship : research and practice. 
Jun 2014;8(2):248-259.
15. van de Poll-Franse LV, Horevoorts N, van Eenbergen M, et al. The Patient Reported Outcomes 
Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and 
design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship 
cohorts. European Journal of Cancer. 2011;47(14):2188-2194.
16. Campbell MK, Piaggio G, Elbourne DR, Altman DG, . Consort 2010 statement: extension to cluster 
randomized trials. BMJ. 2012;345: e5661.
17. Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, van de Poll-Franse LV, Kruitwagen RF. Oncology 
providers’ evaluation of the use of an automatically generated cancer survivorship care plan: 
longitudinal results from the ROGY Care trial. J Cancer Surviv. 2014;8 (2):248-259.
18. de Rooij BH, Ezendam NP, Nicolaije KA, et al. Factors influencing implementation of a survivorship 
care plan-a quantitative process evaluation of the ROGY Care trial. Journal of cancer survivorship : 
research and practice. Aug 1 2016.
19. Ezendam NP, Nicolaije KA, Kruitwagen RF, et al. Survivorship Care Plans to inform the primary care 
physician: results from the ROGY care pragmatic cluster randomized controlled trial. Journal of 
cancer survivorship : research and practice. Dec 2014;8(4):595-602.
Chapter 3
60
20. Hewitt M, Greenfield S, Stovall E, eds. From cancer patient to cancer survivor: lost in transition. 
Washington, DC: National Academies Press; 2006.
21. Ganz PA, Hahn EE. Implementing a survivorship care plan for patients with breast cancer. J Clin 
Oncol 2008;26:759-767.
22. Netherlands Cancer Registry (NCR). Netherlands Cancer Registration URL: http://www.
cijfersoverkanker.nl/ [accessed 30-01-2015] 2015.
23. Van Duijn C, Keij I. Sociaal-economische status indicator op postcode niveau. Maandstatistiek van 
de bevolking. 2002;50(2):32-35.
24. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: 
A new method to assess comorbidity for clinical and health services research. Arthritis Rheum 
2003;49:156-163.
25. Arraras JI, Greimel E, Sezer O, et al. An international validation study of the EORTC QLQ-INFO25 
questionnaire: an instrument to assess the information given to cancer patients. Eur J Cancer 
2010;46:2726-2738.
26. Bredart A, Bottomley A, Blazeby JM, et al. An international prospective study of the EORTC cancer 
in-patient satisfaction with care measure (EORTC IN-PATSAT32). Eur J Cancer 2005;41:2120-2131.
27. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom 
Res. 2006;60:631-637.
28. Twisk JWR. Applied Multilevel Analysis: A Practical Guide for Medical Researchers. New York: 
Cambridge University Press 2006.
29. Peters SAE, Bots ML, den Ruijter HM, et al. Multiple imputation of missing repeated outcome 
measurements did not add to linear mixed-effects models. Journal of Clinical Epidemiology. 
2012;65:686-695.
30. Beunckens C, Molenberghs G, Kenward MG. Direct likelihood analysis versus simple forms of 
imputation for missing data in randomized clinical trials. Clinical Trials. 2005;2:379-386.
31. Cox A, Faithfull S. ‘They’re survivors physically but we want them to survive mentally as well’: health 
care professionals’ views on providing potential late effect information. Support Care Cancer. 
2013;21:2491-2497.
32. Kvale EA, Huang CS, Meneses KM, et al. Patient-centered support in the survivorship care 
transition: Outcomes from the Patient-Owned Survivorship Care Plan Intervention. Cancer. Oct 15 
2016;122(20):3232-3242.
33. Sanson-Fisher R, Girgis A, Boyes A, Bonevski B, Burton L, Cook P. The unmet supportive care needs 
of patients with cancer. Supportive Care Review Group. Cancer. Jan 01 2000;88(1):226-237.





Patients’ information coping styles influece the benefit 
of a survivorship care plan in the ROGY Care Trial: 
new insights for tailored delivery











Background: In efforts to improve implementation of Survivorship Care Plans (SCPs), 
we aim to assess whether the impact of SCPs on patient reported outcomes is different 
in patients with an information seeking (‘monitoring’) versus an information avoiding 
(‘blunting’) coping style. 
Methods: In the ROGY Care Trial, twelve hospitals in the Netherlands were randomized 
to ‘SCP care’ or ‘usual care’. All newly diagnosed endometrial and ovarian cancer patients 
in the ‘SCP care’ arm received a SCP that was automatically generated by the oncology 
provider through the web-based Registrationsystem Oncological GYnecology (ROGY). 
Outcomes (satisfaction with information provision and care, illness perceptions and health 
care use) were measured directly after initial treatment and after 6, 12 and 24 months. 
Information coping style was measured at 12 months after initial treatment.
Findings: Among patients with a ‘monitoring’ coping style (N=123), those in the ‘SCP care’ 
arm reported higher satisfaction with information provision (73.9 vs. 63.9, p=0.04) and 
care (74.5 vs. 69.2, p=0.03) compared to those in the ‘usual care’ arm. Among patients 
with a ‘blunting’ coping style (N=102), those in the ‘SCP care’ arm reported a higher 
impact of the disease on life (5.0 vs 4.5, p=0.02) and a higher emotional impact of the 
disease (5.4 vs. 4.2, p=0.01) compared to those in the ‘usual care’ arm.
Conclusions: SCPs may be beneficial for patients who desire information about their 
disease, while SCPs may be less beneficial for patients who avoid medical information, 
suggesting a need for tailored SCP delivery to improve survivorship care.
Trial Registration: clinicaltrials.gov Identifier: NCT01185626




For more than a decade, Survivorship Care Plans (SCPs) have been broadly endorsed 
as a means to improve care coordination and to address the unmet information needs 
in the growing population of cancer survivors.1 Since the first recommendation by the 
Institute of Medicine in 20061, SCPs have been the focus of survivorship care research.2 
Despite these efforts, the evidence base for the impact of SCPs among cancer survivors is 
still inconclusive and directions for future implementation of SCPs remain under debate.3 
Randomized controlled trials (RTCs) failed to identify benefits of SCP delivery on patient 
satisfaction, quality of life and distress in various patient populations, including breast4,5, 
gynecological6-8, colorectal9 and prostate10 cancer. However, SCPs may be beneficial for 
selected subgroups of survivors, such as underserved populations11 and patients who do 
not use other sources of medical information such as the internet12, reflecting that we 
should focus on those individuals that benefit most from SCPs.
Ample research in health communication demonstrates that individuals respond differently 
to medical information, due to different coping strategies.13,14 Miller identified two main 
information coping styles for dealing with health threats such as cancer: ‘monitoring’ 
and ‘blunting’.15 Monitors typically seek for information relevant for them with regard to 
their health threat, while blunters prefer to avoid medical information and distract from 
it. Monitors report more anxiety related to their cancer treatment,16 they desire more 
voluminous and detailed information about their disease and tend to be more often 
dissatisfied with the information they receive.17 Conversely, among blunters, excessive 
information before a diagnostic procedure resulted in more self-reported tension, 
depression and physical discomfort among patients with a blunting coping style.18 Hence, 
in a sample of gynecologic patients at risk of cancer, stress reduction appears to be most 
optimal for monitors when they receive much information, while blunters respond better 
when they receive minimal information.19 These findings suggest that SCPs may be more 
beneficial for cancer survivors with a monitoring coping style compared to those with a 
blunting coping style.  
In efforts to improve future implementation of SCPs, we aim to assess whether information 
coping style moderates the impact of SCPs on patient reported outcomes among 
gynecological cancer patients in the pragmatic cluster-randomized ROGY Care Trial, 
including satisfaction with information provision and care, illness perceptions and health 
care use. In main analyses of this trial, the overall effects of SCPs among endometrial 
and ovarian cancer patients were assessed. We demonstrated that SCPs did not improve 
satisfaction with information provision and care, but increased worry, emotional impact 
and experienced symptoms among endometrial cancer patients7, and decreased trust 
in the treatment among ovarian cancer patients.8 Yet, we hypothesize that SCPs have a 
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positive effect on satisfaction with information provision and care, and health care use 
in patients with a monitoring coping style but not with a blunting coping style, whereas 
SCPs may increase threatening illness perceptions in patients with a blunting coping style 
but not with a monitoring coping style. 
METHODS
Design
The ROGY Care Trial is a pragmatic cluster-randomized controlled trial that aimed to 
assess the impact of automatically generated SCPs on patient reported outcomes among 
endometrial and ovarian cancer patients during 2-year follow-up. Twelve hospitals in the 
Netherlands were randomized to either ‘SCP care’ or ‘usual care’. The trial was centrally 
approved by a Medical Research Ethics Committee and is registered as NCT01185626 in 
clinicaltrials.gov. Further details about the design are described in the trial protocol.20
Participants and recruitment
After initial treatment, all patients newly diagnosed with endometrial cancer between 
April 2011 and October 2012, or ovarian cancer between April 2011 and March 2014, 
were invited to participate by their own gynecologist with a letter and an informed 
consent form. After consent, questionnaires were sent to the patient after treatment, 
and after 6, 12 and 24 months. Because of the pragmatic nature of the trial, exclusion 
criteria were limited. Only patients with a borderline ovarian tumor, undergoing palliative 
care or unable to complete a Dutch questionnaire were excluded from participation.20 
The current analysis only includes patients who completed the questionnaire assessing 
information coping style at 12 months after initial treatment (Appendix I). Primary effects 
of SCPs on patient reported outcomes in endometrial7 and ovarian8 cancer patients have 
been described previously.
Randomization and blinding
Randomization was performed via a table of random numbers, by an independent 
researcher blinded to the identity of the hospitals. Patients, but not oncology providers or 
researchers assessing the outcomes, were blinded to trial assignment.20
SCP care versus usual care
In the hospitals providing ‘usual care’, standard care was provided in accordance to the 
Dutch oncology guidelines (www.oncoline.nl). In the ‘SCP care’ hospitals, all oncology 
providers (gynecologist/gynecologic oncologist and oncology nurses) were instructed 
to provide an SCP to patients at the consultation where the results of histopathology 
and (adjuvant) treatment plan were discussed (i.e. 7-14 days after surgery). An updated 
version of the SCP could optionally be discussed in a follow-up consultation. Practical 
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guidelines were given on the components of the SCP that should minimally be discussed 
with each patient during the consultation.. The SCP was based on the Dutch translation of 
the American Institute of Medicine (IOM) SCP template,1 adjusted to the local situation.20 
Texts of the SCP were based on pilot-tested patient education material from the Dutch 
Cancer Society. In addition, the SCP was pilot-tested on patients with a low/intermediate 
educational level to ensure that the SCP was understandable. The SCP contained a 
treatment summary and a follow-up care plan, including detailed information on short- 
and long-term effects of the treatments received, effects on social and sexual life, 
possible signs of recurrence and secondary tumors, and information on rehabilitation, 
psychosocial support, and supportive care services. Details about the intervention20 and 
implementation21 have been described previously. 
Measures
Age, socio-economic status (SES) and clinical data were obtained from the Netherlands 
Cancer Registry (NCR).22 SES was based on postal code of the residence area of the 
patient, combining aggregated individual fiscal data on the economic value of the 
home and household incomes23 and categorized into low, medium or high. Additional 
socio-demographic information was assessed in the first questionnaire. Marital status 
(‘married/living together’ versus ‘divorced/widowed/never married’) and employment 
status (‘having a paid job’ versus ‘not having a paid job’) were dichotomized. Comorbidity 
was assessed by the adapted Self-administered Comorbidity Questionnaire (SCQ), and 
categorized into no comorbidities, one comorbidity or more than one comorbidity.24 
Disease-related internet use and receipt of an SCP (“Did you receive a Survivorship Care 
Plan?”) were dichotomous measures. 
Information coping style was assessed using the shortened version of The Threatening 
Medical Situations Inventory (TMSI)25, consisting of two hypothetical descriptions of 
medical situations. The internal consistency of the monitoring (Cronbach’s alpha=0.79) 
and blunting (Cronbach’s alpha=0.73) subscales were good and test-retest reliability has 
been established as sufficient for both scales (Pearson correlations 0.64-0.83).25,26 As 
described previously,15 a sum score was calculated by subtracting the blunting subscale 
from the monitoring subscale. Individuals with sum scores below or equal to the median 
were categorized as ‘monitors’ and individuals with scores above the median were 
categorized as ‘blunters’. 
Outcome scales were assessed in each questionnaire. Information provision was measured 
with the EORTC-QLQINFO25,27 using four multi-item subscales (information about the 
disease, medical tests, treatment and other care services) and four single-item scales 
(information about different places of care, things you can do to help yourself get well, 
satisfaction with the information, helpfulness of the information). Internal consistency of 
the scales in our sample (Cronbach’s alphas 0.75-0.90) were good. Test-retest reliability 
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(intraclass correlations 0.71-0.91) has been established as good previously.27 Satisfaction 
with care was assessed with the EORTC INPATSAT32 that was adjusted to make the 
questionnaire appropriate for use during survivorship care28 using two multi-item scales 
(doctor’s interpersonal skills and nurses’ interpersonal skills) and two singe-item scales 
(exchange of information between caregivers and general satisfaction with care). Internal 
consistency of the scales in our sample (Cronbach’s alphas 0.93-0.94) were good. Previously, 
test-retest reliability (intraclass correlations 0.66-0.85) have been established as good.28 
Illness perception was assessed with the Brief Illness Perception Questionnaire (B-IPQ).29 
Scales included eight single-item scales. Test-retest reliability (Pearson correlations 0.42-
0.75) was fair to good.29 Health care use was assessed by the number of visits to a medical 
specialist or primary care physician in relation to cancer in the past 6 months. 
Statistical Analysis
Statistical analyses were conducted using Statistical Analysis System (SAS) version 9.4. 
(SAS Institute, Cary, NC, 1999). Differences in characteristics between patients included 
in the analyses and lost to follow-up, between trial arms, and between patients with 
monitoring and blunting coping styles were compared using t-tests for normally 
distributed continuous variables, Mann-Whitney U-tests for not-normally distributed 
variables and chi-square tests for categorical variables. 
Linear multilevel regression analysis was performed to assess the moderating effect of 
information coping style on the impact of SCPs on patient reported outcomes. A random 
intercept on the patient-level was included in the model to adjust for intra-dependency 
between repeated measures. 30 Random intercepts on the hospital-level (ICCs<0.16) and 
random-slopes on the patient-level (ICCs<0.14) were not included because they did 
not improve the models.30 To assess the moderating effect of information coping style, 
an interaction term of information coping style and trial arm, and all a priori-selected 
covariates (i.e. cancer type, age, time since diagnosis, marital status, socio-economic 
status, employment, comorbidities, stage, and treatment) were added to the model. 
Dependent variables were the information provision and care-, illness perceptions-, and 
health care utilization-scales. For outcome scales where the interaction term of coping 
style and trial arm was significant, stratified analyses were by information coping style. 
For all analyses, patients in the ‘SCP care’ arm were compared to all patients in the ‘usual 
care’ arm (Intention-to-treat analysis). In addition, per-protocol analyses were conducted 
to compare patients in the ‘SCP care’ arm who reported having received an SCP to all 
patients in the usual care arm, because no SCPs were provided in the hospitals in the usual 
care arm. Interactions with cancer type were assessed by a three-way interaction of cancer 
type, coping style and trial arm. Prior analyses showed a moderating effect of disease-
related internet use on the outcome scales12. Therefore, we additionally assessed whether 
there was a three-way interaction between disease-related internet-use, information 
coping style and trial arm on any of the outcome scales, adjusted for covariates. 




In total, 221 endometrial cancer patients and 174 ovarian cancer patients participated in 
the trial. As described previously, endometrial cancer patients who did not participate in 
the trial were older and had higher cancer stages.7,8  Furthermore, endometrial cancer 
patients in the ‘SCP Care’ arm completed the questionnaire later after diagnosis compared 
to endometrial cancer patients in the ‘Usual Care’ arm.7 Ovarian cancer patients in the 
‘SCP Care’ arm had more comorbidities compared to ovarian cancer patients in the ‘Usual 
Care’ arm.8
Table 1: baseline characteristics of participants lost to follow-up versus participants included in 
analysis, stratified by cancer type, univariate analyses


















Age at first questionnaire
   Mean (SD) 65.9 (8.7) 71.3 (8.4) <0.01 61.9 (9.3) 65.9 (12.7) <0.01
SESa, n (%)
   High 55 (42) 18 (20) <0.01 39 (41) 29 (36) 0.85
   Intermediate 49 (37) 42 (47) 37 (39) 37 (46)
   Low 19 (15) 24 (27) 17 (55) 14 (17)
   Unknown 8 (6) 6 (7) 1 (1) 1 (1)
Marital statusb, n(%)
   Partner 106 (81) 55 (61) <0.01 74 (79) 57 (70) 0.20
   No partner 25 (19) 35 (39) 20 (21) 24 (30)
Employed, n (%)
   Yes 24 (18) 13 (14) 0.34 33 (35) 18 (22) 0.06
   No 98 (75) 66 (73) 61 (65) 63 (78)
Months from diagnosis, n(%)
   Median (IQR) 3.0 (1.8) 3.0 (1.6) 0.62 2.4 (2.4) 2.8 (2.5) 0.20
FIGO-stage, n (%)
   I 122 (93) 69 (77) <0.01 31 (33) 21 (26) 0.57
   II 3 (2) 4 (4) 10 (11) 6 (8)
   III 5 (4) 13 (14) 39 (41) 37 (46)
   IV 1 (1) 4 (4) 14 (15) 16 (20)
Treatment, n (%)
   Surgery 131 (100) 86 (97) 0.03 88 (96) 71 (88) 0.054
   Chemotherapy 2 (2) 13 (14) <0.01 71 (75) 64 (79) 0.58
   Radiotherapy 42 (32) 33 (37) 0.48
Comorbidity, n (%)
   None 24 (18) 14 (16) 0.17 29 (31) 27 (33) 0.33
   1 29 (22) 26 (29) 33 (35) 20 (25)
   2 or more 77 (59) 46 (51) 31 (33) 34 (42)
aSocio-economic status (SES) was based on postal code of the residence area of the patient. bMarital status included: partner 
= married/living together; no partner = divorced/widowed/never married.  The numbers may not always add up to 100, 
because percentages have been rounded off to whole numbers.
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Blunting Coping Style 
(N=102)
P-value 
Age at first questionnaire 
   Mean (SD) 63.3 (9.1) 65.4 (9.2) 0.10
SESa, n (%)
   High 54 (44) 41 (40) 0.30
   Intermediate 46 (37) 40 (39)
   Low 16 (13) 20 (19)
   Unknown 7 (6) 2 (2)
Marital statusb, n (%)
   Partner   108 (88) 72 (70) <0.01
   No partner 15 (12) 31 (30)
Employed, n (%)
   Yes 33 (28) 24 (24) 0.46
   No 83 (72 76 (76)
Cancer type, n (%)
   Endometrial 74 (60) 57 (55) 0.46
   Ovarian 49 (40) 46 (45)
Months from diagnosis, n(%)
   Median (IQR) 3.0 (2.0) 2.8 (2.2) 0.77
FIGO-stage, n (%)
   I 80 (65) 74 (72) 0.06
   II 8 (7) 5 (5)
   III 22 (18) 22 (21)
   IV 13 (11) 2 (1)
Treatment, n (%)
   Surgery 120 (98) 100 (98) 0.86
   Chemotherapy 42 (34) 31 (30) 0.52
   Radiotherapy 15 (17) 27 (19) 0.73
Comorbidity, n (%)
   None 31 (26) 22 (21) 0.86
   1 32 (26) 30 (29)
   2 or more 58 (48) 50 (49)
Disease-related internet use, n(%)
   Yes 67 (54) 36 (35) <0.01
   No 56 (46) 66 (65)
aSocio-economic status (SES) was based on postal code of the residence area of the patient. bMarital status included: partner 
= married/living together; no partner = divorced/widowed/never married.  The numbers may not always add up to 100, 
because percentages have been rounded off to whole numbers. Note: The monitoring and blunting groups are not of equal 
size because 19 patients had a median score on the TMSI.
The current analysis included 131 (59%) endometrial and 95 (55%) ovarian cancer patients 
who completed the questionnaire at 12 months after treatment (Appendix). Compared 
to patients lost to follow-up, patients included in the current analysis were younger, 
and endometrial cancer patients more often had a partner, a higher SES, lower cancer 
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stages, more often received surgery and less often chemotherapy (Table 1). Patients with 
a monitoring coping style more often had a partner  and more often used the internet 
to look up medical information  compared to patients with a blunting coping style (Table 
2). Additional analyses stratified by cancer type showed that ovarian cancer patients with 
higher cancer stages more often had a monitoring coping style (p<0.01). The monitoring 
and blunting groups are not of equal size because 19 patients had a median score on the 
TMSI.
There was no significant interaction between cancer type and information coping style 
for any of the outcome scales. Among both endometrial and ovarian cancer patients, 
information coping style significantly moderated the impact of SCPs on the outcomes 
scales shown in Table 3. No moderating effect of information coping style on the impact 
of SCPs was found on satisfaction with information about medical tests and other services, 
the interpersonal skills of the doctor, exchange of information between caregivers, 
perceptions about the timeline, personal control, treatment control, identity, emotions 
and understanding of the disease, and cancer-related contact with the medical specialist 
and primary care physician. Crude means at all time points stratified by information 
coping style and trial arm are shown in Figure 1. Overall, patients with a monitoring 
coping style were more satisfied with information and care, and had less threatening 
illness perceptions, compared to patients with a blunting coping style. Stratified multilevel 
linear regression analyses subsequently showed that among patients with a monitoring 
coping style, patients in the ‘SCP care’ arm compared to patients in the ‘usual care’ arm 
reported higher receipt of information about treatments (β=8.9, CI=2.2-15.5; p<0.01), 
information about things to do to get well (β=11.6, CI=3.3-19.9, p<0.01), satisfaction with 
information received (β=7.7, CI=0.3-15.1, p=0.04), perceived helpfulness of the information 
received (β=8.4, CI=1.4-15.3, p=0.02), and higher general satisfaction with care (β=6.2, 
CI=0.7; 11.8, p=0.03). Among patients with a blunting coping style, patients in the ‘SCP 
care’ arm compared to patients in the ‘usual care’ arm reported a higher impact of the 
disease on life (β=0.9, CI=0.2-1.7, p=0.02) and more concerns about the illness (β=1.1, 
CI=0.3-1.9, p=0.01; Table 3). In addition, a significant three-way interaction was observed 
between disease-related internet use and information coping style on the ‘helpfulness’ 
scale: patients in the ‘SCP care’ arm with a monitoring coping style who did not use the 
internet for medical information reported higher helpfulness of the information received 
(β=14.7, CI=3.4-25.9, p=0.01), while patients with a monitoring coping style who did use 
the internet for medical information did not (β=6.8, CI=-2.6-16.2, p=0.15). Per-protocol 
analysis, comparing patients in the ‘SCP Care’ arm who reported receipt of an SCP 
(endometrial, N=60, 87%; ovarian, N=24, 75%) with all patients in the ‘Usual Care’ arm 
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Table 3: Effects of the intervention in endometrial and ovarian cancer patients, stratified by infor-
mation coping style: Intention-to-treat analyses of the overall effects at all time points combined 
(0, 6, 12 and 24 months)
Monitoring Coping Style 
(Nsubjects=123, Nobservations=453)
















Satisfaction with information provision
  Disease 64.4 (20) 58.9 (22) 3.5 (-2.7; 9.7) 60.7 (19) 63.5 (23) -4.8 (-12.5; 2.8)
  Treatment 57.0 (24) 47.3 (24) 8.9 (2.2; 15.5)** 50.2 (24) 54.7 (27) -3.5 (-12.5; 5.6)
  Things to do 44.5 (29) 34.4 (30) 11.6 (3.3; 19.9)** 40.4 (32) 42.0 (36) -3.3 (-14.5; 8.0)
  Satisfaction 73.9 (23) 63.9 (24) 7.7 (0.3; 15.1)* 74.5 (21) 75.1 (25) -1.4 (-9.5; 6.7)
  Helpfullness 76.5 (24) 66.8 (22) 8.4 (1.4; 15.3)* 75.0 (21) 75.4 (24) -1.2 (-9.1; 6.8)
Satisfaction with care
  Nurse interpersonal skills 75.0 (19) 72.5 (19) 2.9 (-4.3; 10.2) 72.9 (18) 79.9 (20) -6.5 (-13.2; 0.3)
  General satisfaction with 
care 74.5 (18) 69.2 (19) 6.2 (0.7; 11.8)* 74.5 (17) 76.1 (20) -1.7 (-7.2; 2.9)
Ilness perceptions 
  How much illness affects life 5.4 (2.7) 5.2 (2.8) 0.0 (-0.7; 0.8) 5.0 (2.6) 4.5 (2.6) 0.9 (0.2; 1.7)*
  How concerned about illness 5.5 (2.7) 5.4 (2.9) 0.2 (-0.6; 1.1) 5.4 (2.4) 4.2 (2.6) 1.1 (0.3; 1.9)*
Note: Linear multilevel regression analyses were performed, stratified by coping style and adjusted for covariates. Only the 
scales where the interaction term was significant are shown. Analyses report the results of the main effect of the intervention 
after diagnosis, and after 6, 12 and 24 months, stratified by coping style. Values in bold indicate that the main effect of the 
intervention was significant in stratified analysis.* p<0.05 ** p<0.01.Crude means and standard deviations (SD) are reported 
for SCP Care and Usual Care. Unstandardized betas and confidence intervals are reported for SCP Care (ref=Usual Care). 
EORTC-QLQ-INFO25 and EORTC-IN-PATSAT32 scales ranging from 0-100: higher scores reflect better perceived information 
and care received. B-IPQ scale ranging from 1-10: higher scores indicate more endorsement of that item.
DISCUSSION
We demonstrated that information coping style moderates the impact of SCPs on patient 
reported outcomes among gynaecological cancer patients during 2-year follow-up. SCPs 
appear to improve satisfaction with information and care among patients who desire 
information about their disease (i.e. monitors), while SCPs seem to increase worry and 
perceived consequences of the cancer among patients who avoid medical information 
(i.e. blunters), suggesting a need for tailored delivery of SCPs. No moderating effect of 
coping style was found on health care use.
In line with literature regarding information coping styles,17,31 monitors were generally 
less satisfied with information and care compared to blunters, suggesting that there 
is room for improvement in patients with a monitoring coping style. Consistent with 
our hypothesis, SCPs appear to meet the high information needs among monitors by 
substantially increasing satisfaction in this subgroup (up to 12 points on a 0-100 scale), 
resulting in similar satisfaction levels as blunters. The other side of the coin is that 
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blunters, who generally have lower baseline levels of distress,32 appear to experience 
increased worry and a higher impact of the disease on life when they receive an SCP. 
This is consistent with a trial among gynecologic patients that shows that stress reduction 
among blunters is most optimal when they receive minimal information, as opposed 
to excessive information.19 Excessive information may increase arousal among blunters 
because they are confronted with detailed information about a health threat they did 
not worry about initially.18,25 In a sample of gynecologic patients with a blunting coping 
style, this resulted in self-reported tension, depression and physical discomfort before 
and during a diagnostic procedure.19 In contrast, an information brochure for patients 
undergoing gastrointestinal coloscopy was beneficial in reducing anxiety among patients 
with a monitoring coping style.18 Hence, our results are in line with previous health 
information intervention studies. 
In addition, we found that monitors more often used the internet to look up information 
about their disease compared to blunters, while SCPs appeared most helpful for monitors 
who did not do so. These findings suggest that SCPs are most valuable for patients that 
desire information about their disease but do not have access to resources such as the 
internet. This is in line with earlier findings from our trial that showed that endometrial 
cancer patients who did not use the internet benefited from SCPs.12 Notably, prior analyses 
of our trial demonstrated that more threatening illness perceptions due to the SCP (i.e. 
more worry, experienced symptoms and lower trust in the treatment) resulted in worse 
long-term health-related quality of life (HRQoL) and more anxiety.33 Therefore, we should 
be aware of potential harmful effects of SCPs in patients with a blunting coping style. Yet, 
appropriate counselling accompanied with the SCP may reduce the harmful effects on 
HRQoL.34
Interestingly, a previous publication of our trial demonstrated that SCPs increased cancer-
related contact with the primary care physician (PCP) among endometrial cancer patients 
in the first year after treatment7, which appeared to be related to anxiety.35 Therefore, we 
hypothesized that patients with an information coping style, who generally have higher 
levels of distress, would be more often encouraged to contact their care providers for 
additional questions and concerns with regard to the SCP. However, we did not find a 
moderating effect of information coping style on health care use. Perhaps, our findings 
were diluted by our overall analyses of all time-points combined. Unfortunately, numbers 
were too small to conduct analyses for each time-point separately. 
A limitation of this study includes the selective sample of patients that participated in 
our trial until at least 12 months after initial treatment to complete the questionnaires 
included in the current analysis. Patients of higher age and with higher cancer stages were 
more often lost to follow-up, which may be due to death or ill-health. As a consequence, 
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the number of patients in the current study was too small to conduct stratified analyses 
for endometrial and ovarian cancer patients separately, since our trial was powered on 
analyses of patients that were included from baseline (N=75 per trial arm per cancer 
type). Although there were no significant interactions with cancer type, the magnitude 
of the moderating effect of coping style may differ between cancer types. Further, 
although patients were told they participated in an observational study and response 
rates were high, patients with a blunting coping style may be underrepresented in our 
trial because they do not like to be reminded of their cancer32. This may have resulted in 
an underestimation of the potential harmful effects of SCPs among blunters. Further, due 
to our pragmatic approach, not all patients in the intervention arm reported receipt of an 
SCP, resulting in an underestimation of the impact when all patients would receive an SCP. 
Also, unlike most trials, SCPs were provided after initial treatment while some patients 
were still receiving adjuvant treatment. This may have enlarged the detrimental impact 
on illness perceptions among blunters because information may have been provided too 
early. 
Another limitation is that information coping style was assessed at 12 months after 
initial treatment. Although information coping style has shown to be fairly stable over 
a 1-month period,25,26 we found that ovarian cancer patients with higher cancer stages 
more often had a monitoring coping style. Although information coping style has not 
been associated with disease-related characteristics earlier,36 our finding may suggest 
that information coping style has been modified by the experience of a cancer diagnosis, 
and possibly even by the receipt of an SCP. Yet, the distribution of monitors and blunters 
did not differ between trial arms, indicating that this probably did not affect our results. 
It does, however, imply that repeated assessments of information coping style may be 
needed in order to provide appropriate information when needs have been changed. 
Further, there is no consensus on whether the outcomes in our analysis such as patient 
satisfaction are the most relevant in evaluations of SCPs. Future studies may need to focus 
on more proximal outcomes, such as the understanding of survivorship care issues, care 
provider roles, self-management and sense of control.3,37 
It is important to note that the SCPs provided in our trial were extensive documents (i.e. up 
to 25 pages), containing detailed information about potential long-term and late effects 
and explicit information about chance of recurrence.20 The impact of such a voluminous 
SCP may be much higher compared to treatment summaries or brief SCPs comprising 
only a couple of pages of information.38 Yet, these extensive SCPs may principally meet the 
high information needs of monitors, while brief SCPs may be more beneficial for blunters. 
The heterogeneity of information needs among cancer survivors may also explain why 
neither brief nor extensive SCPs appear to be beneficial for patient populations as a whole 
in current SCP trials.3 Hence, either withholding information or providing information to all 
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patients uniformly would not utilize patient satisfaction. Rather, we may need to develop 
distinct templates of SCPs that are tailored to patients’ information needs, which would not 
only improve survivors’ outcomes, but may also contribute to a more efficient distribution 
of the limited resources in survivorship care. Hence, we feel that risk stratification according 
to information and care needs, similar as applied in individualized follow-up,39 is needed 
to accomplish effective and efficient survivorship information provision. Whether SCPs 
should be individualized according to information ‘dose’ only (i.e. extensive versus brief 
SCPs), or also on content (i.e. focus on physical versus psychological aspects)40, requires 
further research. Possibly, a simple set of screening questions to determine information 
needs may be sufficient to utilize tailored SCPs in clinical practice, although repeated 
assessments may be required as needs may change over time. This may be particularly 
feasible in a setting where information is provided online. Further, our findings may apply 
to other types of health information provision, suggesting that careful evaluation of the 
effects of various information prevision interventions across coping styles is needed 
before implementation in clinical practice. 
Conclusion
Although SCPs may not be helpful for all cancer survivors,7,8 they appear valuable for 
subgroups of survivors. We demonstrated that SCPs may be beneficial for patients who 
desire detailed information about their cancer, while they may be less beneficial and 
perhaps even harmful for patients who prefer to avoid medical information. Our study 
emphasizes the need to individualize delivery of SCPs according to patients’ information 
needs.
















 (n=180, 73%) 
 
Patients receiving questionnaire
 Endome trial (n=154), ovarian (n=91) 
Patients com pleting questionnaire 
  Endome trial (n=119, 77%), ovarian (n=61, 67%) 
Refused participation (n=65) 
     Endometrial (n=35), ovarian (n=30) 
Patients wanting to stop after 1 questionnaire (n=42) 
Endome trial (n=32), ovarian (n=10)
(n=299) 
After treatment 
Patients receiving questionnaire 
 Endometrial (n=142), ovarian (n=157) 
Patients completing questionnaire  (n=215, 72%) 
     Endometrial (n=102, 72%), ovarian (n=113, 72%) 
Refused participation (n=84) 
     Endometrial (n=40), ovarian (n=44) 
Patients wanting to stop after 1 questionnaire (n=42) 
 Endometrial (n=21), ovarian (n=21) 
(n=138) 
6 months 
Patients recei ving a questionnaire 
 Endomet rial (n=87), ovarian (n=51) 
Patients com pleting the questionnaire  (n=129, 93%) 
     Endomet rial (n=85, 98%), ovarian (n=44, 86%) 
Refused parti cipation: endometrial (n=2), ovarian (n=3) 
Deceased:  endometrial (n=0), ovarian (n=4) 
12 months 
Patients receiving a questionnaire    (n=134) 
 Endometrial (n=87), ovarian (n=47) 
Patients completing the questionnaire  (n=114, 85%) 
 Endometrial (n=79, 91%), ovarian (n=35, 74%) 
Refused participation: endometrial (n=7), ovarian (n=7) 
Deceased:  endometrial (n=1), ovarian (n=5) 
24 months
Patients recei ving a questionnaire (n=110) 
 Endometrial (n=70), ovarian (n=40) 
Patients completing the questionnaire  (n=98, 89%) 
 Endometrial (n=69, 99%), ovarian (n=29, 73%) 
Refused participation: endometrial (n=8), ovarian (n=8)
Deceased: endometrial (n=2), ovarian (n=4)
6 months 
Patients receiving a questionnaire (n=172) 
 Endometrial (n=81), ovarian (n=91) 
Patients completing the questionnaire (n=153) 
 Endometrial (n=73), ovarian (n=80) 
 Refused participation: endometrial (n=7), ovarian (n=7) 
(n=167) 
 Deceased: endometrial (n=1), ovarian (n=4) 
12 months 
Patients receiving a questionnaire 
Endometrial (n=80), ovarian (n=87) 
Patients completing the questionnaire  (n=134, 80%) 
     Endometrial (n=68, 85%), ovarian (n=66, 76%) 
Refused participation: endometrial (n=10), ovarian (n=13) 
Deceased: endometrial (n=2), ovarian (n=8) 
24 months 
Patients receiving a questionnaire (n=140) 
 Endometrial (n=69), ovarian (n=71) 
Patients completing the questionnaire  (n=105, 75%) 
 Endometrial (n=59, 86%), ovarian (n=46, 65%) 
Refused participation: endometrial (n=10), ovarian (n=17)







     Endome trial (n=69), ovarian (n=32) 
6 months follow-up  
     Endometrial (n=69), ovarian (n=32) 
12 months follow-up  
     Endometrial (n=69), ovarian (n=32) 
24 months follow-up  (n=88) 
Endometrial (n=61), ovarian (n=27)
Hospitals allocated to intervention (n=6) 






     Endometrial (n=62), ovarian (n=62) 
6 months follow-up  
     Endometrial (n=62), ovarian (n=62) 
12 months follow-up  
     Endometrial (n=62), ovarian (n=62) 
24 months follow-up  (n=94) 
Endometrial (n=51), ovarian (n=43)
Hospitals allocated to usual care (n=6) 
Received allocated usual care  (n=6) 
Analysis 
Randomized hospitals (n=12) Enrollment 
Enrollment of patients 
Allocation 
After treatment 
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Survivorship Care Plans have a negative impact on long-
term quality of life and anxiety through more threatening 
illness perceptions in gynecological cancer patients 
– the ROGY care trial








L.V. van de Poll-Franse 




Purpose: Prior results from the ROGY care trial showed that Survivorship Care Plans 
(SCPs) increased threatening illness perceptions in gynecological cancer survivors, but it 
remained unclear whether this would result in poorer physical and psychosocial outcomes. 
The aim of the current study is to assess the direct and indirect effects of SCPs on health-
related quality of life (HRQoL) and anxiety and depression, through illness perceptions.
Methods: Twelve hospitals in the South of the Netherlands were randomized to 
providing ‘SCP care’ or ‘usual care’. Newly diagnosed endometrial and ovarian cancer 
patients completed questionnaires after initial treatment (endometrial, 221 [75%]; ovarian, 
174 [71%]) and after 6, 12 and 24 months. SCPs were automatically generated after 
initial treatment by the oncology providers through the web-based Registration system 
Oncological GYnecology (ROGY). Illness perceptions were measured after initial treatment 
and HRQoL and anxiety and depression after 6, 12 and 24 months. 
Results: Structural equation models showed that endometrial cancer patients who 
experienced more symptoms or concern due to the SCP reported worse social functioning 
(β=-0.82; P=0.01) and more fatigue, insomnia, pain and anxiety (β=0.58-0.86, P<0.05) 
within 12 months after treatment. Ovarian cancer patients who had lower trust that the 
treatment would cure their disease due to the SCP reported worse emotional functioning 
6 months after treatment (β=0.27, P=0.02).
Conclusions: Current results show that SCPs may have negative effects on HRQoL and 
anxiety in patients who experience more threatening illness perceptions due to the SCP. 
We should be aware of the potential negative consequences of SCPs.




Over the last decade, Survivorship Care Plans (SCPs) have been recommended as a 
standard of care for all cancer patients. SCPs contain written information to support 
patients in their physical and psychological challenges in life after treatment.1 To date, 
a limited number of randomized controlled trials (RCTs) have been conducted to assess 
the impact of SCPs on patient reported outcomes.2-7 As opposed to observational and 
qualitative studies,8,9 RCTs failed to identify beneficial effects of SCPs on patient satisfaction 
with information provision and care, quality of life or distress.2-5,7,10 However,  SCPs may 
be beneficial for underserved patient populations.6 The Registration system Oncological 
GYnecology (ROGY) care trial was the first pragmatic cluster randomized controlled trial 
that assessed the impact of automatically generated SCPs, and did find a negative effect 
on illness perceptions.5,10
Illness perceptions are generally defined as a patient’s belief about the disease through 
cognitive representations, including the perceived impact on life, duration of the illness, 
experienced symptoms and treatment trust, and also emotional representations, including 
concern, emotional impact and personal control over illness.11 In the ROGY care trial, 
SCPs caused more threatening illness perceptions: they increased experienced symptoms, 
emotional impact and concern in endometrial cancer patients,5 and led to lower trust that 
the treatment would help to cure the disease in ovarian cancer patients.10
Previous studies in cancer patients show that more threatening illness perceptions 
are associated with poorer quality of life and more psychological morbidities12-18 in 
accordance with Leventhals’ common-sense model of self-regulation (CSM). CSM 
presumes that individuals who are confronted with a health threat (i.e. cancer diagnosis) 
form illness perceptions, which impact physical and psychosocial outcomes through 
coping responses.11,19 To support emotional coping, psychological interventions have 
been developed that aim to decrease psychological distress after an event such as a 
cancer diagnosis.20 Exposure therapies, such as psychological debriefing do not seem 
to decrease psychological morbidity, but may even worsen it due to exacerbation of 
the symptoms.21  Similarly, SCPs containing extensive information on the disease and 
potential side-effects may exacerbate psychological distress and symptoms experienced 
among cancer patients. Consequently, prior results of the ROGY care trial suggest that 
SCPs may intervene in the pathway of the CSM by causing more threatening illness 
perceptions,5,10 which may in turn affect physical and psychosocial outcomes. However, 
no evidence exists on the possible causal relationships between SCP provision, illness 
perceptions and physical and psychosocial outcomes. It is important to consider the 
potential negative consequences of threatening illness perceptions due to SCPs before 
widespread implementation is decided upon. 
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The aim of the current study is to assess whether SCPs have a negative effect on long-term 
health-related quality of life (HRQoL), anxiety and depression in patients who experience 
more threatening illness perceptions due to the SCP. Illness perceptions scales that have 
earlier shown to be affected by SCPs5,10 (i.e. increased experienced symptoms, concern 
and emotional impact in endometrial cancer, and lower treatment trust in ovarian cancer) 
are included in the current analysis. We hypothesize that SCPs have a negative impact on 
HRQoL, anxiety and depression through more threatening illness perceptions.
METHODS
Design
The ROGY care trial among endometrial and ovarian cancer patients aimed to assess the 
longitudinal impact of automatically generated SCPs on patient reported outcomes. A 
cluster-randomized design was used to avoid potential contamination between the trial 
arms. Twelve hospitals in the Netherlands were randomly allocated to either ‘usual care’ 
or ‘SCP care’. The trial was centrally approved by a Medical Research Ethics Committee22 
and was registered as NCT01185626 in clinicaltrials.gov.
Participants and recruitment
All newly diagnosed women with endometrial cancer as a primary tumor between April 
2011 and October 2012, or ovarian cancer between April 2011 and March 2014, were 
invited to participate shortly after initial treatment, by means of a letter and an informed 
consent form, sent directly to the patients’ home address by their own gynecologist. After 
consent, questionnaires were sent after treatment and follow-up questionnaires were sent 
at 6, 12 and 24 months after treatment (Appendix I). 
Because of the pragmatic nature of the trial, exclusion criteria (i.e. borderline ovarian 
tumor, undergoing palliative care or unable to complete a Dutch questionnaire) were 
limited 22. Earlier analysis showed that 73% of endometrial and 66% of ovarian cancer 
patients in the SCP care arm reported receipt of an SCP 23. In the current analysis, all 
patients of both trial arms were included (intention-to-treat) to reflect real-life clinical 
practice in which not all patients receive an SCP.
Randomization and blinding
To prevent imbalance between the trial arms, stratified randomization was used according 
to whether a hospital has a Gynecologic Oncology Center, and the annual number of 
endometrial and ovarian cancer patients diagnosed in each hospital. Randomization was 
performed via a table of random numbers, by an independent researcher blinded to the 
identity of the hospitals. Patients, but not oncology providers or researchers assessing the 
outcomes, were blinded to trial assignment.22
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SCP care versus usual care
In ‘usual care’ hospitals, standard care was provided in accordance to the Dutch follow-up 
guidelines (www.oncoline.nl). In most hospitals, verbal information and the generic 
brochures of the Dutch Cancer Society were provided.22 None of the hospitals provided 
SCPs as developed for this study.
In the ‘SCP care’ hospitals, all oncology providers (gynecologist/gynecologic oncologist 
and oncology nurses, N=24) attended an instruction evening devoted to when and how 
SCPs should be provided. They were instructed to provide an SCP to patients at the 
consultation where the results of histopathology and (adjuvant) treatment plan were 
discussed, mostly 7-14 days after surgery. If applicable (i.e. if there were any changes 
in the cancer, treatment or oncology provider), an updated version of the SCP could 
optionally be discussed in a follow-up consultation. Practical guidelines were given on the 
components of the SCP that should minimally be discussed with each patient during the 
consultation (i.e. diagnosis, prognosis, treatment(s), most important side-effects). Because 
of the pragmatic approach of the trial, care providers in the ‘SCP care’ arm were free to 
choose whether the gynecologist/gynecologic oncologist, or oncology nurse provided 
the SCP fitting their clinical practice.22
Survivorship care plan
The SCP was based on the Dutch translation of the American Institute of Medicine 
(IOM) SCP template1, adjusted to the local situation.22 by a group of gynecologists/
gynecologic oncologists, oncology nurses, a radiotherapist, medical oncologist, primary 
care physician, and patients.22 The SCP consisted of information on diagnostic tests, type 
of cancer, stage, grade and treatments received and contact details of the hospital and 
medical specialists. In addition, the SCP contained a tailored follow-up care plan, including 
detailed information on the most common short- and long-term effects of the treatments 
received, effects on social and sexual life, possible signs of recurrence and secondary 
tumors, and information on rehabilitation, psychosocial support, and supportive care 
services.22 Texts of the SCP were based on pilot-tested patient education material from 
the Dutch Cancer Society. In addition, the SCP was pilot-tested on patients with a low/
intermediate educational level to ensure that the SCP was understandable.
Measures
Age, socio-economic status (SES) and clinical data, such as cancer type, cancer stage 
and date of diagnosis, were obtained from the Netherlands Cancer Registry (NCR). 
The NCR routinely collects data on newly diagnosed cancer patients in all hospitals in 
the Netherlands.24 SES was based on postal code of the residence area of the patient, 
combining aggregated individual fiscal data on the economic value of the home and 
household incomes.25 SES was categorized into low, medium or high. Additional socio-
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demographic information (i.e. marital status, employment status and comorbidities) 
was assessed in the first questionnaire. Marital status (‘married/living together’ versus 
‘divorced/widowed/never married’) and employment status (‘having a paid job’ versus ‘not 
having a paid job’) were dichotomized. Comorbidity was assessed by the adapted Self-
administered Comorbidity Questionnaire (SCQ), and categorized into no comorbidities, 
one comorbidity or more than one comorbidity.26
The Brief Illness Perception Questionnaire (B-IPQ) was used to assess illness perceptions 
after initial treatment.27 The B-IPQ includes eight single-item scales (impact of disease on 
life, perceived duration of illness, personal control over illness, trust that the treatment 
would help to cure the illness, experienced symptoms, concern about the illness, 
understanding of the illness and emotional impact of the illness).Only the scales that have 
earlier shown to be affected by SCPs in our trial 5,10 were used in the analysis, including the 
amount of symptoms experienced, concerns about the illness, emotional impact of the 
illness with respect to endometrial cancer, and trust that the treatment would help to cure 
with respect to ovarian cancer.28 The latter scale was reversed to ascertain that all B-IPQ 
scales were one-directional: a higher score indicates more threatening illness perceptions. 
Test-retest reliability (Pearson correlations 0.42-0.75) was fair.27
The EORTC QLQ-C30 (version 3.0) was used to assess HRQoL 6, 12 and 24 months after 
diagnosis.29 It contains five functional scales on physical, role, cognitive, emotional and 
social functioning, a global QoL scale, three symptom scales on fatigue, nausea and 
vomiting, and pain, and six single items. Response scales included: ‘Not at all’, ‘A bit’, 
‘Quite a bit’, and ‘Very much’, except for the global QoL scale, which ranges from ‘Very 
poor’ to ‘Excellent’. Latent variables of the scales were defined by the items of each scale.30 
Higher scores on global quality of life and the function scales indicate a better HRQoL, 
while higher scores on the symptom scales indicate more symptoms. Test-retest reliability 
was good (Pearson correlations=0.82-0.91).31 Internal consistency of the multi-item scales 
(Cronbach’s alphas 0.71-0.92) in our study was good.
The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of 
anxiety and depression 6, 12 and 24 months after diagnosis.32 The HADS assesses separate 
anxiety and  depression scales, which both consist of 7 items. All items were scored on a 
0 to 3-point scale, with higher scores indicating more symptoms. Test-retest reliability of 
the scales (Pearson correlations=0.86-0.88) was good.32 Internal consistency of the scales 
(Crohnbach’s alphas 0.71-0.77) in our study was good.
Statistical Analysis
Statistical analyses were conducted using Statistical Analysis System (SAS) version 9.4. (SAS 
Institute, Cary, NC, 1999). Differences in characteristics of patients between the trial arms 
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for endometrial and ovarian cancer were compared using independent samples t-tests 
for normally distributed continuous variables, Mann-Whitney U-tests for not normally 
distributed variables and chi-square tests for categorical variables. Differences in baseline 
B-IPQ scores between the trial arms were assessed using chi-square tests of categorical 
variables defined by the 25th, 50th, 75th and 100th percentile scores of the separate B-IPQ 
scales.
Pearson’s correlation coefficients were computed to assess the correlations between the 
illness perception scales at baseline and outcomes (HRQoL, anxiety and depression) 6, 
12, and 24 months after initial treatment, for endometrial and ovarian cancer separately. 
P-values smaller than .05 were considered to be statistically significant.
Structural equation models (SEM) were used to test the hypothesized causal relationships 
between trial allocation (SCPs), illness perceptions and the HRQoL, and anxiety and 
depression scales, with a linear equation system. SEMs are used to assess unobservable 
‘latent’ variables by using observed variables, and to assess the relationships between 
those (observed and latent) variables.33 Both direct and indirect effects of trial allocation 
on outcome variables were assessed using the effpart statement in the CALIS procedure in 
SAS. Direct effects would indicate an effect of SCPs on the outcome scales in all patients, 
while indirect effects would indicate an effect of SCPs on the outcome scales in patients 
who have altered illness perceptions due to the SCP.  Statistical power was sufficient to 
detect indirect effects, but low to detect direct effects.34 The CALIS procedure was used 
to define the model paths (i.e. hypothesized relationships between variables). First, simple 
mediation models were built to assess the direct and indirect effects of trial allocation 
on the separate outcome scales (HRQoL, anxiety and depression scales) 6, 12 and 24 
months after initial treatment. Mediators were the separate BIPQ scales measured after 
initial treatment that have earlier shown to be associated with trial allocation (i.e. increased 
experienced symptoms, concern and emotional impact in endometrial cancer, and lower 
treatment trust in ovarian cancer; Fig 1). Models were defined for endometrial and ovarian 
cancer separately. The paths in each simple mediation model were defined as:  trial 
allocation ---> [BIPQ item score after diagnosis] ---> [outcome variable at time-point X]. 
When outcome scales consisted of multiple items, a latent variable was defined by the 
items of that scale. When standardized factor loadings of scale items were low (β<0.6), 
they were removed from the model to obtain a better model fit.35 When (semi-)complete 
separation of the outcome scales occurred, no SEM could be determined.36 Second, the 
full SEMs were built by entering all significant paths (P<0.05) of the simple mediation 
models into one model, for endometrial and ovarian separately, and for each time-point 
separately. Third, the insignificant paths (p>0.05) were removed from the model to obtain 
a good model fit. Finally, the covariates that were significantly associated with any of 
the outcome scales were entered into the model. For all SEM models, full information 
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maximum likelihood (FIML) was used, which handles missing data within the model 
without needing to impute data.37 Model fit was assessed with the chi2 statistic, adjusted 
goodness-of-fit-index (AGFI), Bentler’s comparative fit index (CFI), standardized root 
mean squared residual (SRMR) and root mean squared error approximation (RMSEA).38 
Standardized beta coefficients were used to interpret the models, and range from -1 to 
1, in which coefficients closer to zero indicate smaller effects. An increase of 1 standard 
deviation of the independent variable corresponds to an increase in standard deviation 
of the dependent variable by the standardized beta coefficient.39 Standardized beta 
coefficients of indirect effects can be considered small (0.05-0.10), moderate (0.1-0.25) or 
large (>0.25).39
RESULTS
Table 1 shows the clinical and socio-demographic baseline characteristics for both 
endometrial and ovarian cancer patients in the SCP care and usual care conditions. In 
endometrial cancer, patients in the ‘SCP care’ took more time after diagnosis to complete 
the questionnaires than patients in the ‘Usual care’ arm (p<0.01). No differences in baseline 
characteristics were found between the trial arms in ovarian cancer patients. 
Figure 1 shows the differences in illness perceptions between the SCP care and usual 
care arms. Significantly more endometrial patients in the SCP care arm compared to 
the usual care arm reported high experienced symptoms (18% vs. 9%, p=0.02) and 
high concerns about the illness (16% vs. 7%, p=0.02). No significant differences between 
the trial arms were found in emotional impact of the disease (19% vs. 14%, p=0.27) in 
endometrial cancer, or low trust that the treatment would help to cure the illness (16% vs. 
14%, p=0.60) in ovarian cancer. However in earlier multilevel linear mixed model analyses, 
SCPs significantly increased threatening illness perceptions on these scales.5,10
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Table 1: baseline clinical and socio-demographic characteristics endometrial and ovarian cancer 
patients, SCP care versus usual care












   Mean (SD) 67.4 (9.1) 67.8 (8.9) 0.71 63.6 (11.2) 64.3 (10.7) 0.67
SESa, n (%)
   High 43 (36) 36 (35) 0.60 25 (41) 44 (39) 0.12
   Intermediate
49 (41) 42 (41) 15 (25) 44 (39)
   Low 21 (18) 22 (22) 12 (20) 18 (16)
   Unknown 6 (5) 2 (2) 9 (15) 7 (6)
Months since diagnosis, n(%)
   Median 2.2 1.5 <0.01 3.0 2.4 0.31
   <1 12 (10) 24 (24) 8 (13) 26 (23)
   1-2 40 (34) 46 (45) 18 (30) 39 (34)
   2-3 33 (28) 20 (20) 8 (13) 17 (15)
   >3 34 (29) 12 (12) 27 (44) 32 (28)
Comorbidity, n(%)
   None 19 (16) 18 (18) 0.53 21 (34) 28 (25) 0.18
   1 32 (27) 20 (20) 12 (20) 36 (32)
   2 or more 64 (54) 62 (61) 26 (43) 48 (36)
   Unknown 4 (3) 2 (2) 2 (3) 8 (7)
Marital statusb, n(%)
   Partner
   85 (71) 76 (75) 0.74 48 (79) 82 (73) 0.39
   No partner 31 (26) 25 (25) 13 (21) 31 (27)
   Unknown 3 (3) 1 (1) 0 (0) 0 (0)
Employed, n (%)
   Yes 22 (18) 15 (15) 0.40 20 (33) 31 (27) 0.44
   No 85 (71) 79 (77) 41 (67) 83 (73)
   Unknown 12 (10) 8 (8) 0 (0) 0 (0)
FIGO-stage, n (%)
   I 102 (85) 89 (87) 0.34 21 (34) 31 (27) 0.63
   II 6 (5) 1 (1) 7 (11) 9 (8)
   II 9 (8) 9 (8) 23 (38) 50 (44)
   IV 2 (2) 3 (3) 10 (16) 20 (18)
  Unknown 0 (0) 0 (0) 0 (0) 3 (3)
Treatment, n (%)
   Surgery
   117 (99) 97 (98) 0.46 54 (88) 104 (93) 0.33
   Chemotherapy 6 (5) 12 (12) 0.06 44 (72) 92 (82) 0.13
   Radiotherapy 44 (37) 37 (37) 0.99
aSocio-economic status (SES) was based on postal code of the residence area of the patient. bMarital status included: partner 
= married/living together; no partner = divorced/widowed/never married.  The numbers may not always add up to 100, 
because percentages have been rounded off to whole numbers.
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Table 2 shows the correlations between illness perception scales after diagnosis and 
HRQoL, anxiety and depression after 6, 12 and 24 months, corrected for multiple testing 
(Bonferroni correction, α<0.003). Consistent with our hypothesis, in both endometrial and 
ovarian cancer, significant moderate negative Pearson’s correlations were found between 
B-IPQ items and functioning scales (r= -0.25 to -0.41, p<0.003). Significant moderate 
positive Pearson’s correlations were found between B-IPQ items and symptom scales 
(r=0.27 – 0.41, p<0.003), and between B-IPQ scales and anxiety and depression (r= 0.28 
– 0.46, p<0.003). 
Note: Only the illness perception items were included that have earlier been associated with trial allocation. High, med-high, 
med-low, and low illness perception categories were defined by the 25th, 50th, 75th and 100th percentile scores of each B-IPQ 
scale separately





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The SEM models showed no direct effects of SCPs on HRQoL, anxiety and depression scales. 
However, indirect effects trough illness perceptions were observed. In endometrial cancer, 
SCPs indirectly increased fatigue, insomnia and anxiety after 6 months (standardized, 
β=0.58, SE=0.09, p<0.01; β=0.69, SE=0.08, p<0.01; β=0.58, SE=0.09, P=0.01), through 
more experienced symptoms (standardized, β=0.21, SE=0.09, p=0.02; Fig 2). Model fit 
was reasonable to good (AGFI=0.87; CFI=0.93; SRMR=0.07; RMSEA=0.047 [95% CI=0.03-
0.06]; Chi2=87.2, P<0.01) and effect sizes of the indirect effects are moderate (standardized, 
β=0.12, SE=0.06, p=0.03; β=0.15, SE=0.06, p=0.02; β=0.12, SE=0.05, p=0.03).39 Further, SCPs 
indirectly decreased social functioning after 12 months (standardized, β=-0.82, SE=0.06, 
p<0.01), and increased fatigue and pain after 12 months (standardized, β=0.84, SE=0.05, 
p<0.01; β=0.86, SE=0.05, p<0.01), through more concern (standardized, β=0.25, SE=0.09, 
p<0.01;Fig 2). Model fit was good (AGFI=0.90; CFI=0.98; SRMR=0.046; RMSEA=0.04 
[95% CI=0.00-0.06]; Chi2=34.4, P=0.08) and the effect sizes of the indirect effects were 
moderate (standardized, β=- 0.20, SE=0.07, p<0.01; β= 0.21, SE=0.07, P<0.01; β= 0.22, 
SE=0.08, p<0.01)39. In ovarian cancer, SCPs indirectly decreased emotional functioning 
after 6 months (standardized, β=-0.66, SE=0.20 p<0.01), through lower trust that the 
treatment would help to cure the disease (standardized, β=0.27, SE=0.12, p<0.05) (Fig 2). 
Model fit was good (AGFI=0.90; CFI=0.96; SRMR=0.06; RMSEA=0.06 [95% CI=0.01-0.09]; 
Chi2=23.1, P=0.04), and the effect size of the indirect effect was moderate (standardized, 
β=- 0.18, SE=0.08, p=0.02)39. No significant paths in the simple mediation models were 
found for outcomes after 24 months, for both endometrial and ovarian cancer. 
DISCUSSION
The current study among endometrial and ovarian cancer patients shows that SCPs 
have a negative impact on long-term HRQoL and anxiety in patients who experience 
more threatening illness perceptions due to the SCP. Endometrial cancer patients who 
experience more symptoms or concerns due to the SCP, report worse social functioning 
and more fatigue, insomnia, pain and anxiety in the year following treatment. Ovarian 
cancer patients who have lower trust that the treatment would cure their disease due to 
the SCP report worse emotional functioning 6 months after initial treatment. 
Earlier findings from the ROGY Care trial already showed that SCPs increased threatening 
illness perceptions: higher experienced symptoms, concern and emotional impact 
in endometrial cancer patients, and decreased trust that the treatment would help to 
cure the disease in ovarian cancer patients.5,10 However, it was yet unclear whether these 
threatening illness perceptions would deteriorate long-term physical and psychosocial 
outcomes. Our study confirms earlier findings in cancer patients that more threatening 
illness perceptions are associated with worse physical and psychosocial outcomes.12-18 
Consequently, our analyses confirmed that threatening illness perceptions due to the 
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Note: only the significant paths between the intervention (SCP), illness perception items, and outcome scales were entered 
in this model to obtain good model fit. Standardized coefficients are shown. Standardized beta coefficients were used to 
interpret the models, and range from -1 to 1, in which coefficients closer to zero indicate smaller effects.  Error terms and 
covariates in the model (age, FIGO stage, number of comorbidities) have been removed from the figure. *P<0.05, **P<0.01.




SCP led to worse HRQoL and more anxiety. Although no direct effects of SCPs were 
found, our results support our hypothesis that SCPs have a negative impact on HRQoL 
and anxiety through more threatening illness perceptions, consistent with Leventhal’s 
CSM.11Illness perceptions that mediated between SCP provision and HRQoL and anxiety 
were experienced symptoms and concern in endometrial cancer, and low treatment 
trust in ovarian cancer patients. Possibly, endometrial cancer patients, who are often 
diagnosed with low cancer stages, may perceive their cancer as a more serious condition 
due to information provided in the SCP (i.e. the diagnosis and treatments received, 
possible long-term and late effects, and chance of recurrence) than would otherwise 
be communicated by the oncology provider. The overall perception of a more serious 
condition in endometrial cancer patients may have caused higher symptom awareness, 
more anxiety and the belief that one is unable to participate in social activities.17 In ovarian 
cancer patients, who are more often diagnosed at advanced stages, the SCP led to 
lower treatment trust, possibly due to information on chance of recurrence in the SCP. 
Although this information may be realistic, it led to decreased emotional functioning after 
6 months, meaning that patients felt more tense, worried, irritable or depressed. Indeed, 
fear of recurrence has earlier been found to be most strongly associated with emotional 
functioning, of all EORTC QLQ-C30 functioning scales.40
A limitation of the current study is that not all patients in the SCP arm reported receipt of 
an SCP.23 A process evaluation of the ROGY Care Trial showed that ovarian cancer patients, 
older patients and patients who have a distressed (type D) personality less often received 
an SCP.23 We performed intention-to-treat analysis to reflect real-life clinical practice in 
which not all patients receive an SCP. Therefore, our results possibly underestimate the 
effects of SCPs on HRQoL, anxiety and depression in the total population, as patients with 
a type D personality may be more likely to experience threatening illness perceptions 
due to the SCP.41 Further, as shown earlier,10 ovarian cancer patients with higher cancer 
stages were more often lost to follow-up due to death or ill-health, and were therefore 
not included in our longitudinal analyses. Therefore, current results in ovarian cancer may 
represent the healthier patient with lower cancer stages. However, we aimed to minimize 
selection bias by limiting exclusion criteria and our response rates were relatively high.
Our SEM analyses violated the well-known recommendation of Baron and Kenny’s (1986) 
that a significant relationship between the independent variable (SCPs) and outcome 
(HRQoL, anxiety and depression) is required, in order to evaluate mediation effects.42 
However, this recommendation has since been criticized.34,43 Kenny and Judd (2014) argued 
that sample sizes needed to detect direct effects between independent and dependent 
variables, should be much larger than to detect indirect effects through mediation.34 
Therefore, our sample sizes of endometrial and ovarian cancer separately, were too small 
to detect direct effects of SCPs on the outcome scales. Possibly, direct effects of SCPs on 
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the outcome scales would be found in larger sample sizes. An alternative explanation 
of our findings is the presence of a suppressing mediator, such as coping, which may 
ameliorate the indirect impact of SCPs on physical and psychological outcomes, while at 
the same time illness perceptions deteriorate the indirect impact of SCPs on outcomes. 
Therefore, there may be indirect effects but no direct effects of SCPs on HRQoL and 
anxiety,43 which would indicate that the impact of SCPs works differently across coping 
styles.
In earlier studies of the ROGY care trial,5,10 we argued that information provided in an 
SCP could be perceived as threatening but may also be realistic. Providing patients with 
honest and realistic information may be considered best to prepare patients for potential 
consequences of the cancer and cancer treatments, or would encourage patients to 
find social support to cope with the disease.44 However, the current study shows that 
realistic information is not self-evidently beneficial for all patients. Instead, patients may 
attain worse expectations about negative outcomes such as side-effects or a recurrence, 
which has shown to potentially cause clinical worsening (“nocebo effect”).45 Similarly, 
psychological interventions that expose individuals to facts and rethinking of an event (i.e. 
cancer diagnosis and treatments) may not necessarily decrease psychological distress but 
rather exacerbate symptoms.21 Possibly, patients with certain personality types or coping 
styles may be more vulnerable to the harmful effects of exposure interventions such as 
SCPs. On the other hand, one may argue that patients benefit from having received 
realistic information on the chance of recurrence in an SCP, after they eventually develop a 
recurrence. Little is known about the effect of exposure to information about a potentially 
negative outcome, after the negative outcome has manifested.  Unfortunately, numbers 
of patients with a recurrence in our trial were too small to investigate the impact of SCPs 
in these patients after diagnosis of a recurrence. Further moderation analysis considering 
patient characteristics, personality and coping could further reveal which patients do, and 
which patients do not benefit from SCPs.
In conclusion, no beneficial effects of SCPs on satisfaction with information provision and 
care in both endometrial and ovarian cancer patients were shown as primary outcomes 
of our trial.5,10 The current study highlights that SCPs may even have negative effects 
on HRQoL and anxiety in patients who experience more threatening illness perceptions 
due to the SCP. Therefore, we should be aware of the potential negative consequences 
of SCPs in some patients. A more tailored approach such as personalized SCPs fitting 









Patients receiving questionnaire 
     Endometrial (n=154), ovarian (n=91) 
Patients completing questionnaire  
     Endometrial (n=119), ovarian (n=61) 
Refused participation 
     Endometrial (n=35), ovarian (n=30) 
Patients wanting to stop after 1 questionnaire (n=42) 





Patients receiving questionnaire 
     Endometrial (n=142), ovarian (n=157) 
Patients completing questionnaire  
     Endometrial (n=102), ovarian (n=113) 
Refused participation 
     Endometrial (n=40), ovarian (n=44) 
Patients wanting to stop after 1 questionnaire (n=42) 





Patients receiving a questionnaire 
 Endometrial (n=87), ovarian (n=51) 
Patients completing the questionnaire 
     Endometrial (n=85), ovarian (n=44) 
Refused participation: endometrial (n=2), ovarian (n=3) 
Deceased: endometrial (n=0), ovarian (n=4) 
12 months 
Patients receiving a questionnaire 
 Endometrial (n=87), ovarian (n=47) 
Patients completing the questionnaire (n=114) 
 Endometrial (n=79), ovarian (n=35) 
 Refused participation: endometrial (n=7), ovarian (n=7) 
(n=110) 
(n=98) 
 Deceased: endometrial (n=1), ovarian (n=5) 
24 months 
Patients receiving a questionnaire 
     Endometrial (n=70), ovarian (n=40) 
Patients completing the questionnaire 
     Endometrial (n=69), ovarian (n=29) 
Refused participation: endometrial (n=8), ovarian (n=8) 





Patients receiving a questionnaire 
     Endometrial (n=81), ovarian (n=91) 
Patients completing the questionnaire  
     Endometrial (n=73), ovarian (n=80) 
Refused participation: endometrial (n=7), ovarian (n=7) 
Deceased: endometrial (n=1), ovarian (n=4) 
12 months 
Patients receiving a questionnaire  
     Endometrial (n=80), ovarian (n=87) 
Patients completing the questionnaire  (n=134) 
     Endometrial (n=68), ovarian (n=66) 
Refused participation: endometrial (n=10), ovarian (n=13) 
Deceased: endometrial (n=2), ovarian (n=8) 
24 months 
Patients receiving a questionnaire  (n=140) 
     Endometrial (n=69), ovarian (n=71) 
Patients completing the questionnaire (n=105) 
     Endometrial (n=59), ovarian (n=46) 
Refused participation: endometrial (n=10), ovarian (n=17) 
Deceased: endometrial (n=0), ovarian (n=12) 
Follow-up 
Patients analyzed 
After treatment  (n=180) 
     Endometrial (n=119), ovarian (n=61) 
6 months follow-up  (n=129) 
     Endometrial (n=85), ovarian (n=44) 
12 months follow-up  (n=114) 
     Endometrial (n=79), ovarian (n=35) 
24 months follow-up  (n=98) 
Endometrial (n=69), ovarian (n=29)
Hospitals allocated to intervention (n=6) 
Received allocated intervention  (n=6) 
Patients analyzed 
After treatment  (n=215) 
     Endometrial (n=102), ovarian (n=113) 
6 months follow-up  (n=152) 
     Endometrial (n=73), ovarian (n=79) 
12 months follow-up  (n=133) 
     Endometrial (n=68), ovarian (n=65) 
24 months follow-up  (n=105) 
Endometrial (n=59), ovarian (n=46)
Hospitals allocated to usual care (n=6) 
Received allocated usual care  (n=6) 
Analysis 
Randomized hospitals (n=12)Enrollment 
Enrollment of patients 
Allocation 
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Chapter 6
Optimistic, realistic and pessimistic illness perceptions, 
quality of life and survival among 2457 cancer survivors: 
the population-based PROFILES registry 
B.H. de Rooij 
M.S.Y. Thong 








Background: Threatening illness perceptions (IPs) have been associated with poorer 
health outcomes. However, to the authors’ knowledge, it remains unclear whether 
threatening IPs that are consistent with disease severity are equally harmful. The aim 
of the current study is to 1) identify subgroups of cancer survivors based on IPs and 
prognosis, and 2) assess health-related quality of life (HRQoL) and survival associated 
with these subgroups. 
Methods: The authors used survey data from the population-based PROFILES registry, 
which were collected between 2008 and 2015 and included 2,457 cancer survivors who 
were <5 years after their cancer diagnosis (colon, rectal, prostate, endometrial, ovarian, 
or non-Hodgkin lymphoma). Clinical and survival data were collected through the 
Netherlands Cancer Registry. Subgroups were defined by IP (Brief Illness Perceptions 
Questionnaire) and prognosis (conditional 5-year relative survival) into survivors with a) 
IP consistent with prognosis (‘realistic’), b) less threatening IP than expected based on 
prognosis (‘optimistic’), and c) more threatening IP than expected based on prognosis 
(‘pessimistic’). 
Findings: Compared to survivors with realistic IPs (1230 survivors), those with optimistic IPs 
(582 survivors) were found to have a higher HRQoL (p<.01 on all European Organization 
for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC 
QLQ-C30] scales), and a lower all-cause mortality (hazard ratio, 0.72; p<.01), whereas 
those with pessimistic IPs (N=645) had a lower HRQoL (p<0.01 on all scales) and a higher 
all-cause mortality (hazard ratio, 1.52; p<0.01).
Conclusions: Optimistic IPs are associated with a better HRQoL and survival, even if 
they may appear to be unrealistic with respect to cancer survivors’ prognosis. Survivors 
with pessimistic IPs appear to have the worst outcomes. Therefore, efforts are needed to 
provide better support to patients with pessimistic IP to improve their outcomes.  




The illness perceptions (IPs) of patients, comprising both cognitive and emotional 
responses to their illness, are increasingly studied in relation to physical and psychological 
outcomes.1 Threatening IPs, such as concern about the disease and the number of 
symptoms experienced, have been associated with poor health-related quality of life 
(HRQoL), psychological morbidities, and low survival among cancer survivors.2-10 These 
findings suggest that having threatening IPs affect survivors’ outcomes. However, IPs may 
accurately reflect a patients’ true disease status, indicating that the associations between 
IP and outcomes largely are explained by disease severity (i.e., prognosis).4 Conversely, 
patients also could hold more optimistic or pessimistic beliefs of the disease that are not 
consistent with disease severity or prognosis. 
The IPs of cancer survivors may become more concordant with disease severity or 
prognosis when these individuals receive explicit information regarding the diagnosis, 
side effects, and prognosis of their cancer.11-13 In patients with cancer who are receiving 
palliative care, realistic perceptions of prognosis may contribute to acceptance of the 
disease and its consequences, without being disappointed or frustrated with unachievable 
expectations.14-16 However, to the best of our knowledge, the advantages of realistic IPs 
among cancer survivors remain unclear. Efforts to investigate the benefits of realistic, 
pessimistic or optimistic IPs relative to prognosis among cancer survivors may provide 
insights into survivors’ perspectives, and may provide information with which to guide 
information provision and support to those at risk of physical and emotional symptoms. 
In a large observational cohort of cancer survivors with various cancer diagnoses, we 
sought to identify subgroups of survivors with realistic, pessimistic or optimistic IPs relative 
to prognosis at the time of the questionnaire. In addition, we aimed to assess the HRQoL 
and survival associated with these subgroups. In parallel with literature demonstrating the 
benefits of prognostic awareness in patients receiving palliative care,14,15 we hypothesized 
that realistic IPs among cancer survivors are associated with better outcomes compared 





We used data from the PROFILES (‘Patient Reported Outcomes Following Initial treatment 
and Long term Evaluation of Survivorship’) registry.17 Patient-reported outcomes are 
collected within a sampling frame of the Netherlands Cancer Registry (NCR) and can be 
linked with clinical data of all individuals newly diagnosed with cancer in the Netherlands. 
Data collection
A detailed description of the data-collection has been presented previously.17 In brief, 
in each study sample, cancer survivors were informed about the study via a letter from 
their attending specialist. This letter contained either an informed consent form and 
a paper questionnaire, or a secured link to a Web-based informed consent form and 
online questionnaire. In study samples in which the secured link was provided, the patient 
could return a postcard to request a paper-and-pencil questionnaire if preferred. Data 
from the PROFILES registry are freely available for non-commercial scientific research, 
subject to study question, privacy and confidentiality restrictions, and registration (www.
profilesregistry.nl).  
Study population
The current analysis included 5 study samples from the PROFILES registry for which data 
were available regarding dependent and independent variables. Only short-term cancer 
survivors (<5 years after diagnosis) were included, because, among long-term cancer 
survivors, the IP may be less likely to be related to the cancer diagnosis and more likely 
the consequence of comorbid conditions. Cancer types included colon, rectal, prostate, 
endometrial, and ovarian cancer as well as non-Hodgkin lymphoma. In all study samples, 
a core set of the same questionnaires was used, with inclusion between May 2009 
and March 2014. Participants were excluded if they were not able to complete a Dutch 
questionnaire according to their (ex-)attending specialist (ie, due to cognitive impairment, 
being a non-native speaker, being too ill to participate). Also excluded were individuals 
who died or emigrated before the initiation of the study, according to data from the 
hospital of diagnosis and/or data from the Dutch municipal personal records database 
(ie, mortality and residential data from all citizens through municipal registries). Ethical 
approval was obtained for all study samples separately from a local certified medical 
ethics committee.
Measures
Clinical data, such as the date of diagnosis, tumor type, tumor stage, and primary 
treatments received were obtained from the NCR. The NCR routinely collects data 
concerning newly diagnosed patients with cancer in all hospitals in the Netherlands. 
Tumor type was classified according to the International Classification of Diseases for 
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Oncology, 3rd Edition (ICD-O-3),18 and cancer stage was classified according to TNM19 
or Ann Arbor Code (Non-Hodgkin lymphoma). Primary treatments received were 
classified as surgery, systemic therapy (chemotherapy, targeted therapy, immune 
therapy), radiotherapy (including brachytherapy), hormone therapy, no treatment/active 
surveillance or unknown. The time from diagnosis at time of questionnaire invitation was 
categorized into quartiles (0-2 years, 2-3 years 3-5 years and >5 years). Sociodemographic 
information (i.e. education, marital status, employment status and comorbidity) was 
assessed in the questionnaire. Marital status (‘married/living together’ versus ‘divorced/
widowed/never married’) and employment status (‘having a paid job’ versus ‘not having 
a paid job’) were dichotomized. Comorbidity was assessed using the adapted Self-
administered Comorbidity Questionnaire (SCQ), and categorized into no comorbidities, 
one comorbidity or more than one comorbidities.20 Comorbidities included heart disease, 
stroke, hypertension, airway disease (asthma, chronic bronchitis or chronic obstructive 
pulmonary disease (COPD)), diabetes, stomach disease, kidney disease, liver disease, 
anemia or other blood disease, thyroid disease, depression, arthrosis, back pain, and 
rheumatic disease.
The Brief Illness Perception Questionnaire (B-IPQ) was used to assess IPs.21 The B-IPQ 
includes eight items. Test-retest reliability (Pearson correlations 0.42-0.75) of the items 
is fair.21 Similar to earlier studies22-25, a 2-factor structure was found using principal 
components factor analysis. A multi-item scale was computed of 5 BIPQ items selected 
through the factor analysis (factor loadings > 0.70), and included consequences (“How 
much does your illness affect your life?”), timeline (“How long do you think your illness 
will continue?”), identity (“How much do you experience symptoms from your illness?”), 
concern (“How concerned are you about your illness?”), and emotional response (“How 
much does your illness affect you emotionally?”). A multi-item scale was computed of 
these items by averaging the item scores, when ≤1 item response was missing. The 
internal consistency of the scale was good (standardized Cronbach alpha,.85). Higher 
scores indicated more threatening IPs. 
Prognosis at the time of the questionnaire was determined by conditional 5-year relative 
survival (ie, the probability of surviving an additional 5 years on the condition that the 
patient has survived x number of years after diagnosis). Estimates were calculated using 
data from the NCR, including mortality data from patients diagnosed between 1989 and 
2008 who were followed for up to 15 years, and were determined by years survived after 
diagnosis, tumor type, tumor stage, age group (ages 15-44 years, ages 45-59 years, 
ages 60-74 years, and ages 75-89 years), and sex. Conditional relative survival data from 
the NCR has been described previously for colorectal26 and prostate27 cancer, and Non-
Hodgkin Lymphoma28. For endometrial and ovarian cancer survivors in our sample, who 
were included within one year after diagnosis, 5-year survival at time of diagnosis by 
cancer stage was determined (www.cijfersoverkanker.nl). 
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To create the optimistic, realistic, and pessimistic IP groups, the sample was divided into 
conditional 5-year relative survival strata (<60%, 60%-69%, 70%-79%, 80%-89%, and 
90%-100%). Then, in each stratum, quartiles of BIPQ multi-item scores were defined. 
Survivors with the lowest quartile of BIPQ scores in their stratum (<25%) were allocated 
to “pessimistic” IP, those with interquartile scores (25%-75%) were allocated to “realistic” 
IP, and those with the highest quartile (>75%) were allocated to “optimistic” IP (Table 1). 
The European Organization for the Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30; version 3.0) was used to assess HRQoL among 
the participants.29 The scores were linearly transformed into a score between 0 and 100.30 
Higher scores on the functioning scales indicated better functioning and global QOL, 
whereas higher scores on the symptom scales indicated more symptom complaints and 
financial difficulties. Vital status and date of death data were obtained from the Dutch 
municipal personal records database and last were verified on February 1, 2017. Anxiety 
and depression were measured in survivors of colon cancer, rectal cancer, and lymphoma 
using the Hospital Anxiety and Depression Scale (HADS)31 The HADS assesses separate 
anxiety and depression scales, both of which consist of 7 items. Higher scores indicate 
more anxiety and depressive symptoms.
Statistical analysis
Statistical analyses were conducted using SAS statistical software (version 9.4; SAS 
Institute Inc, Cary, North Carolina). Frequencies with percentages and means with 
standard deviations were used to describe the baseline characteristics, and chi-square 
tests, independent Student t tests, and Mann-Whitney U tests were used to test the 
differences between patients with optimistic, realistic, and pessimistic IPs. P values < .05 
were considered to be statistically significant. 
Correlations were computed to assess whether BIPQ items were interrelated with HRQoL 
scales. General linear models were conducted to assess differences in HRQoL between 
survivors with optimistic, realistic, and pessimistic IPs. Bonferroni-corrected pairwise 
comparisons were made to compare survivors with optimistic versus realistic IPs and 
pessimistic versus realistic IPs, adjusted for a priori selected covariates (age at the time 
of the questionnaire, sex, educational level, years from diagnosis, tumor type, tumor 
stage, treatment [surgery, radiotherapy, or systemic therapy], number of comorbidities, 
employment, and marital status). Additional analyses were adjusted for anxiety and 
depression.
Kaplan-Meier curves were conducted to show differences in survival between the 
3 subgroups. A Cox proportional hazards regression model was performed to assess 
differences in survival between patients with optimistic, realistic, and pessimistic IPs. The 
survival duration was specified as the time from the questionnaire until either death or 
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the censoring date (February 1, 2017). To adjust for survivorship bias, a variable with 
the left truncation time (time between diagnosis and questionnaire) was added as an 
argument and the time of the questionnaire was set as the entry time. In addition, the 
model was adjusted for covariates controlling for factors influencing survival (age at the 
time of the questionnaire, sex, educational level, tumor type, tumor stage, treatment 
[surgery, radiotherapy, or systemic therapy], number of comorbidities, employment, and 
marital status).
RESULTS
A total of 3882 cancer survivors were invited to participate in 1 of the 5 studies, 2744 
of whom (71%) returned the questionnaire. The current analysis included 2457 cancer 
survivors (63%) for whom no data were missing regarding the grouping variable (tumor 
stage to determine prognosis, BIPQ scale) (see Supporting Fig. 1). Cancer survivors were 
classified into those with optimistic (582 survivors), realistic (1230 survivors), and pessimistic 
(645 survivors) IPs (Table 1). 
Compared with survivors with realistic IPs, those with optimistic IPs tended to be older, 
were more often male, were more often survivors of colon cancer and less often survivors 
of rectal and ovarian cancer, had lower stages of disease, had fewer comorbidities, and 
were less often employed. Survivors with pessimistic IPs tended to be younger, were 
more often female, were more often less educated, were less often survivors of colon 
cancer and more often survivors of rectal cancer, had more comorbidities, less often had 
a partner, and more often received radiotherapy (Table 2). 
Table 1: Group allocation of survivors into ‘optimistic’, ‘realistic’ and ‘pessimistic’ IPs within 5-year 
conditional survival strata
Quartiles of illness perception scoresb
















<60% 148 <4.4 4.4-7.3 >7.3
60-69% 234 <2.4 2.4-6.2 >6.2
70-79% 384 <2.4 2.4-5.8 >5.8
80-89% 806 <2.6 2.6-6.0 >6.0
90-100% 885 <2.0 2.0-5.2 >5.2
Abbreviation: IPs, illness perceptions. aThe IPs score was based on the average of Brief Illness Perception Questionnaire 
(BIPQ) scores (1-10) of items selected in factor analysis (consequences, timeline, identity, concern, and emotional response). 
A higher score indicates more threatening IPs. bThe probability of surviving an additional 5 years on the condition that the 
patient has survived x number of years after diagnosis, based on years survived from diagnosis, tumor type, tumor stage, 
age group, and sex. 
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    Mean (SD) 68.1 (10.1) 69.3 (9.5) 68.3 (10.3) 66.7 (10.2) 0.03 <0.01
Sex, n(%)
    Male











   Lower education
   Secondary education 
(high school)
   Secondary 
(vocational) education

















105 (16) 0.63 0.03
Years from diagnosis
    Median (IQR)
    <2
    2-3






















Cancer type, n (%)
    Colon
    Rectal
    Prostate
    Ovarian
    Endometrial
    Non-Hodgkin 
Lymphoma  (aggressive)





























53 (8) <0.01 <0.01
Comorbidity, n (%)
    None
    1












328 (51) <0.01 <0.01
Marital status, n (%)
    Partner








139 (29) 0.28 0.10
Employed, n (%)
    Yes








514 (82) 0.09 0.28
TNM/ Ann Arbor stage, 
n (%)
    I
    II
    III
















73 (37) 0.01 0.18
Treatment, n (%)
    Surgery
    Radiotherapy



















Abbreviations: IPs, illness perceptions; IQR, interquartile range; SD, standard deviation. Percentages do not always add up to 
100 because they were rounded off to whole numbers. aBold type indicates statistical significance. 
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Table 3: General linear models comparing HRQoL and symptoms between cancer survivors with 





















Global quality of life 75.0 (19) 85.2 (14) 77.1 (16) 61.9 (22) <0.01 (S) <0.01 (L)
Functioning scales
   Physical functioning 80.5 (20) 88.0 (15) 82.4(18) 70.1 (23) <0.01 (S) <0.01 (S)
   Social functioning 85.0 (23) 95.5 (12) 88.0 (19) 70.0 (29) <0.01 (S) <0.01 (L)
   Cognitive functioning 83.7 (21) 90.2 (15) 85.1 (19) 75.2 (26) <0.01 (S) <0.01 (M)
   Emotional functioning 84.4 (20) 94.4 (11) 87.4 (17) 69.9 (24) <0.01 <0.01
   Role functioning 77.8 (28) 89.8 (19) 80.2 (25) 62.4 (33) <0.01 (S) <0.01 (S)
Symptom scales
   Fatigue 25.1 (25) 13.4(17) 23.0 (22) 40.0 (27) <0.01 (S) <0.01 (M)
   Nausea/ vomiting, 4.4 (13) 1.7 (7) 3.4 (11) 8.5 (18) <0.01 (T) <0.01 (S)
   Pain 17.5(25) 9.5 (18) 15.7 (23) 28.3 (30) <0.01 (S) <0.01 (S)
   Dyspnoea 15.3 (25) 8.2 (19) 13.4 (23) 25.4 (31) <0.01 (S) <0.01 (M)
   Insomnia 21.8 (30) 11.7 (22) 20.3 (28) 33.6 (34) <0.01 (S) <0.01 (M)
   Appetite loss 6.8 (18) 2.7 (11) 5.3 (16) 13.5 (25) <0.01 (T) <0.01 (S)
   Constipation 9.4 (21) 5.2 (15) 9.3 (20) 13.3 (25) <0.01 (T) <0.01 (T)
   Diarrhoea 9.6 (21) 5.0 (14) 9.2 (20) 14.1 (26) <0.01 (S) <0.01 (S)
   Financial problems 7.2 (19) 2.7 (11) 5.4 (16) 14.7 (26) <0.01 (T) <0.01 (S)
Abbreviations: HRQOL, health-related quality of life; IP, illness perception; L, large difference, M, medium difference; S, small 
difference; SD, standard deviation; T, trivial difference. aAnalyses were adjusted for age at the time of the survey, sex, educa-
tional level, years from diagnosis, tumor type, tumor stage, treatment (surgery, radiotherapy, or systemic therapy), number 
of comorbidities, employment, and marital status. Higher scores on global QOL and functioning scales and lower scores on 
symptom scales indicate a better HRQOL. The size of the mean difference was determined based on guidelines of clinical 
relevance from Cocks et al.32 The guideline for the emotional functioning subscale is unknown. 
Correlations between BIPQ items that were included in the IPs scale were weak to 
moderate (correlation coefficient, -0.53 to 0.45) (see Appendix 1). For all HRQOL scales, 
functioning and global QOL were higher and symptom burden was lower in those with 
optimistic IPs compared with those with realistic IPs (all P < .01). According to guidelines 
for clinical relevance, mean differences were trivial or small.32 Functioning was lower and 
symptoms were higher in those with pessimistic IPs compared with those with realistic IPs 
(all P < .01), and mean differences were trivial to large (Table 3).32 Differences remained 
significant after additional adjustment for anxiety and depression, and when analyses 
were stratified by prognosis group. 
Overall, all-cause mortality was found to be higher in survivors with pessimistic IPs 
compared with those with realistic IPs (adjusted hazard ratio, 1.52; 95% confidence 
interval, 1.27-1.84 [P < .01]). In addition, all-cause mortality was found to be slightly but 
significantly lower in survivors with optimistic IPs compared with those with realistic IPs 
(adjusted hazard ratio, 0.72; 95% confidence interval, 0.57-0.90 [P < .05]) (Table 4) (Fig. 1).
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Table 4: Cox hazard regression models for optimistic versus realistic and pessimistic versus realistic 
IP
N Person-Years Deaths Unadjusted HR (95% CI) Adjusted HRa (95% CI)
Total
      Realistic IPs 582 6194.4 288 1.00 (ref) 1.00 (ref)
      Optimistic IPs 1,230 3159.4 106 0.74 (0.58-0.91)** 0.72 (0.57-0.90)**
      Pessimistic IPs 645 3065.2 218 1.52 (1.28-1.81)** 1.52 (1.27-1.84)**
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; IPs, illness perceptions. a Bold type indicates statistical 
significance. b Adjusted for age at the time of the survey, sex, educational level, tumor type, tumor stage, treatment surgery, 



















Figure 1: Kaplan-Meier survival curves of survivors with optimistic, realistic and pessimistic IPs
DISCUSSION
We demonstrated that having optimistic IPs, even when they may appear unrealistic with 
respect to prognosis, are associated with higher HRQoL and lower mortality, whereas 
having pessimistic IPs are associated with poorer outcomes compared with IPs that are 
consistent with disease severity (ie, realistic IPs). This violates our hypothesis that realistic 
IPs are more beneficial than more optimistic IPs, and demonstrates that IPs are important 
predictors of survivors’ health outcomes regardless of disease prognosis. In addition, 
the comparison of the 3 IPs groups in the current study elucidated that differences in 
outcomes were much larger between the pessimistic IPs group and the realistic IPs group 
compared with between the optimistic and realistic IPs groups, specifically with respect 
to social functioning, cognitive functioning, fatigue, nausea, insomnia, and global QoL.
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Similar to previous work focusing on the relationship between IPs and physical and 
psychological outcomes, including HRQoL, psychological distress, and mortality,2-10 we 
found that less threatening (ie, more positive) IPs were associated with more favorable 
outcomes, whereas more threatening (ie, more negative) IPs were associated with 
unfavorable outcomes. The results of the current study demonstrate that IPs are associated 
with HRQoL and survival independent of disease severity (ie, prognosis). According to the 
common sense model of self-regulation of Leventhal et al, the relationship between IPs 
and health outcomes is mediated through coping.33 Accordingly, threatening IPs have 
been associated with passive coping strategies, such as anxious preoccupation and 
helplessness/hopelessness among cancer survivors,4which may explain the relation to 
poor health outcomes. An alternative explanation may be that the IPs in the current 
study simply were a more inclusive reflection of disease severity, comprising symptoms, 
disease progression, and comorbidities. This is in parallel with self-rated health as an 
inclusive measure of health status, reflecting bodily sensations or symptoms indicating 
physiological dysregulations or preclinical disease,34,35 as well as internal or external 
resources that affect health (ie, educational level, financial status and social support, 
optimism, or self-control).36 Inclusiveness also may explain why IPs in the current study 
appeared to be predictive of health outcomes independent of prognosis, reflecting that 
all groups in the current study were rather “realistic” about their outcomes. 
Consistent with literature regarding threatening IPs, pessimistic IPs were found to be 
associated with sociodemographic factors, including younger age, being female, and 
having a low educational level.37,38. In addition, we found that higher cancer stage and 
more comorbidities were associated with having pessimistic IPs. Furthermore, survivors 
with pessimistic IPs more often received radiotherapy, which previously has been 
associated with higher levels of psychological distress,39, fatigue 40 and a lower HRQoL. 
Limitations
Using comprehensive historical cancer registry data to estimate prognosis at the time of 
the questionnaire, we tried to adjust for the (clinical) factors that interfere with IPs and 
health outcomes (ie, years from diagnosis, cancer stage at the time of diagnosis, patient 
age and sex). However, other factors comprising prognosis were not covered in this 
estimate, such as comorbidities, disease progression, or disease recurrence. For example, 
the high prevalence of comorbidities in the group with pessimistic IPs may explain their 
low survival. Although adjustment for comorbidities at the time of the questionnaire did 
not alter the current study results, we could not adjust for comorbidities at the time of 
diagnosis or in the years after questionnaire completion. In addition, no data were available 
regarding disease progression or recurrence. The inclusion of survivors with recurrent 
disease may have inflated the results of the current study because these individuals were 
likely allocated to the pessimistic IPs group and inevitably had poorer health outcomes.
Chapter 6
114
Furthermore, our composite BIPQ scale was based on a factor structure that was 
similar to that of other studies,22-25, but does not support the theoretical model by 
Leventhal etal that presents emotional and cognitive representations as distinct factors. 
As a consequence, the groups in the current study were not only based on cognitive 
perceptions regarding disease severity, such as perceptions of how long the disease will 
continue, but also on emotional representations. Therefore, it is not surprising that the 
groups were strongly associated with HRQoL subscales. To further elucidate whether 
more optimistic perceptions of prognosis are indeed more beneficial for cancer survivors 
than (clinically) accurate perceptions of prognosis, a prognostic awareness measure could 
be used to create the groups, similar to the questionnaires used in palliative research.41 
In addition, use of supportive care services should be measured as this may influence 
survivors’ IPs. 
The current study included a large and heterogeneous sample of survivors of various 
cancer types, but there were relatively many survivors with favorable prognoses, and 
a lack of common cancer types such as breast and lung cancer. Thus, despite our high 
response rate (71%), the findings of the current study may not be fully generalizable 
to other cancer survivor populations. Furthermore, although our survival analyses 
demonstrated longitudinal associations, we could not confirm the causal relationship 
between IPs and HRQoL using a cross-sectional survey. Longitudinal surveys are needed 
to confirm the long-term benefit of optimistic perceptions of illness and prognosis. It also 
should be noted that our groups were created based on quartile cutoff values of the BIPQ 
scores, which are clinically arbitrary and are not validated using specific questionnaires 
for optimistic, realistic, or pessimistic IPs. Future studies are needed to confirm these IP 
groups in other cancer survivor populations.
Future directions
Although we acknowledge that the current study had limitations with regard to its design 
and the availability of data, and that further research is needed, we believe that its 
results provide valuable new insights into the importance of IPs among cancer survivors 
in relation to HRQoL and survival. The classification of survivors into groups based on 
IPs relative to their prognosis is a novel way with which to assess the impact of having 
threatening IPs on health outcomes, in contrast to a body of literature focusing on linear 
relationships between IPs and outcomes.2-10 In a previous trial in which survivorship care 
plans were found to provide accurate and honest diagnostic and prognostic information, 
they induced more threatening IPs among cancer survivors.11-13 Because the results of the 
current study indicate that holding realistic or pessimistic IPs may be associated with lower 
HRQoL and survival, we may need to be careful when providing information to survivors, 
such as diagnostic or prognostic information. However, further research regarding this 
topic is warranted. Therefore, future interventions that include diagnostic or prognostic 
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information should include an assessment of the potential harmful effects through more 
threatening IPs. Furthermore, rather than assuming that we need to encourage survivors 
with pessimistic IPs to be more optimistic, we believe it is important to understand why 
these individuals have pessimistic or threatening IPs. It is possible that their perceptions are 
a much more inclusive reflection of their state of health than a set of objective measures 
comprises.36
Survivors with IPs that are relatively optimistic with respect to their prognosis appear to 
have the most favorable health outcomes, whereas those with pessimistic IPs relative to 
their prognosis have the worst outcomes compared with those with realistic IPs. Hence, 
IPs may be important predictors of health outcomes independent of prognosis. We need 
to acknowledge the pessimistic or threatening IPs among cancer survivors and provide 




Flow chart of survivors included in analysis
 
Questionnaires sent: N=3,882 
- Colon: N=1,218 
- Rectal: N=682 
- Endometrial: N=295 
- Ovarian: N=243 
- Prostate: N=805 
- NHL (indolent): N=350 
- NHL (aggressive): N=299 
Questionnaires received: N=2,744 (71%) 
- Colon: N=905 
- Rectal: N=515 
- Endometrial: N=220 
- Ovarian: N=173 
- Prostate: N=540 
- NHL (indolent): N=241 
- NHL (aggressive): N=150 
Number in analysis: N=2,457 (63%) 
- Colon: N=779 
- Rectal: N=449 
- Endometrial: N=197 
- Ovarian: N=142 
- Prostate: N=516 
- NHL (indolent): N=228 
- NHL (aggressive): N=146 
Missing data: N=419 (7%) 
 
Cancer stage to determine prognosis: N=159 
- Colon: N=82 
- Rectal: N=42 
- Endometrial: N=8 
- Ovarian: N=27 
- Prostate: N=0 
- NHL (indolent): N=0 
- NHL (aggressive): N=0 
B-IPQ multi-item scale: N=230 
- Colon: N=44 
- Rectal: N=24 
- Endometrial: N=15 
- Ovarian: N=4 
- Prostate: N=24 
- NHL (indolent): N=13 
- NHL (aggressive): N=4 
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Background: In efforts to inform clinical screening and development of survivorship care 
services, we sought to characterize patterns of healthcare needs among cancer survivors 
by 1) identifying and characterizing subgroups based on self reported health care needs, 
and 2) assessing socio-demographic, clinical and psychosocial factors associated with 
these subgroups.
Methods: We conducted a cross-sectional self administered survey among patients 
presenting for routine follow-up care for early stage cancer at our academic medical 
center. Latent class cluster analysis was used to identify clusters of survivors based on 
survivorship care needs within 7 domains. Multiple logistic regression analyses were used 
to assess factors associated with these clusters. 
Results: Among 292 respondents, the highest unmet needs were related to information 
regarding side effects (53%), self-care (51%) and emotional coping (43%) domains. Our 
analysis identified 4 clusters of survivors: 1) low needs (N=123, 42%), 2) mainly physical 
needs (N=46, 16%), 3) mainly psychological needs (N=57, 20%) and 4) both physical 
and psychological needs (N=66, 23%). Compared to cluster 1, those in clusters 2, 3, and 
4 were younger (P<0.03); those in clusters 3 and 4 had higher levels of psychological 
distress (P<0.05); and those in clusters 2 and 4 reported higher levels of fatigue (P<0.05). 
Conclusions: Unmet needs among cancer survivors are prevalent, however a substantial 
group of survivors report low or no healthcare needs. The wide variation in healthcare 
needs among cancer survivors suggests a need for screening all patients, followed by 
tailored interventions in clinical care delivery and research.  




Due to advances in health care and ageing of the population, the number of cancer 
survivors is increasing. In the United States, there were approximately 15.5 million cancer 
survivors in 2016, and this number is expected to exceed 20.3 million by 2026.1 This 
growing group of cancer survivors often faces physical and psychosocial issues as a result 
of cancer and cancer treatment2. Previous work has found that survivors have unmet 
needs regarding management of persistent complications from cancer therapy, practical 
assistance in daily living, and help with psychosocial problems such as anxiety and fear of 
recurrence.3-5 However, the level and type of needs differ across survivor populations and 
settings.6 Identifying needs clusters, as opposed to focusing only on distinct individual 
symptoms and problems, may provide insight into the challenges faced by cancer 
survivors and the best way to address them.
Over the past decades, the need to identify and address health concerns for patients who 
are expected to live years beyond initial therapy for cancer (defined as cancer survivors, for 
purposes of this paper) has been well described.7,8  In the American Institute of Medicine’s 
(IOM) report, “From cancer patient to cancer survivor, lost in transition,” Survivorship Care 
Plans (SCPs) containing a treatment summary and follow-up care plan were advocated 
as an available and efficient means to meet the needs of cancer survivors7. Although 
the face validity of SCPs seemed acceptable, several randomized controlled trials have 
failed to identify beneficial effects of SCPs in various study populations.9-12 In addition, 
the provision of SCPs has shown to be more resource intensive than anticipated, resulting 
in low implementation and dissemination of SCPs in clinical practice.13-15 However, SCPs 
may be beneficial for subgroups of patients, particularly underserved populations.16 
Consequently, debates on how best to address the needs of cancer survivors persist.6,17,18 
The optimal method to effectively and efficiently identify and address needs of cancer 
survivors remains undefined. Because cancer survivors constitute a heterogeneous 
population with different cancer types, treatment plans, ongoing/maintenance therapy, 
long term health risks, individual health care needs and preferences, we sought to 
determine if distinct subgroups of patients could be identified with similar needs that 
might be addressed through select group interventions and services.   In this study, we 
present a cluster analysis based on individual self-reported care needs among cancer 
survivors that aims to 1) characterize subgroups of patients with similar patterns of 
health care needs and 2) assess the socio-demographic, clinical and psychosocial factors 





We conducted a cross-sectional self-administered comprehensive needs assessment 
survey. All English speaking adult patients with a history of cancer presenting for 
follow-up care to the Massachusetts General Hospital Cancer Center between February 
and July of 2016 were eligible to participate. Only English questionnaires were used due 
to our pragmatic method of survey distribution. Surveys were provided by clinicians in 
clinic, research assistants in the waiting rooms, and clinic staff at the check-in desk across 
multiple disease specific clinics and two affiliated community oncology practices.  Due to 
the pragmatic method of survey distribution, the number of patients offered or eligible 
for the survey cannot be assessed. The Dana-Farber/Harvard Cancer Center institutional 
review board approved the study. 
Study population 
A total of 636 patients participated in the survey. For the purposes of this analysis, we 
included only patients participating in the cancer center wide survey who self-identified as 
having no evidence of distant metastases and who were a) on therapy with curative intent 
within 2 years of cancer diagnosis, b) on adjuvant endocrine therapy or c) off therapy in 
long term follow-up. Patients reporting incurable cancer, or reporting curable cancer 
but currently receiving radiation therapy or chemotherapy greater than 2 years from 
the time of diagnosis (indicating potential stage IV disease) were excluded (N=298). In 
addition, patients with early stage disease that did not complete the survivorship care 
needs assessment (N=46) were excluded from the current analysis.  
Measures
Socio-demographic variables included age, gender, race, marital status, employment, 
internet access, educational level and income. Clinical variables included cancer type 
category, years since diagnosis, treatment (both current and previous), and number of 
listed comorbidities. 
Survivorship care needs
The comprehensive needs assessment survey was developed by a multidisciplinary 
team of health services researchers, oncologists, psychologists, nurses, and primary 
care physicians with input from patients and family members of patients. The survey 
included 66 study-specific items on information to help survivors cope with their cancer 
or treatments, subdivided into seven domains: side-effects, lifestyle/self-care, emotional 
coping, social support, sexual health, complementary services and practical support. 
Participants were asked to report the concern (‘I do have this problem’) and to indicate 
their interest in receiving information to help them cope with this concern (‘I have enough 
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information’, ‘Not at all interested’, ‘A little interested’ and ‘Very interested’). All items 
were dichotomized into needs (‘A little interested/ ‘very interested) versus no needs 
(no concern indicated, ‘I have enough information’, or ‘not at all interested’). For each 
of the seven domains, a dichotomous scale was computed based on needs in domain 
(needs on at least one item in domain) versus no needs in domain. Internal consistency 
of the domain scales in our sample was good (Cronbach’s Alpha’s, side effects= 0.89; 
emotional coping=0.88; social support=0.88; lifestyle/self care=0.77; sexual health=0.75; 
complementary services=0.91; practical support=0.74).
Emotional and physical symptoms
Fear of recurrence was measured using the revised 5-item Assessment of Survivor 
Concerns (ASC).19 Internal consistency of the scale in our sample was good (Cronbach’s 
Alpha = 0.88). Depression, anxiety, insomnia, pain and fatigue were single-item scales 
based on a modified version of the FACT-G.20 Items were measured on a 5-point Likert 
frequency scale (‘never’, ‘rarely’, ‘sometimes’, ‘very often’ and ‘always’), and included 
depression (‘I feel sad or depressed’), anxiety (‘I feel nervous or worried’), insomnia (‘I 
have problems falling or staying asleep’), pain (‘I have pain’) and fatigue ( ‘my fatigue 
interferes with my usual activities’). Higher scores indicate greater problems. 
Statistical Analysis
Latent class cluster analysis was conducted to identify clusters of cancer survivors based 
on survivorship care needs across seven domains. Latent class modeling is a data-driven 
approach, which aims to classify similar objects, with respect to a set of variables, into 
mutually exclusive groups.21 Variables used to define the need-clusters were seven 
dichotomous scales indicating needs in domain. The optimal number of clusters was 
derived from goodness-of-fit statistics. Bivariate residuals were assessed to check if the 
local independency assumption was met (values <3).21 Cluster analyses were conducted 
with Latent GOLD version 5.2.0 (Statistical Innovations Inc., Belmont, MA, USA). 
Further statistical analyses were conducted using Statistical Analysis System (SAS) version 
9.4. (SAS Institute, Cary, NC, 1999). Differences in baseline characteristics between need-
clusters were assessed using analysis of variance (ANOVA) for continuous variables and 
chi-square tests for categorical variables. Characteristics that differed across clusters (P≤0.1) 
were entered into a multiple logistic regression analysis. Both univariate and multivariate 
models were built to assess the odds that a cancer survivor was in a need-cluster as 
indicated by the conditional socio-demographic or clinical characteristic, compared to 
cluster 1. Odds ratios and 95% confidence intervals (CI) are shown.  
For further exploratory purposes, emotional and physical symptoms that were assessed 
separately from the survivorship care needs survey  were compared between need-
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clusters. Bonferroni-corrected ANOVA pairwise comparisons were made to statistically 
assess the differences between clusters. Means and standard deviations, and statistical 
differences between the clusters compared to cluster 1, are shown. P-values smaller than 
.05 were considered to be statistically significant.
RESULTS
The 292 patients that were included in the current study had an average age of 58.6 
years, the majority was female (67%), of white race (91%), of high income (59%) and 
not currently on treatment (59%). The most common cancer types were breast (34%), 
hematologic (23%) and gastro-intestinal (11%). Participants completed the survey on 
average 3.7 years after the most recent cancer diagnosis (Table 1). 
In our latent class cluster analysis, the four-cluster model was shown to have the best 
model fit, based on goodness-of-fit-statistics (Akaike’s Information Criterion [AIC]; 
Consistent Akaike’s Information Criterion [CAIC]; Table 2). Although the more conventional 
Bayes’ Information Criterion (BIC) shows that the two cluster model has best model fit, 
we feel that the more liberal four-cluster model best describes variation in survivorship 
care needs in our sample. This model identified four clusters of survivors, including 1) 
low needs (N=123, 42%), 2) mainly physical needs (N=46, 16%), 3) mainly psychological 
needs (N=57, 20%) and 4) both physical and psychological needs (N=66, 23%; Figure 1). 
Among those with low needs (cluster 1), 77 survivors (26% of total) reported no needs on 
any domain. 
Baseline characteristics significantly differed across clusters with respect to age 
(continuous and categorical; P<0.01), employment (P=0.05) and genito-urinary cancer 
type (P=0.03) (Table 3). Multiple logistic regression analysis showed that survivors with 
mainly physical needs (cluster 2), mainly psychological needs (cluster 3) and both physical 
and psychological needs (cluster 4) were younger compared to survivors with low 
needs (cluster 1), independent of income, education, employment or being currently on 
treatment (continuous age per 10 years, ORs 0.70, 0.72, 0.72; p<0.03; Table 4).
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Table 1: survivor characteristics 
Total sample (N=292)
Age, M (SD) 58.6 (16.6)
Gender, N (%)
   Male




   White 
   Non-white
266 (91)
26 (9)
Educational levela, N (%)
   low
   medium





   low
   medium




Partner/married, N (%) 214 (73)
Employed, N (%) 147 (50)
Internet access, N (%) 263 (95)
Cancer type
   Breast, N (%)
   Gynecologic, N (%)
   Neurologic, N (%)
   Gastro-intestinal, N (%)
   Genito-urinary, N (%)
   Thoracic, N (%)
   Head & neck, N (%)
   Melanoma, N (%)
   Sarcoma, N (%)












   Surgery, N (%)
   Chemotherapy, N (%)




Currently on treatment, N (%) 119 (41)
Years since last diagnosis, M (SD) 3.7 (4.7)
Comorbiditiesc, N (%)
   0





alow=completed high school or lower, medium=2 years college or college graduate, high=masters or doctoral. bannual 
household income: low=<$40,000, medium=$40,000 - $80,000, high=>$80,000. cbased on disease categories (diabetes, 
kidney disease, overweight/obesity, underweight, liver disease, lung disease and heart disease)
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Table 2: Goodness of fit indexes for cluster models
Model L2 statistic
L2 statistic 
p-value BICLL AICLL AIC3LL CAICLL
One cluster 666.66 <0.01 2660.67 2634.93 2641.93 2667.67
Two cluster 155.68 <0.01 2195.10 2139.95 2154.95 2210.10
Three cluster 113.85 0.03 2198.68 2114.12 2137.12 2221.68
Four cluster 90.71 0.63 2220.96 2106.98 2137.98 2137.98
Five cluster 81.29 0.73 2256.95 2113.56 2152.56 2295.95
Six cluster 71.97 0.79 2293.05 2120.24 2167.24 2340.05
AIC: Akaike’s Information Criterion; BIC: Bayes’ Information Criterion; CAIC: Consistent Akaike’s Information Criterion; LL: 



































Side effects Lifestyle / selfcare Emotional coping Social support Sexual health Complementary services Practical support
Figure 1: distribution of survivorship care needs across domains, per needs-cluster 
Emotional and physical issues that were assessed in a distinct section of the survey from 
the needs assessment questions, were associated with the needs clusters. Emotional issues 
, including fear of recurrence, depression, anxiety, and insomnia, were more prevalent 
among survivors with mainly psychological needs (cluster 3) and with both physical and 
psychological needs (cluster 4), compared to low needs (cluster 1; P <0.05). Fatigue was 
more prevalent among survivors in clusters with mainly physical needs (cluster 2) and 
with both physical and psychological needs (cluster 4) compared to low needs (cluster 1; 
P<0.05; Figure 2). 
Overall, survivors reported the highest unmet needs regarding side effects (53%), self-
care (51%) and emotional coping (43%) domains. Needs related to side effects were 
highest for fatigue (30%), memory problems (20%) and weight gain (20%); needs related 
to self-care were highest for diet/nutrition counselling (34%), physical activity (30%) and 
meditation/relaxation (30%); and needs related to emotional coping were highest for fear 
of recurrence (34%), anxiety or worry (28%) and managing stress (22%; Appendix I).
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Age, M (SD) 61.9 (12.5) 58.0 (15.1) 55.8 (12.2) 55.4 (1.4) <0.01
Age categories, N (%)
 <50
   50-59



















   Male










   White 









Educational levela, N (%)
   low
   medium














   low
   medium















Partner/married, N (%) 90 (73) 36 (78) 44 (77) 44 (67) 0.47
Employed, N (%) 56 (45) 18 (39) 35 (61) 38 (58) 0.05
Internet access, N (%) 107 (93) 42 (95) 52 (96) 62 (97) 0.66
Cancer type
   Breast, N (%)
   Gynecologic, N (%)
   Neurologic, N (%)
   Gastro-intestinal, N (%)
   Genito-urinary, N (%)
   Thoracic, N (%)
   Head & neck, N (%)
   Melanoma, N (%)
   Sarcoma, N (%)




















































   Surgery, N (%)
   Chemotherapy, N (%)
















Currently on treatment, N (%) 40 (32) 21 (46) 25 (44) 33 (50) 0.09
Years since last diagnosis, M (SD) 4.0 (4.8) 3.4 (5.4) 4.3 (4.8) 3.1 (4.0) 0.50
Comorbiditiesc, N (%)
   0














Note of table 3:*p-value indicates differences between any of the clusters in Chi2-tests or ANOVA (Bonferroni corrected). 
alow=completed high school or lower, medium=2 years college or college graduate, high=masters or doctoral. bannual 
household income: low=<$40,000, medium=$40,000 - $80,000, high=>$80,000. cbased on disease categories (diabetes, 
kidney disease, overweight/obesity, underweight, liver disease, lung disease and heart disease)
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Age, per 10 years 1.00 (REF) 0.79 (0.61-1.03) 0.70 (0.55-0.89)** 0.69 (0.55-0.87)**
Education, lowa 1.00 (REF) 0.71 (0.30-1.71) 0.33 (0.12-0.90)* 0.68 (0.31-1.47)
Income, lowb 1.00 (REF) 0.87 (0.34-2.21) 0.27 (0.08-0.95)* 0.40 (0.14-1.11)
Employed 1.00 (REF) 0.77 (0.39-1.53) 1.90 (1.00-3.61) 1.62 (0.89-2.97)
Currently on treatment 1.00 (REF) 1.74 (0.87-3.48) 1.62 (0.85-3.09) 2.08 (1.13-3.83)
MULTIVARIATE
Age, per 10 years 1.00 (REF) 0.70 (0.53-0.92)** 0.72 (0.54-0.96)* 0.72 (0.54-0.97)*
Education, lowa 1.00 (REF) 0.96 (0.43-2.32) 0.48 (0.17-1.39) 0.77 (0.30-2.00)
Income, lowb 1.00 (REF) 0.34 (0.11-1.05) 0.32 (0.08-1.20) 0.74 (0.26-2.11)
Employed 1.00 (REF) 0.94 (0.47-1.91) 1.07 (0.51-2.24) 0.47 (0.21-1.05)
Currently on treatment 1.00 (REF) 1.83 (0.96-3.48) 1.41 (0.71-2.78) 1.53 (0.74-3.14)
Note: only variables that differed across clusters (p≤0.1, table 1) were included. acompleted high school or lower. Bannual 






















Cluster 1: low needs (N=123) Cluster 2: mainly physical needs (N=46)
Cluster 3: mainly psychological needs (N=57) Cluster 4: both physical and psychological needs (N=66)
*
* *




*indicates a significant difference (p<0.05) compared to cluster 1, in ANOVA post-hoc analysis (Bonferroni corrected). Error 
bars show +1 standard deviation.
Figure 2: mean scores of emotional and physical symptoms across clusters




We demonstrate that the unmet needs of cancer survivors who participated in this study 
are indeed heterogeneous. Interestingly, our analysis suggests that over 40% of survivors 
report no or low unmet needs for survivorship care. For others who reported needs, we 
show that they may be broken down into separate subgroups: those with a) primarily 
physical needs related to chronic or late effects of cancer or cancer therapy, b) primarily 
psychological needs, and c) those with both physical and psychological unmet needs.  
The identification of these subgroups and sociodemographic and clinical predictors 
of each subgroup does not diminish the need to screen each individual patient for 
survivorship care needs.  It does however, provide clinical insight into how programs 
to address the needs of diverse survivors might be structured, and it underscores the 
importance of both tailored information provision and accounting for differences in needs 
when testing interventions in survivorship care research.  
Overall, unmet survivorship care needs were highest regarding side-effects, followed by 
self-care and emotional coping domains. This is in line with earlier studies using other 
surveys, including the Supportive Care Needs Survey (SCNS),22 and the Cancer Survivors 
Unmet Needs measure (CaSUN),23 that reported the importance of psychological issues 
such as anxiety and fear of recurrence, information on things to do to get well, and 
physical issues such as side-effects. 3-5. Our study demonstrates that needs within these 
domains do not always occur together and that high needs in all areas simultaneously is 
uncommon.  Our findings are consistent with a similar cluster analysis in a population of 
breast cancer survivors that characterized an even greater 63% of patients within a ‘few-
needs’ cluster. 24 This suggests that one of the goals for cancer survivorship programs 
could be to screen for patients’ needs (or lack thereof) and then triage individuals to 
services focused on management of their specific issues, rather than trying to develop a 
single program to address all needs. 
In line with previous research,25-27 older age was associated with lower unmet survivorship 
care needs as compared to their younger counterparts, suggesting that more effort is 
needed to identify and address the needs of younger cancer survivors. Previous work 
suggests that younger patients experience a greater impact of the cancer and treatments on 
functioning and psychological wellbeing 28,29 and have higher expectations of services and 
people around them than older patients 30,31, while older patients show better adjustment 
to cancer.32 Resilience among older patients has been explained by more experience with 
coping with challenging events throughout life.33 We did not find substantial differences in 
cancer type across clusters, except that survivors with a genito-urinary cancer had more 
often low or no needs compared to the other cancer types, probably because of older 
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average age (68 years). Other clinical factors, such as treatment type, being currently on 
treatment, and time since diagnosis were not associated with need patterns in our study. 
Possibly, statistical power was too low to detect these associations, due to relatively small 
cluster sizes. 
Consistent with previous literature, physical and psychological problems were associated 
with higher unmet needs.34 Specifically, patients reporting current psychological issues, 
including fear of recurrence, depression, anxiety and, interestingly, those with insomnia 
were more likely to identify needs for care and information related specifically to coping 
or across all care domains. Patients reporting current physical issues, such as fatigue, 
were more likely to report needs for care and information related to management of 
chronic and late effects of disease and treatment, or needs across all care domains. 
These associations are not surprising, but it is important to note that these were distinct 
questions in different sections of our survey, the former focused on current symptoms 
or problems and the latter on patients’ reported needs for assistance in care. Although 
we feel that further research is needed to confirm associations with need clusters using 
validated questionnaires measuring physical and psychological symptoms,  our findings 
may suggest that screening for current symptoms and problems, as advocated by the 
National Comprehensive Cancer Network (NCCN) survivorship guideline panel, can be an 
effective way of identifying patients’ needs for survivorship care.35 This is also consistent 
with recent efforts to integrate patient-reported outcome measures (PROMs) into 
survivorship care pathways.36
Limitations
This is a single institution study, conducted primarily at an urban academic medical 
center serving a population with relatively high socio-economic status (SES). Due to the 
pragmatic nature of offering this survey across the cancer center we cannot determine 
response rates, making it more difficult to assess selection bias. Although this study 
includes a broad range of patients with regard to age and cancer type, it is possible that 
patients with higher symptom burden or care needs, may have been more motivated to 
complete the survey and may be overrepresented in our sample.37 However, alternatively, 
patients with higher symptom burden may have been too stressed or fatigued to 
complete the questionnaire and are therefore underrepresented in our sample. Further, 
resources precluded translation of the survey into Arabic, Cantonese, French, Mandarin, 
Spanish, and Russian, which are spoken by a minority of patients at our center. Needs 
may differ among non-English speaking patients, and in particular there may be greater 
barriers related to access to care and practical assistance faced by these patients who for 
pragmatic reasons are not included in our sample. Nevertheless, even in a selective sample 
of cancer survivors, there were variations in survivorship care needs and meaningful 
clusters of needs among this population. These patterns may be more pronounced in a 
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more diverse sample. Further, a larger sample size could increase the number of clusters 
to be identified, which allows for assessment of need patterns in more detail. 
Our study is cross-sectional and did not account for changes in survivorship care needs 
over time. While time from diagnosis was not associated with need-clusters, individual 
patterns of survivorship care needs may not be static. Repeated evaluations of survivorship 
care needs could elucidate the degree to which individual survivors have changing needs 
over time. In addition, we included all patients with curable disease, including those who 
were on intravenous therapy, consistent with the survivorship definition from the National 
Coalition for Cancer Survivors and endorsed by the American Society of Clinical Oncology 
which begins at diagnosis.38 This definition mirrors the work of Dr. Mullan who recognized 
different phases of survivorship.39 Needs are expected to vary based on specific regimens, 
time of assessment within a given regimen or from completion of therapy, as well as 
by use of any long term/maintenance therapies. A growing number of extended oral, 
intramuscular and intravenous therapies that can extend for years, now blurs the lines 
of completion of initial therapy and precludes a simple definition of survivorship.  We 
chose to use a broad definition, and to be inclusive of curable patients in our analysis to 
mirror the pragmatic challenges of clinical practice, when needs must be assessed and 
addressed across this continuum. Needs for individual patients clearly do change over 
time depending on changes in therapy and many other factors.
We used primarily study specific survey questions. Although scales of need within domains 
showed good internal consistently, we cannot assure that constructs of domains were fully 
captured using our questionnaire. This survey relied on patient reported clinical data, not 
chart review, and we did not feel that determination of detailed staging information was 
possible. 
Future directions
Because of increasing healthcare costs and limited resources for survivorship care, there 
is a need for efficient provision of information, interventions and care to cancer survivors. 
The classification of survivors into clusters based on survivorship care needs is a novel way 
to assess patterns of needs across survivors, in contrast to a body of literature focusing 
on associations with the number of needs or individual domains3. To our knowledge, this 
is the first study that assessed clusters of needs on multiple domains among patients with 
multiple types of cancer.  
Our study demonstrates that the majority of patients (58%) do have substantial needs, 
even years after diagnosis, and these patients need to be identified through careful 
screening in follow-up care. However, we also found that a large group of cancer survivors 
(42%) report relatively few symptoms or problems after cancer diagnosis and identify few 
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care and informational needs. These patients still need quality cancer follow-up care, 
screening for late effects and recurrence and ongoing assessment of needs, but they 
do not appear to need intensive survivorship care resources. Consequently, our study 
may provide an explanation for the failure of some survivorship interventions, such as 
SCPs, to improve outcomes in randomized trials.9-12 The impact of these interventions 
may be diluted by a substantial subgroup of survivors with few or no needs. In future 
research, interventional studies should consider identifying patients with documented 
needs and seeking to improve outcomes, rather than delivering an intervention to an 
unselected population of cancer survivors.  In this respect, survivorship care interventions 
may need to be tested with the same rigor applied to precision cancer therapy, with the 
right intervention for the right patient at the right time.   
We feel the needs clusters identified in our study merit validation using other needs 
assessment tools and across more diverse populations of patients with cancer.  However, 
the characterization of patients as having few needs, predominantly physical needs, 
predominantly psychological needs, or substantial both physical and psychological needs 
provides a productive framework for clinical care of cancer survivors and to guide further 
research in this field. Further research is needed to define the tailored information and 
services appropriate for each group of patients, and to define optimal screening tools to 
efficiently identify the needs of individuals in oncology practice.   


























Side effects, total 154 (53) 9 (7) 43 (93) 36 (63) 66 (100)
Pain 46 (16) 3 (2) 11 (24) 5 (9) 27 (41)
Fatigue 87 (30) 6 (5) 17 (37) 20 (35) 44 (67)
Hot flashes 49 (17) 2 (2) 11 (24) 13 (23) 23 (35)
Lymphedema/swelling 34 (12) 4 (3) 6 (13) 4 (7) 20 (30)
Osteoporosis/bone health 35 (12) 2 (2) 7 (15) 5 (9) 21 (32)
Nausea/vomiting 23 (8) 3 (2) 2 (4) 4 (7) 14 (21)
Trouble swallowing 18 (6) 3 (2) 4 (9) 2 (4) 9 (14)
Dental or mouth problems 28 (10) 2 (2) 7 (15) 4 (7) 15 (23)
Diarrhea or constipation 40 (14) 3 (2) 8 (17) 8 (14) 21 (32)
Bowel or bladder changes 32 (11) 3 (2) 5 (11) 8 (14) 17 (26)
Memory problems 59 (20) 2 (2) 11 (24) 12 (21) 34 (52)
Concentration difficulties 58 (20) 2 (2) 7 (15) 16 (28) 33 (50)
Body changes 40 (14) 2 (2) 3 (7) 10 (18) 25 (38)
Hair and skin care changes 47 (16) 4 (3) 8 (17) 5 (9) 30 (45)
Coordination 29 (10) 2 (2) 2 (4) 5 (9) 20 (30)
Weight gain 57 (20) 3 (2) 13 (28) 9 (16) 32 (48)
Weight loss 28 (10) 3 (2) 4 (9) 3 (5) 18 (27)
Lifestyle/ self-care, total 149 (51) 13 (11) 31 (67) 39 (68) 66 (100)
Diet/nutrition counseling 98 (34) 9 (7) 19 (39) 20 (35) 51 (77)
Physical activity 89 (30) 7 (6) 16 (35) 16 (28) 50 (76)
Sleep specialist 67 (23) 0 (0) 15 (33) 19 (33) 33 (50)
Weight center 61 (21) 3 (2) 9 (20) 11 (19) 38 (58)
Tobacco treatment 5 (2) 0 (0) 0 (0) 1 (2) 4 (6)
Meditation/ relaxation 88 (30) 7 (6) 11 (24) 20 (35) 50 (76)
Emotional coping, total 126 (43) 4 (3) 2 (4) 57 (100) 63 (95)
Anger 28 (10) 0 (0) 0 (0) 9 (16) 19 (29)
Grief or loss 34 (12) 0 (0) 0 (0) 9 (16) 25 (38)
Sadness 49 (17) 1 (1) 0 (0) 16 (28) 32 (48)
Anxiety or worry 83 (28) 2 (2) 0 (0) 36 (63) 45 (68)
Fear of cancer recurrence 100 (34) 2 (2) 2 (4) 46 (81) 50 (76)
Managing stress 63 (22) 0 (0) 0 (0) 26 (46) 37 (56)
End of life 33 (11) 0 (0) 1 (2) 10 (18) 22 (33)
























Complementary services, total 121 (41) 9 (7) 23 (50) 25 (44) 64 (97)
Counseling 35 (12) 1 (1) 2 (4) 8 (14) 24 (36)
Music therapy 34 (12) 0 (0) 7 (15) 2 (4) 25 (38)
Art therapy 26 (9) 0 (0) 6 (13) 2 (4) 18 (27)
Pain clinic 19 (7) 0 (0) 4 (9) 1 (2) 14 (21)
Chaplain/spiritual counseling 21 (7) 0 (0) 2 (4) 2 (4) 17 (26)
Social work 17 (6) 0 (0) 0 (0) 2 (4) 15 (23)
Acupuncture 55 (19) 3 (2) 10 (22) 8 (14) 34 (52)
Chiropractor 29 (10) 1 (1) 6 (13) 4 (7) 18 (27)
Hypnosis 19 (7) 0 (0) 2 (4) 1 (2) 16 (24)
Yoga/Tai Chi/Qi gong 65 (22) 4 (3) 10 (22) 13 (23) 38 (58)
Physical therapy 42 (14) 2 (2) 5 (11) 7 (12) 28 (42)
Massage therapy 82 (28) 2 (2) 13 (28) 15 (26) 52 (79)
Energy Healing 60 (21) 1 (1) 8 (17) 11 (19) 40 (61)
Herbal Supplements 58 (20) 5 (4) 14 (30) 9 (16) 30 (45)
Social support, total 97 (33) 3 (2) 11 (24) 21 (37) 62 (94)
Meeting others with cancer 39 (19) 1 (1) 3 (7) 6 (11) 29 (44)
Peer support group 44 (15) 1 (1) 3 (7) 8 (14) 32 (49)
Social activities 25 (9) 1 (1) 3 (7) 3 (4) 19 (29)
Retreats/camps 24 (8) 1 (1) 1 (2) 2 (4) 20 (30)
Talking 26 (9) 1 (1) 0 (0) 5 (9) 20 (30)
Giveback/volunteer 51 (17) 3 (2) 3 (7) 9 (16) 26 (55)
Return to work 33 (11) 0 (0) 3 (7) 5 (9) 25 (38)
Religious/ spiritual support 18 (6) 0 (0) 0 (0) 1 (2) 17 (26)
Finding support children 36 (12) 0 (0) 3 (7) 6 (11) 27 (41)
Finding support caregiver 30 (10) 0 (0) 3 (7) 4 (7) 23 (35)
Finding support family 32 (11) 0 (0) 2 (4) 6 (11) 24 (36)
Sexual health, total 70 (24) 4 (3) 11 (24) 21 (37) 34 (51)
Sexual issues 48 (16) 3 (2) 8 (17) 14 (25) 23 (35)
Fertility issues 15 (5) 1 (1) 1 (2) 3 (5) 10 (15)
Body image concerns 34 (12) 0 (0) 4 (9) 10 (18) 20 (30)
Intimacy concerns 35 (12) 1 (1) 4 (9) 9 (16) 21 (32)
Practical support, total 71 (24) 8 (7) 23 (50) 1 (2) 39 (59)
Finding PCP 17 (6) 0 (0) 3 (7) 1 (2) 13 (20)
Transitioning care 9 (3) 0 (0) 1 (2) 0 (0) 8 (12)
Childcare 8 (3) 0 (0) 2 (4) 1 (2) 5 (8)
Financial counseling 23 (8) 0 (0) 6 (13) 1 (2) 16 (24)
Assistance paying 19 (7) 1 (1) 5 (11) 0 (0) 13 (20)
Insurance questions 29 (10) 1 (1) 7 (15) 0 (0) 21 (32)




1. Miller K, Siegel R, Lin C, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 
2016;66(4):271-289.
2. Aaronson NK, Mattioli V, Minton O, et al. Beyond treatment–psychosocial and behavioural issues in 
cancer survivorship research and practice. European Journal of Cancer Supplements. 2014;12(1):54-64.
3. Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the unmet supportive care 
needs of people with cancer? A systematic review. Supportive Care in Cancer. 2009;17(8):1117-1128.
4. Geller BM, Vacek PM, Flynn BS, Lord K, Cranmer D. What are cancer survivors’ needs and how well 
are they being met? The Journal of family practice. Oct 2014;63(10):E7-16.
5. Kent EE, Arora NK, Rowland JH, et al. Health information needs and health-related quality of 
life in a diverse population of long-term cancer survivors. Patient education and counseling. 
2012;89(2):345-352.
6. Mayer DK, Nasso SF, Earp JA. Defining cancer survivors, their needs, and perspectives on survivorship 
health care in the USA. The Lancet. Oncology. Jan 2017;18(1):e11-e18.
7. Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Translation. 
Committee on Cancer Survivorship: Improving Quality Care and Quality of Life, National Cancer 
Policy Board. Washington, DC: National Academies Press; 2006.
8. Page AE, Adler NE. Cancer care for the whole patient: Meeting psychosocial health needs. National 
Academies Press; 2008.
9. Brothers BM, Easley A, Salani R, Andersen BL. Do survivorship care plans impact patients’ evaluations 
of care? A randomized evaluation with gynecologic oncology patients. Gynecologic oncology. 
2013;129(3):554-558.
10. Grunfeld E, Julian JA, Pond G, et al. Evaluating survivorship care plans: results of a randomized, 
clinical trial of patients with breast cancer. Journal of Clinical Oncology. 2011;29(36):4755-4762.
11. Hershman DL, Greenlee H, Awad D, et al. Randomized controlled trial of a clinic-based survivorship 
intervention following adjuvant therapy in breast cancer survivors. Breast cancer research and 
treatment. 2013;138(3):795-806.
12. Nicolaije KA, Ezendam NP, Vos MC, et al. Impact of an Automatically Generated Cancer Survivorship 
Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a 
Pragmatic, Cluster Randomized Trial. Journal of Clinical Oncology. 2015;33(31):3550-3559.
13. Birken SA, Mayer DK, Weiner BJ. Survivorship care plans: prevalence and barriers to use. Journal 
of cancer education : the official journal of the American Association for Cancer Education. Jun 
2013;28(2):290-296.
14. Stricker CT, Jacobs LA, Risendal B, et al. Survivorship care planning after the institute of medicine 
recommendations: how are we faring? Journal of cancer survivorship : research and practice. Dec 
2011;5(4):358-370.
15. Salz T, McCabe MS, Onstad EE, et al. Survivorship care plans: is there buy-in from community 
oncology providers? Cancer. Mar 01 2014;120(5):722-730.
16. Maly RC, Liang L-J, Liu Y, Griggs JJ, Ganz PA. Randomized Controlled Trial of Survivorship Care Plans 
Among Low-Income, Predominantly Latina Breast Cancer Survivors. Journal of Clinical Oncology. 
2017;35(16):1814-1821.
17. Nekhlyudov L, Ganz PA, Arora NK, Rowland JH. Going Beyond Being Lost in Transition: A Decade of 
Progress in Cancer Survivorship. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology. Jun 20 2017;35(18):1978-1981.
18. Parry C, Kent EE, Forsythe LP, Alfano CM, Rowland JH. Can’t see the forest for the care plan: a call to 
revisit the context of care planning. Journal of Clinical Oncology. 2013;31(21):2651-2653.
19. Gotay CC, Pagano IS. Assessment of Survivor Concerns (ASC): a newly proposed brief questionnaire. 
Health Qual Life Outcomes. Mar 13 2007;5:15.
20. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development 
and validation of the general measure. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. Mar 1993;11(3):570-579.
Chapter 7
140
21. Vermunt JK, Magidson J. Latent GOLD 4.0 User’s Guide. Belmont, Massachusetts: Statistical 
Innovations Inc2005.
22. Boyes A, Girgis A, Lecathelinais C. Brief assessment of adult cancer patients’ perceived needs: 
development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). J Eval Clin 
Pract. Aug 2009;15(4):602-606.
23. Hodgkinson K, Butow P, Hunt GE, et al. The development and evaluation of a measure to assess 
cancer survivors’ unmet supportive care needs: the CaSUN (Cancer Survivors’ Unmet Needs 
measure). Psycho-oncology. Sep 2007;16(9):796-804.
24. Aranda S, Schofield P, Weih L, et al. Mapping the quality of life and unmet needs of urban women 
with metastatic breast cancer. European journal of cancer care. 2005;14(3):211-222.
25. Barg FK, Cronholm PF, Straton JB, et al. Unmet psychosocial needs of Pennsylvanians with cancer: 
1986–2005. Cancer. 2007;110(3):631-639.
26. Sanson-Fisher R, Girgis A, Boyes A, Bonevski B, Burton L, Cook P. The unmet supportive care needs 
of patients with cancer. Cancer. 2000;88(1):226-237.
27. Soothill K, Morris S, Harman J, Francis B, Thomas C, McIllmurray M. The significant unmet needs of 
cancer patients: probing psychosocial concerns. Supportive care in Cancer. 2001;9(8):597-605.
28. Ganz PA, Schag CC, Heinrich RL. The psychosocial impact of cancer on the elderly: a comparison 
with younger patients. Journal of the American Geriatrics Society. 1985;33(6):429-435.
29. Kroenke CH, Rosner B, Chen WY, Kawachi I, Colditz GA, Holmes MD. Functional impact of breast 
cancer by age at diagnosis. Journal of Clinical Oncology. 2004;22(10):1849-1856.
30. Sitzia J, Wood N. Patient satisfaction: a review of issues and concepts. Social science & medicine. 
1997;45(12):1829-1843.
31. Thompson AG, Sunol R. Expectations as determinants of patient satisfaction: concepts, theory and 
evidence. International journal for quality in health care. 1995;7(2):127-141.
32. Cohen M, Baziliansky S, Beny A. The association of resilience and age in individuals with colorectal 
cancer: an exploratory cross-sectional study. Journal of geriatric oncology. 2014;5(1):33-39.
33. Brandtstädter J. Sources of resilience in the aging self: Toward integrating perspectives. Social 
cognition and aging: Elsevier; 1999:123-141.
34. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G. Breast cancer survivors’ 
supportive care needs 2-10 years after diagnosis. Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer. May 2007;15(5):515-523.
35. Denlinger CS, Ligibel JA, Are M, et al. Survivorship: screening for cancer and treatment effects, 
version 2.2014. Journal of the National Comprehensive Cancer Network. 2014;12(11):1526-1531.
36. Warrington L, Absolom K, Velikova G. Integrated care pathways for cancer survivors - a role for 
patient-reported outcome measures and health informatics. Acta oncologica (Stockholm, Sweden). 
May 2015;54(5):600-608.
37. Paganini-Hill A, Hsu G, Chao A, Ross RK. Comparison of early and late respondents to a postal health 
survey questionnaire. Epidemiology. 1993:375-379.
38. McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving 
high-quality cancer survivorship care. Journal of Clinical Oncology. 2013;31(5):631-640.
39. Mullan F. Seasons of survival: reflections of a physician with cancer. Mass Medical Soc; 1985.





Survivorship care planning in gynecologic oncology – 
perspectives from patients, caregivers and health care 
providers







*these authors contributed equally to this work




Purpose: This qualitative study sought to describe the challenges following treatment and 
the preferences regarding survivorship care among patients treated for gynecological 
cancer, their caregivers and health care providers.  
Methods: Between July and August 2017, in-depth semi-structured interviews regarding 
survivorship were conducted at a large academic hospital in the United States among 
patients who recently completed treatment (<12 months) for a gynecological cancer 
(ovarian, endometrial, cervical and vulvar) and their primary caregivers. A focus group 
was conducted among health care providers (oncologists, nurses and fellows). Main 
themes were identified using descriptive content analysis. 
Results: A total of 30 individuals participated in this study (13 patients, 9 caregivers, 8 
health care providers). Almost all participants reported a desire for more information on 
how to address survivorship needs, specifically as they related to side effects, follow-up 
schedule, and psychological assistance. Despite this uniformly identified need for more 
information, preferences for survivorship care planning differed across cancer types and 
individuals, with respect to content, timing and mode of delivery. Health care providers 
expressed challenges in communicating with patients about survivorship, a desire to 
shift post-treatment conversations to the goal of improving quality of life as opposed to 
focusing on disease recurrence, and an unmet need for disease specific and individualized 
survivorship care planning.
Conclusions: Patients, caregivers and health care providers each expressed a need for 
gynecologic cancer-tailored survivorship care resources.
Implications for cancer survivors: The variation of disease types and patient and 
caregiver needs may require multi-faceted, individualized survivorship care planning. 




Each year, almost 106,000 women in the United States are diagnosed with a gynecological 
cancer.1 Ovarian cancer remains the deadliest gynecological cancer, followed by vaginal, 
cervical, endometrial and vulvar cancer. The estimated five-year survival rates vary widely 
from 46% for women with ovarian cancer to over 80% for women with endometrial 
or vulvar malignancies.1 Survival rates for gynecological cancers have slightly increased 
during the past decades,1 reflecting advances in treatment that ultimately help patients 
survive their disease. 
Regardless of prognosis, a wide body of literature supports the notion that women 
treated for gynecological cancer experience a significant level of disease- and treatment-
related symptoms that persist after the end of first-line treatment and greatly impact their 
long-term quality of life.2-7 In addition, one of the most significant and overwhelming 
psychological concerns cancer survivors struggle to manage is the fear of cancer 
recurrence, which is associated with increased symptom burden, overwhelming anxiety, 
post-traumatic stress, and hopelessness.4,6,8-10
The National Academy of Medicine (NAM) acknowledged that these factors are important 
in the ongoing care for cancer patients ending treatment, and in 2006 recommended 
that all cancer survivors receive a Survivorship Care Plan (SCP).11 SCPs typically contain 
written information on diagnosis, documentation of all treatments, short- and long term 
effects of the treatments, and recommendation for follow-up care.11 To date, multiple 
randomized controlled trials evaluating the impact of SCPs among cancer patients,12-17 
including gynecological cancer,13,16,18 have failed to demonstrate beneficial effects of SCPs 
on short or long-term satisfaction with information provision and care, quality of life or 
distress. These outcomes suggest that patients with gynecological cancer may not receive 
the intended benefits of an SCP as proposed by the NAM without further refinement and 
evaluation of these interventions.19
Part of the disconnect between the prominent calls for SCPs as a self-evident beneficial 
intervention and the lack on strong evidence supporting SCPs in their current format may 
stem from a failure to adequately tailor these interventions to the needs of specific cancer 
patient populations. Additionally, there may be a need to further adapt the intervention to 
the needs and preferences of the individual patient. Given the lack of evidence to support 
existing SCP models in the setting of gynecologic oncology, we sought to describe the 
perspectives of patients with gynecological cancer, as well as their caregivers and health 
care providers (HCPs). This may provide insights into the unmet needs of patients and 
their caregivers as well as challenges to the healthcare team and identify opportunities for 
effective intervention through SCPs or other aspects of survivorship care.
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The aim of the current study is to describe the 1) challenges following treatment and 2) 
the preferences regarding survivorship care among patients treated for gynecological 
cancer, their caregivers and HCPs.  
METHODS
Design
This study employed an open-ended qualitative descriptive design including in-depth 
semi-structured interviews among three stakeholder groups: patients with a gynecological 
cancer, their caregivers, and gynecologic oncology HCPs with whom we conducted a 
focus group. The study protocol was approved by the Dana-Farber/Harvard Cancer 
Center Institutional Review Board. 
Participants and recruitment
Patients older than 18, able to read and respond in English, that completed treatment for 
any type of gynecological cancer within the past 12 months, were eligible to participate 
in the study. The study team reviewed upcoming clinic schedules for eligible patients 
and invited those patients to participate during a scheduled outpatient clinic visit at the 
Cancer Center, or were invited by phone. Patients were asked to identify their primary 
caregiver defined as a spouse, family member or friend who provides care and support 
to the patient. Caregivers were introduced to the study at the Cancer Center, or by phone 
when not present at the Cancer Center. After informed consent, telephone or in-person 
interviews with patients and caregivers were scheduled at a time convenient for them. 
HCPs that primarily provide care for patients with gynecologic cancer (gynecologic 
oncolgists, medical oncologists, gynecologic oncology fellows and nurse practitioners) 
were invited to participate in a focus group interview during a regular gynecologic 
oncology staff meeting. Informed consent was obtained at the beginning of the meeting.
Data collection
Telephone or in-person interviews with patients and caregivers and the HCPs focus 
group were digitally recorded. Audio-recordings were transcribed verbatim to text using 
TranscribeMe.com. In addition, demographic questionnaires were completed by patients 
and caregivers. Measures included age, sex, ethnicity, education and employment. Clinical 
patient data was extracted from each patient’s electronic medical record.
Interview guide
Semi-structured qualitative interview guides were developed by members of the study 
team. We purposefully included open-ended questions to determine patient and 
caregiver needs a priori with minimal predetermined categories of survivorship care 
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planning topics. While the patient and caregiver questionnaire guides included similar 
items tailored for each group, separate questionnaire guides were developed for HCPs. 
The interview guides were discussed and refined by study team members resulting in a 
list of questions and follow-up probes for each group.
Data analysis
Data transcripts were coded in NVivo 11 (QSR International) using descriptive content 
analysis techniques. The initial coding scheme for patient and caregiver interviews was 
based on the first 3 patient interviews and iteratively refined and expanded while reviewing 
additional interviews. Two study researchers (THT and BHR) generated the categories 
independently through a close reading of the transcript texts, jointly comparing their 
categories, reviewing any discrepancies and disagreements, and resolving discrepancies 
through consensus. We continued reviewing coding until saturation was achieved and 
no new category themes emerged. After developing a comprehensive list of categories, 
we then summarized and classified the categories into higher-order themes. To ensure 
consistency between themes, categories, and the raw data, we selected representative 
quotations of each theme to illustrate its meaning and assist with data interpretation. 
Codebooks were developed for patient interviews first, and applied to the caregivers’ 
interviews after determining similar content between these interviews. The HCP focus 
group was coded separately due to their distinct perspective and ideas discussed. We 
calculated the frequency of specific categories and compare these to patients’ and 
caregivers’ responses. Based on emerging categories indicating differences in type of 
gynecological cancer, we also decided to compare the perspectives of patients and 
caregivers with ovarian cancer versus other gynecological cancer types. As a qualitative 
study, we focused our comparisons on basic descriptive statistics and did not use our 
quantified data to statistically test group differences to avoid over-simplifying our 
qualitative exploratory data.
RESULTS
In total, we had 30 participants included in this study (thirteen patients, nine caregivers 
and eight HCPs). Five patients that were approached did not want to participate (no 
time/busy or did not want to be reminded of their cancer) and one patient was lost to 
follow-up. Four caregivers identified by patients chose not to participate in the study. 
Only one patient had an in-person interview, all other patients and caregivers preferred 
telephone interviews. Interviews for patient and caregiver participants lasted 30 – 40 




Table 1 describes patient and caregiver characteristics. Patients (n=13) represented various 
gynecological cancer types, including ovarian (n=5), endometrial (n=4), cervical (n=2), 
fallopian tube (n=1) and vulvar (n=1), had an average age of 63, were predominantly 
white (92%), unemployed at the time of the interview (62%) and completed treatment 
6 months before the interview. Caregivers of patients (n=9) were mostly the patient’s 
spouse (n=6), had an average age of 59, were predominantly male (78%), white (100%), 
and employed at the time of the interview (56%). The HCP focus group (n=8) included 
gynecologic oncolgists (n=2), gynecologic oncology fellows (n=3), a medical oncologist 
(n=1), a radiation oncologist (n=1) and a nurse practitioner, (n=1), and were predominantly 
female (n=5, 63%). 
Perspectives of patients and caregivers 
The major categories found in patient and caregiver interviews were: (1) symptoms and 
concerns, (2) fear of recurrence, (3) information, (4) needs, (5) satisfaction with care, (6) 
self-management and coping (7) preferences for survivorship care planning. Illustrative 
quotations are presented below and additional quotations are stated in Table 2. 
Symptoms and concerns. Patient symptoms causing distress were described by the 
majority of both patients and caregivers (10/13 patients; 9/9 caregivers). Pain (4/13 
patients; 2/9caregivers), neuropathy (3/13 patients; 2/9 caregivers), fatigue (3/13 patients, 
1/9 caregivers) and anxiety/depression (2/13 patients; 4/9 caregivers) were the most 
commonly discussed distressing symptoms. One patient noted that managing her 
symptoms after treatment ended was particularly challenging:
“Post-treatment… that was the hardest time during the whole process because 
there were a multitude of side-effects that I was dealing with that … I didn’t have 
enough information about …I just wasn’t reassured enough that it was going to get 
better. Or maybe I was unable to absorb that it was going to get better.” (Patient 11, 
vulvar cancer, stage unknown).
Almost half of patients (6/13) expressed that they had limited or no post-treatment 
symptoms, indicating that whatever symptoms they did experience were not distressing. 
While some caregivers reported a similar desire for reassurance that physical symptoms 
would subside post-treatment, they reported many more concerns about dealing with 
the emotional adjustment. For example, one caregiver described his lack of training in 
medical symptoms and concern about his ability to emotionally support his wife:
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Age, M (min-max) 63.1 (48-71) 63.0 (48-71) 61.7 (51- 75) 58.7 (34-73) 60.4 (34-73) 56.5 (37-79)
Sex
   Male














   White














   High school diploma or 
2 year/associate’s degree
   4 year/ bachelor’s 
degree
   Graduate/professional 
degree


























   Yes
   No




















Cancer type, N (%)
    Ovarian
    Endometrial
    Cervical

























Cancer stage, N (%)
    I
    II
    III
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Treatment type, N (%)
    Surgery only
    Chemotherapy 
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“I’m not too concerned with the physical stuff. I can deal with that. Her feet don’t 
work. Her hands don’t work. And she’s had a profound hearing loss. I have no 
training background or anything in how to assist with that. But she’ll say, “Can you 
open this for me?” … those easy things…. I’m more concerned with the emotional 
support and maybe being sensitive, those types of things.” (Caregiver 7, Fallopian 
tube cancer, stage IIB).
Fear of Recurrence. Fear of recurrence was common among both patients and caregivers 
(9/13 patients; 8/9 caregivers). Some patients reported overwhelming preoccupation with 
the chance that their cancer could return: 
“I’ve had a lot of anxiety over it. Like if I get a pain, right away, my head goes to the 
worst-case scenario. So the fact that I had the cancer, it makes me more anxious 
about thinking that I could get it somewhere else.” (Patient 3, fallopian tube cancer, 
stage IIB).
Of interest, despite the majority confirming they experienced fear of recurrence, most 
also noted they were not preoccupied with this fear (10/13 patients; 2/9 caregivers).
Informational Needs. Informational needs were reported by both caregivers and patients 
and included possible signs or symptoms of recurrence (11/13 patients; 8/9 caregivers), 
management of side-effects (7/13 patients; 6/9 caregivers), contact information for care 
providers or sources of specialized services (6/13 patients; 2/9 caregivers), symptom 
management (4/13 patients, 4/9 caregivers) and methods to reduce risk of recurrence or 
new cancers (no patients; 5/9 caregivers).
Self-management and coping. Patients and caregivers wanted to know what the range 
of expected ongoing issues might be so that they could make informed decisions about 
when to contact their oncology HCP. Patients saw this as a way to self-manage and 
control their health:
“I am the best steward for my body. I’m the one that looks at it and feels it every 
day….I need to have as much education as I can have so that I can take care of my 
body” (Patient 8, ovarian cancer, stage IIIC). 
Caregivers felt similar desires:
“That would be my job to decide or not. But no, I don’t want the medical providers 
deciding that. I want to know everything” (Caregiver 7, ovarian cancer, stage IIIB). 
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Some patients did not want to be scared by the post-treatment side-effects:
“I don’t like to get more information than what I really need to know. I don’t want 
to scare myself…. I was going through this with just being calm and see what 
happens” (Patient 2, endometrial cancer, IA).
Satisfaction with care. Although the majority reported satisfaction with the current 
informational resources they received from their oncology HCP (11/13 patients; 9/9 
caregivers), almost all (12/13 patients; 9/9 caregivers) expressed a need for supplemental 
information to address their remaining issues and ongoing concerns. Most patients and 
caregivers reported feeling like they could contact their oncology HCP whenever they 
needed help:
“I’m not that concerned because I know that if something comes up and I’m 
unsure, I can call them and see them, or I can call them and ask them” (Patient 4, 
endometrial cancer, stage IIIA; and ovarian cancer, stage unknown). 
Survivorship care planning. Patients and caregivers mainly prefered to receive an SCP in 
written form (8/13 patients; 5/9 caregivers) though the majority noted that both written 
and online were acceptable (7/13 patients; 6/9 caregivers). Most wanted the SCP to be 
updated overtime (9/13 patients; 6/9 caregivers), and many wanted to receive the SCP at 
first follow-up visit (5/13 patients; 5/9 caregivers). Some did not think that a SCP would 
be applicable to them (3/13 patients; 1/9% caregivers) because they received minimal 
treatment:
“…They were very thorough with telling me everything that happened. Maybe it 
might have been different if I was getting further treatment like the chemo or 
radiation. I think you would want to know more information about that and how 
this is going to work or, I don’t really know.” (Patient 2, endometrial cancer, stage 
IA).
While patients and caregivers varied in their preferences for the ideal content and timing 
of SCPs, most described their choices as based on their evolving state of health. Therefore, 
single review of treatment and care plan at the completion of initial therapy as a one 
time SCP to address survivorship concerns does not appear to be sufficient. Patients and 
caregivers wanted information when it would be immediately relevant to their health and 
well-being at multiple points across the disease trajectory:
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“It all depends on my state of health. If I am very sick, I don’t think I even need the 
information, but if I’m starting with symptoms, as soon as possible. So we, myself 
and my care team, will have that plan in motion for treatment.” (Patient 1, ovarian 
cancer, stage IV).
Ovarian versus non-ovarian cancer
Compared to patients with non-ovarian cancer types (n=7), patients with ovarian cancer 
(n=6) more often reported mood problems such as anxiety and depression (2/6 ovarian; 
0/7 non-ovarian) and chemo-brain (2/6 ovarian; 0/7 non-ovarian), while non-ovarian 
cancer patients more often reported having no or limited symptoms (2/6 ovarian; 4/7 
non-ovarian). Coping strategies of ovarian cancer patients were more often spiritual (4/6 
ovarian; 1/7 non-ovarian) and trying to be optimistic (4/6 ovarian; 1/7 non-ovarian):
“I don’t look back. Right now, I don’t have cancer and I choose not to think that it’s 
coming back. I’m very positive. I live for today and that’s how I manage. I don’t know 
about anybody else but that’s my attitude.” (Patient 1, ovarian cancer, stage IV).
With regard to survivorship care planning, both ovarian cancer patients and caregivers 
preferred to receive written information (6/6 ovarian patients; 2/7non-ovarian patients; 
4/5 ovarian caregivers; 1/4 non-ovarian caregivers). Many of the patients with other types 
of gynecological cancers –  but none of the patients with ovarian cancer – reported 
that they were not interested in a SCP because it was not relevant to their situation (0/6 
ovarian; 3/7 non-ovarian). 
“I think this question [about SCPs] is more for people that have been through a lot 
more than what I have been through.” (Patient 2, endometrial cancer, Stage IA).
Perspectives of health care providers
The HCP focus group included a detailed discussion on the challenges they encounter 
while communicating about survivorship.. Illustrative quotations are presented below and 
additional quotes are stated in Table 3. A major barrier to communication was feeling an 
underlying tension between being direct about the likelihood of a recurrence without 
stripping away the patient’s ability to enjoy life. They reported a reluctance to “scare” 
patients with information about recurrence and ongoing health issues as a way to help 
patients focus on enhancing their quality of life: 
“There’s always this really inherent tension in that visit, between stating that [the 
cancer is incurable] again, and taking away the reprieve that they’re about to 
have.... The tension between being honest and being cruel, or being misleading. 
And it’s very complex, and the language is very complex.... So it’s a tight dance” 
(Provider 4, gynecologic oncologist).  
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Table 3: Themes identified and exemplary quotes of health care providers





cating about survivorship, 
struggling to find necessary 
resources for patients, 
uncertainty about recur-
rence, not wanting to scare 
patients/ improve quality 
of life
“I think I use it as a sort of metric about my degree of 
burnout. If I’m looking at the end-game for them, and 
they’re depressed about the potentially bad outcome, I 
feel like I’m a bit more burned-out. Whereas, if I’m cele-
brating with them now, I’m-- sort of feel like I understand 
the big picture, but where are they at now.” (Provider 2, 
medical oncologist)
“Helping people be able to use that good time that they 
have because I know that ovarian cancer patients actually 
spend a lot of that time just worrying and freaking out. 
And if care plan can help with that, but I’d be hopeful 
it might. Whereas for early stage in endometrial cancer 
patients, who we tell, “You’re probably cured,” I would 
actually want the care plan to be a little bit different and 
I actually want more there to be, like “If you have X kind 
of symptoms, or bleeding, or whatever, please give us a 
call.” So I think, to me, I’d want them to be really shaped 
to what the general trajectory is that diseases tend to be.” 
(Provider 7, gynecologic oncology fellow)
Need for 
survivorship 
care plan and 
resources
Need for SCP (most com-
mon issues/percentages, 
reassurance, sexual health, 
support groups, diet, 
exercise, attitude, how to 
get back to normal, what 
to expect, follow-up plan), 
written information as 
supplement to conversation, 
referencing what to look out 
for and when to come back, 
disease-specific SCPs
“I don’t think I call it the survivorship plan. I think we 
just come up with a strategy for how they’re going to 
move forward with or without their cancer. And we talk 
about what’s sort of important.” (Provider 1, gynecologic 
oncologist)
“[Patients] seem to think that they’re the only ones going 
through this process and they feel alone. And I never 
knew any of the resources to hook them up with. Like are 
there support groups out there? What are the resources 
they have so they don’t feel so alone and can go forward 
in the survivorship period of their lives.” (Provider 5, 
gynecologic oncology fellow)
“if we had more of a standardized thing that we knew, oh, 
80% of people have this, da, da, da, da, and you could 
kind of run through that check off and then have the 
immediate thing that they needed to get plugged into.” 





Barrier of time, not wanting 
to open up difficult needs, 
who should provide SCPs 
(oncologist, nurse, any-
body), logistics of providing 
SCPs, standardized list of 
prompts / screening tools
“What if you ask somebody and they go to pieces in front 
of you, and then you have like a whole new thing and 
you don’t have the ability to unpack it for an hour and a 
half. It’s really hard. So how do you do that? And how do 
you make them feel like you’ve heard them?” (Provider 1, 
gynecologic oncologist)
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Another challenge to communication was prognosis. For patients who were likely to 
experience a recurrence (e.g., patients with ovarian cancer), providers desired to reinforce 
that patients should live life in spite of fear and uncertainty: 
“It’s a question of how do we convey to patients that the time that they have in 
remission is precious and important? And they shouldn’t delay life events thinking 
that they’re going to have a really long time to sort of get to that later” (Provider 
1, gynecologic oncologist). 
Despite the information available, HCPs felt they continued to struggle to find necessary 
resources for patients. They expressed the need for survivorship-care resources to 
facilitate and support conversations about what to expect after treatment including a 
follow-up plan. The examples described by one provider describe the extent and details 
of the resources providers wanted to provide their patients: 
“I think it would be nice just to have resources about how to get back to your 
normal life. So what to do if you’re depressed or anxious, or how to get sexual 
function back, or interest, or exercise. So, things not just about the cancer, but how 
can we get back to your life and living with the cancer” (Provider 6, gynecologic 
oncology fellow).
Providers also expressed that they want tailored and disease-specific SCPs to assist with 
difficult conversations, particularly referring to ovarian cancer as being different from 
other gynecological cancers:
“Because you want to celebrate the win and not tell them that we’re going to run 
out of runway” (Provider 1, gynecologic oncologist).
However, the main barrier to providing a SCP to patients identified by providers was lack 
of time.  In addition to concerns over time to develop and present a SCP, some worried 
that providing a SCP might identify needs or open up conversations that providers could 
not address during the visit. Gynecologic oncologists preferred to have a medical doctor 
or other member of the gynecological cancer team provide an SCP, but some felt that this 





This study reports participants’ self-identified concerns and preferences for survivorship 
care. Findings indicate that patients with a gynecological cancer and their caregivers have 
needs and ongoing issues after treatment, such as side-effects and psychological distress, 
and that they desire information on how to better address these needs. Preferences 
for survivorship care largely differ across cancer types and individuals, with respect to 
content, timing, and mode of delivery and reflect the need for disease-specific, tailored 
SCPs and follow-up care to support care to the diverse group of gynecological cancer 
survivors. Our results contribute to the ongoing discussion about effective and efficient 
means to support survivorship care planning in gynecologic oncology, further highlighting 
the fact that ‘one size fits all’ approaches are unlikely to be successful, and individualized 
assessment and care planning is needed. 
Issues, concerns and symptoms most often discussed in our study are similar to previous 
work and include pain, neuropathy, fatigue and mood problems such as anxiety, 
depression and fear of recurrence.2-7 As reported in previous literature, ovarian cancer 
patients more often described mood problems and fear of recurrence or progression 
compared to non-ovarian cancer patients.20 As a result, compared to non-ovarian cancer 
patients, ovarian cancer patients more often expressed a need for contact information or 
referral for someone to help with these concerns. 
Caregivers in our study reported similar perspectives as patients, but with several notable 
exceptions including more frequent endorsement of being afraid of a cancer recurrence 
or disease progression and wanting to learn health promotion strategies. These results 
complement growing literature describing the changing and often increasing needs 
of caregivers of individuals with gynecological cancer.21,22 For example, Stafford and 
Judd (2010) found that caregivers’ unmet needs were a key predictor of their anxiety, 
depression, and relationship satisfaction.23  Integrating caregivers’ ongoing unmet needs 
such as those identified in our study into survivorship care can address their concerns and 
prevent these negative outcomes. Addressing the concerns and needs of caregivers as 
an aspect of survivorship care may reduce distress among patients and improve quality 
of life.
In spite of most patients and caregivers in our study being highly satisfied with information 
supplied by and resources identified by their HCPs, they still reported informational 
needs that remained unaddressed. Notably, some stakeholders wish to receive a written 
document including information about what to expect after treatment and extensive 
and up to date information on specific topics, which largely resembles a Survivorship 
Care Plan (SCP) as was proposed by the NAM since 2006.11 However, other patients and 
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caregivers did not describe a clear need for additional resources or desire for more 
information. In this wide range of needs and preferences, a ‘one size fits all’ approach 
may not be most effective nor efficient. This might explain why previous trials assessing 
the effectiveness of SCPs failed to identify benefits in unselected populations, including 
samples of American.13 and Dutch16,17 gynecological cancer patients. Though women in 
the latter trial only included endometrial and ovarian cancer, previous analyses suggest 
that patients’ benefit of SCPs is indeed heterogenous24,25  Ideally, survivorship resources 
should be allocated to those with highest neccesity and be updated over time. This 
highlights a need for screening for informational and other needs as an important part of 
survivorship care, and a necessary step in the development of individualized SCPs. Future 
SCP effectiveness trials should focus on individualized SCPs, particularly when assessed in 
heterogenous patient populations such as in gynecological oncology.
As most patients and caregivers did not indicate a clear preference for either written or 
online SCPs, an online, patient-centered application including tailored information for 
those with specific needs could be a solution that fits the needs of all stakeholders. A 
written leaflet including more general information could complement the online tool, or 
even replace it for those with minimal information needs. Further, patients and caregivers 
who were interested in an SCP indicated that they would like to receive one during the 
first follow-up visit after the end of treatment, and prefer a conversation accompanied 
with it, as opposed to generation of a document alone. An important finding of this 
study is that patients and caregivers do not indicate a strong preference for the person 
leading this conversation. Conversely, HCPs in our study believe that patients prefer their 
treating oncologist to provide survivorship care planning. However, they also recognize 
that this may not be feasible in their practice due to increasing clinical burdens and lack 
of time. Previous studies also found that lack of time was cited as the greatest barrier to 
implementation of SCPs.26,27 While oncologists buy into the concepts of survivorship care 
planning, the suggestions from providers in our study offer potential ways to address 
systematic implemention including personalization of care plans to individual patients, 
inclusion of a dedicated support staff to facilitate discussions, and creation of a prompt 
list to initiate the discussion using careful but clear communication strategies. Our 
study supports that patients and caregivers may be amenable to receive SCPs by other 
members of the care team besides the oncologist, depending on the clinical practices’ 
logistics and feasibility. 
This study includes a variety of gynecological cancer types and stages, caregiver types, 
and gynecologic oncology HCP. Even though our sample was reasonably heterogenous, 
we reached data saturation for all groups. Our qualitative data allowed for assessment 
of unique individual and hetergenous experiences of stakeholders. Our findings provide 
detailed in-depth descriptions of the various perspectives in this field and enrich the 
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limited literature available. However, a limitation of this study includes the use of a single 
medical center to recruit participants, serving patients with a relatively high socio-
economic status and few ethnic minorities. Further, only one patient and her caregiver 
were clearly dissatisfied with care at our center, which is not in coherence with literature 
showing much higher proportions of dissatisfaction with care,28,29 resulting in potentially 
biased descriptions of concerns and preferences.  
Conclusion
In conclusion, patients and caregivers in this study endorsed the need for personalized, 
tailored survivorship care planning starting near the end of treatment. Patients with 
ovarian cancer reported qualitatively different experiences and desires as patient with 
non-ovarian gynecological cancers, indicating these groups may require distinct forms 
of care planning. HCPs require assistance in starting sensitive conversations at the end 
of treatment, but are open to providing individualized SCPs to their patients within the 
context of the entire team. These qualitative findings provide a description of the self-
reported needs of multiple stakeholders, highlight barriers and opportunties to address 
survivorship needs within the gynecology oncology clinic, and can be used to support the 
development of patient-centered survivorship care planning interventions.
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Objective: The primary aim of this study was to assess the longitudinal impact of a 
recurrence of gynecological cancer on satisfaction with information provision and care. 
The secondary aim was to assess the impact of a recurrence on illness perceptions, anxiety 
and depression and health-related quality of life (HRQoL).
Methods/ materials: This study is a longitudinal analysis from the ROGY Care trial, 
conducted between 2011 and 2014, including patients with endometrial (N=215) and 
ovarian (N=149) cancer. Patients were invited to complete questionnaires directly after 
initial treatment and after 6, 12 and 24 months. Satisfaction with information provision 
and care, illness perceptions, anxiety and depression  were compared before and after 
the recurrence. Linear mixed model analyses were conducted to assess the differences in 
outcomes of patients with a recurrence compared to patients without a recurrence.
Results: During 2-year follow-up, 25 patients with endometrial cancer (12%) and 64 
patients with ovarian cancer (43%) had recurrent disease, of whom 9 endometrial and 
26 ovarian cancer patients completed at least one questionnaire after their recurrence 
was determined. Patients reported lower satisfaction with care after the diagnosis of 
a recurrence (doctor interpersonal skills, exchange of information between caregivers 
and general satisfaction with care) compared to patients without recurrence. In addition, 
patients reported lower HRQoL, more anxiety and depression more threatening illness 
perceptions after diagnosis of a recurrence.
Conclusion: After diagnosis of recurrent disease, endometrial and ovarian cancer patients 
were less satisfied with care compared to patients without a recurrence. Our findings 
suggest that patients with recurrent cancer are in need of care that is better tailored to 
their needs. 




Over the past decades, the number of cancer survivors has rapidly increased, due to 
earlier diagnosis, improved treatment options and ageing. In 2016, there were about 15.5 
million cancer survivors in the United States, and this number is expected to increase 
to 20.3 million in 2026.1 This increasing cohort of cancer survivors remains at risk for 
long-term physical and psychosocial effects. Therefore, alongside crude survival, patient-
reported outcomes (PROs) are increasingly acknowledged to be important aspects of 
treatment efficacy.2-5   
One of the main concerns of cancer patients is the possibility of recurrent disease 
followed by palliative treatment and imminent death.6 In gynecological cancer, the risk of 
recurrence is highest in ovarian cancer due to its usual diagnosis at an advanced stage 
of the disease; 75% of all ovarian cancer patients will eventually get recurrent disease.7 In 
contrast, endometrial cancer usually presents at an early stage and therefore generally 
has a good prognosis.8  However, even in low-stage endometrial cancer about 6% of 
the patients will have recurrent disease.8,9 Regardless of the risk of recurrence, fear of 
cancer recurrence seems to be a universal concern of cancer survivors.6,10 Thus, insecurity 
about new and remaining symptoms after cancer treatment and the possibility that these 
symptoms may indicate the presence of a recurrence may negatively affect quality of life 
and increase health care use.11,12
Previous research shows that psychological responses to cancer recurrence include the loss 
of hope for recovery, anxiety and depressive symptoms, fear of death and difficulties with 
disability.10,13-16 In breast cancer survivors, patients with recurrent cancer experience lower 
anxiety and confusion compared to patients after their first diagnosis of cancer, but worse 
health-related quality of life (HRQoL), poorer physical functioning, and higher cancer 
related distress compared to patients without a recurrence.17,18 Similarly, a recent study 
in patients with recurrent ovarian cancer showed high levels of anxiety and depression 
among these patients, but anxiety decreased during active treatment of the recurrence .19
Little is known about satisfaction with information provision and care in patients with a 
recurrence. Qualitative studies suggest that patients with a recurrence are less satisfied 
with communication with their health care providers compared to before the recurrence, 
because they felt no longer heard about their concerns and symptom.20,21 A study in 
patients with recurrent digestive cancer requiring palliative care shows that low satisfaction 
with care is associated with low HRQoL22. To our knowledge, no quantitative studies have 




Therefore, the main aim of the current study is to assess the longitudinal impact of 
a recurrence on satisfaction with information provision and care  in endometrial and 
ovarian cancer patients. Secondary, we aim to assess the impact of a recurrence on illness 
perceptions, anxiety and depression and health-related quality of life. We hypothesize that 
patients who develop a recurrence are disappointed with their outcome and therefore 
experience lower satisfaction with information provision and care compared to before 
their recurrence was determined as well as compared to patients without a recurrence.
METHODS
Design
This study included endometrial and ovarian cancer patients from the ROGY Care 
trial. Details of the ROGY Care trial are described in the protocol paper.23 The effects 
of Survivorship Care Plans (SCPs) on health care provider and patient-reported 
outcomes have been described previously.24,25 The present study uses the trial data as an 
observational prospective dataset and does not assess the effects of SCPs.
Participants and recruitment
All patients with newly diagnosed endometrial cancer (N=221) between April 2011 and 
October 2012 or ovarian cancer (N=174) between April 2011 and March 2014 were invited 
to participate to the ROGY Care trial with a letter and informed consent by their treating 
gynecologist.  Follow-up questionnaires were sent to the patients after initial treatment, at 
6, 12 and 24 months after treatment. Patients with primary progressive disease (endometrial 
cancer N=6 and ovarian cancer N=25) were excluded from the current analysis (Figure 1). 
Measures 
Questionnaires included all primary and secondary outcome measures at each time-
point. Outcomes were assessed with validated measures shown to have acceptable 
psychometric properties. Additional clinical data were obtained from the Netherlands 
Cancer Registry (NCR), including date of diagnosis, cancer type, FIGO (Federation 
International of Gynecology and Obstetrics) stage and primary treatment. After closing 
of the trial in July 2016, additional information on the presence or absence of recurrence, 
date of recurrence and the provided treatment for recurrence were extracted from the 
medical records retrospectively.
Primary outcome measures
Satisfaction with information provision was assessed with the EORTC (European 
Organization for Research and Treatment of Cancer) INFO25.26 Scales included four multi-
item subscales (information about the disease, medical tests, treatment and other care 
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services) and four single-item scales (information about different places of care, things 
you can do to help yourself get well, satisfaction with the information, helpfulness of the 
information). All scales were converted to a score between 0 (low perceived information 
provision) and 100 (high perceived information provision).  Additional remarks about 
satisfaction with information provision were examined to find explanations for our findings.
Satisfaction with care was assessed with the EORTC INPATSAT32.27 Scales included three 
multi-item scales (doctor’s interpersonal skills, doctor’s technical skills and doctor’s 
information provision) and two singe-items scales (exchange of information between 
caregivers and general satisfaction with care). All scales were converted to a score 
between 0 (low perceived quality of care) and 100 (high perceived quality of care).  
Secondary outcome measures 
Illness perception was assessed with the Brief Illness Perception Questionnaire (B-IPQ).28 
Scales included eight single-items regarding cognitive illness representations (how much 
illness affects life, how long illness will continue, how much patient has control over 
illness, how much treatment helps to cure illness, how many symptoms are experienced), 
emotional representations (how concerned patient is about illness, how much patient 
is affected emotionally) and comprehensiveness (how well patient understands illness). 
Patients indicated their endorsement with an item on a scale between 1 (low endorsement) 
and 10 (high endorsement).  
Anxiety and depression was assessed with the Hospital Anxiety and Depression scale 
(HADS).29 Scales included 7 items for anxiety and 7 items for depression. Each item 
indicated a score between 0 (no anxiety or depression) and 3 (the worst anxiety or 
depression). The sum of these items resulted in two subscales for anxiety and depression, 
ranging between 0 and 21.  
HRQoL was assessed with the EORTC QLQ-C30.30 This questionnaire included multiple 
scales: global QoL, function scales (physical, role, emotional, cognitive, social) and 
symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, 
constipation, diarrhea, financial difficulties). All scales were converted to a score between 
0 (low QoL/no symptoms) and 100 (high QoL/a lot of symptoms).
Statistical Analysis
The data were analyzed using Statistical Analysis System (SAS) version 9.4 (SAS Institute, 
Cary, NC, 1999). Differences were considered statistically significant at a p-value ≤ 0.05. 
Differences in patients and tumor characteristics between patients with and without 
recurrent disease were analyzed using the t-tests for normally distributed continuous 
variables and chi-square tests for categorical variables. 
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Longitudinal changes in outcomes before and after recurrence were analyzed using 
dependent samples t-tests. In this analysis, only patients with a recurrence who 
completed at least one questionnaire before and after recurrence were included (N=35). 
Measurement time-points included in the analyses differ by time of recurrence (either 0 
and 6, 6 and 12, or 12 and 24 months after initial treatment). Patients without a recurrence 
during follow-up were randomly matched to patients with a recurrence on tumor type and 
questionnaire time-points (N=35), resulting in a representative control group with equal 
numbers of endometrial and ovarian cancer patients, and equal time-point distribution 
likewise the patients with a recurrence. Visual representations of longitudinal changes in 
PROs were computed for patients with a recurrence on the available data of time-points 
before and the available time-points after recurrence and the matched patients without 
a recurrence. 
Multilevel linear mixed models were used to assess the between-subject effects of having a 
recurrence on outcomes, allowing for adjustment of inter-dependency between repeated 
measures within patients31, and correction for missing data at random.32 In this analysis, 
all patients with (N=35) and without (N=255) a recurrence, and all time-points (after 
initial treatment, after 6, 12, and 24 months) were included. Overall effects were assessed 
comparing outcomes of observations of patients with a recurrence  (after diagnosis of 
recurrent disease) to all observations of patients without a recurrence (including patients 
before diagnosis of recurrent disease). In the crude model, no adjustments were made 
for time-point or cancer type and therefore the crude means may show biased results. In 
the adjusted model, adjustments were made for all a-priori selected covariates, including 
time-point (after diagnosis, after 6, 12, and 24 months), age, socio-economic status, 
cancer type, FIGO stage, primary treatment (chemotherapy, radiotherapy), employment 
status, marital status, and trial allocation (SCP care versus usual care).
RESULTS
Of the 544 patients who received an invitation to participate in the trial, 395 patients 
(73%) completed the first questionnaire, of which 221 patients had endometrial cancer 
(75%) and 174 patients had ovarian cancer (70%). Questionnaires were completed by 
282 patients (52%) after 6 months, 248 patients (46%) after 12 months, and 203 patients 
(37%) after 24 months. Over 24 months, 25 patients with endometrial cancer (12%) and 64 
patients with ovarian cancer (43%) had recurrent disease (Figure 1). Only 35 patients with 
a recurrence completed at least one questionnaire after recurrence, of whom 9 patients 
with endometrial cancer and 26 patients with ovarian cancer.
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No statistical tests were conducted to assess the differences in baseline characteristics 
between patients with and without a recurrence because numbers of patients with a 
recurrence were too small. However, higher tumor stages are observed in patients with 
a recurrence (FIGO stage III and IV, 33% vs. 3% in endometrial; 80% vs. 29% in ovarian; 
Table 1). 
Outcomes were significantly different after diagnosis of a recurrence, compared to before 
recurrence: patients reported lower satisfaction with information about the treatment 
(P<0.03), other services (P<0.03), doctor technical skills (P=0.04), doctor interpersonal 
skills (P=0.01), doctor information provision (P=0.03), exchange of information between 
caregivers (P=0.01) and lower general satisfaction with care (P<0.01) after diagnosis of a 
recurrence compared to before. No differences in outcomes were found between patients 
with and without a recurrence at the matched-time points (Table 2; Figure 2).
In addition, patients with a recurrence reported also a significantly more threatening 
illness perceptions; more anxiety and depressive symptoms; lower global QoL and more 
physical symptoms after a recurrence then before the recurrence. (Appendix 1).
In multilevel linear analysis, patients with a recurrence compared to patients without a 
recurrence reported significantly lower satisfaction with doctor interpersonal skills (β=-
7.7, P<0.01), exchange of information between caregivers (β=-7.5, P<.0.01) and general 
satisfaction with care (β=-7.9, P<0.01), after adjustment for potential covariates. 
In the remarks patients with a recurrence made in the open fields of the questionnaire, 
a variation was observed in the perceived of amount of information received from care 
providers. Some wanted to have had more information on recurrence (‘Generally doctors 
give less information about the cancer.’), and others did not want too much information 
(‘I don’t want too much information, it makes me ill.’).
DISCUSSION
In endometrial and ovarian cancer patients with a recurrence, we found lower satisfaction 
with care after their recurrence was determined, compared to before a recurrence and 
compared to patients without a recurrence. No differences were found in satisfaction with 
information provision between patients with and without a recurrence.
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Patients receiving questionnaire: N=544 
(endometrial N=296; ovarian N=248) 
Patients completing questionnaire: N=395 (73%) 
(endometrial N=221; ovarian N=174) 
Patients completing questionnaire: N=282 (52%) 
(endometrial N=158; ovarian N=124) 
Patients with new recurrence: N=3 
(endometrial N=1; ovarian N=2) 
Patients not completing questionnaire: 
 Refused participation: N=149 
(endometrial N=75; ovarian N=74) 
 Deceased: N=8 
(endometrial N=4; ovarian N=4) 
Patients wanting to stop after 1st survey: N=84 
(endometrial N=53; ovarian N=31) 
6 months follow-up 
Patients not completing questionnaire: 
Refused participation: N=37  
(endometrial N=17; ovarian N=20) 
Deceased: N=16  
(endometrial N=3; ovarian N=13) 
Patients with new recurrence: N=18 
(endometrial N=8; ovarian N=10) 
Patients not completing questionnaire: 
 Refused participation: N=19 
(endometrial N=9; ovarian N=10) 
Deceased: N=9 
(endometrial N=1; ovarian N=8) 
Patients with new recurrence: N=14 
(endometrial N=1; ovarian N=13)
Patients completing questionnaire: N=248 (46%) 
(endometrial N=147; ovarian N=101) 
Patients with new recurrence: N=17 
 (endometrial N=5; ovarian N=12)
12 months follow-up 
Patients not completing questionnaire: 
Refused participation: N=40  
(endometrial N=19; ovarian N=21) 
Deceased: N=6 
  (endometrial N=1; ovarian N=5) 
Patients with new recurrence: N=21 
(endometrial N=6; ovarian N=15) 
Patients completing questionnaire: N=203 (37%) 
 (endometrial N=128; ovarian N=75) 
Patients with new recurrence: N=15 
(endometrial N=3; ovarian N=12)
After initial treatment 
Patients included in analysis:
Patients with a recurrence: N=35 
(endometrial N=9; ovarian, N=26) 
Patients without a recurrence: N=255 
(endometrial N=182; ovarian N=73)
Analysis 
Patients not included in analysis: 
Patients with progressive disease: N=31 
     (endometrial N=6; ovarian N=25) 
Patients with recurrence after follow-up: N=20 
     (endometrial N=8; ovarian N=12) 
Missing data on recurrence: N=1 
       (endometrial N=1; ovarian N=0) 
24 months follow-up 
Figure 1: Flow diagram of patient enrolment and follow-up of endometrial and ovarian cancer 
patients
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Table 1: Baseline characteristics of endometrial and ovarian cancer survivors, with and without 
recurrence during follow-up 









Age at survey, mean (SD) 68.2 (5) 67.5 (9) 64.9 (9) 59.6 (12)
SES, n (%)
   High 5 (56) 65 (38) 10 (48) 26 (38)
   Intermediate 2 (22) 76 (43) 7 (33) 29 (43)
   Low 2 (22) 34 (19) 4 (19) 13 (19)
Comorbidity, n (%)
   None 1 (11) 33 (19) 6 (23) 23 (32)
   1 0 (0) 48 (27) 8 (31) 20 (28)
   2 or more 8 (89) 97 (55) 12 (46) 29 (40)
Marital status1, n (%)
   Partner 7 (78) 135 (75) 19 (73) 57 (78)
   No partner 2 (22) 44 (25) 7 (27) 16 (22)
Employed, n (%)
   Yes 0 (0) 35 (21) 10 (38) 28 (38)
   No 8 (100) 133 (79) 16 (62) 45 (61)
FIGO-stage, n (%)
   I 6 (67) 174 (96) 3 (12) 43 (60)
   II 0 (0) 4 (2) 2 (8) 8 (11)
   III 2 (22) 3 (2) 17 (68) 16 (22)
   IV 1 (11) 1 (1) 3 (12) 5 (7)
Primary treatment, n (%)
   Chemotherapy 2 (22) 2 (1) 26 (100) 39 (54)
   Radiotherapy 6 (67) 56 (31) 0 (0) 0 (0)
Recurrence characteristics
Months to recurrence
   Mean (SD) 15.0 (4.6) 15.8 (5.4)
Treatment recurrence, n (%)
   Chemotherapy 5 (56) 17 (81)
   Radiotherapy 1 (11) 1 (5)
   Hormonal therapy 2 (22) 1 (5)
Note: patients were excluded when having a primary progressive cancer (endometrial, N=6; ovarian, N=25), or when they 
did not complete any survey after recurrence (endometrial, N=23 ; ovarian, N=50).  
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Table 2: Primary outcome measures of patient-reported outcomes in patients with recurrence and 
matched patients without recurrence, dependent samples t-tests





















Satisfaction with information 
provision (INFO-25)
 Information disease 34 57.8 (24) 57.4 (25) -0.4 61.3 (19) 60.5 (23) -0.8
 Information medical tests 34 69.0 (31) 65.7 (27) -3.3 71.0 (21) 72.4 (22) 1.4
 Information treatment 33 56.9 (25) 49.6 (21) -7.3* 51.2 (28) 51.9 (26) 0.7
 Information other services 35 37.0 (28) 30.3 (27) -6.7* 35.4 (27) 31.2 (24) -4.2
 Information places to go 34 34.3 (34) 29.4 (34) -4.9 27.6 (31) 26.4 (34) -1.2
 Information things to do 33 40.4 (30) 33.3 (29) -7.1 37.8 (31) 41.1 (29) 3.3
 Satisfaction Information 33 69.7 (24) 65.7 (23) -4.0 76.0 (19) 68.8 (22) -7.3
 Helpfulness information 30 73.3 (20) 67.8 (22) -5.4 75.3 (23) 72.0 (23) -3.7
Satisfaction with care 
(INPATSAT-32)
 Doctor technical skills 34 75.9 (16) 70.6 (17) -5.3* 82.2 (19) 78.6 (18) -3.6
 Doctor interpersonal skills 32 75.4 (17) 68.8 (16) -6.6* 81.0 (18) 77.5 (19) -3.5
 Doctor information provision 34 77.5 (18) 72.0 (19) -5.5* 80.4 (19) 76.7 (19) -3.7
 Exchange information caregivers 30 64.0 (17) 54.7 (20) -9.3* 66.4 (22) 66.4 (22) 0.0
 General satisfaction with care 31 74.8 (14) 61.3 (17) -13.5** 75.6 (19) 71.9 (19) -3.7
aMeasurement time-points differ by time of recurrence between time-points, either 0 and 6, 6 and 12, or 12 and 24 months 
after initial treatment. bpatients without recurrence were randomly matched to patients with recurrence on tumor type and 
time-points of questionnaire (i.e. the ratios of tumor type and measured time-points are equal in recurrence versus non-re-
currence groups). Dependent samples t-tests were performed. *P<0.05, **P<0.01.


































































































































































































































































































































































































































































































































































































































Table 3: multilevel linear mixed model analysis, overall between-subjects effects of recurrence 





















































Satisfaction with information provision (INFO-25)
 Information disease 1034 60.7 (1.0) 59.4 (2.7) -1.3 (-6.6; 4.0) 1.3 (-4.2; 6.7)
 Information medical tests 1025 69.2 (1.1) 64.7 (2.8) -4.5 (-10.0; 1.1) -1.6 (-7.4; 4.2)
 Information treatment 1021 50.8 (1.1) 45.8 (3.4) -5.0 (-11.6; 1.6) -5.8 (-12.4; 0.8)
 Information other services 1033 30.9 (1.2) 26.7 (3.2) -4.2 (-10.5; 2.2) -5.5 (-11.8; 0.7)
 Information places to go 979 25.6 (1.3) 22.5 (4.5) -3.1 (-11.9; 5.7) -5.1 (-14.4; 4.1)
 Information things to do 940 40.9 (1.4) 32.1 (4.9) -8.8 (-17.7; 0.2) -5.3 (-15.2; 4.6)
 Satisfaction Information 1019 72.3 (1.1) 65.2 (3.4) -7.7 (-13.4; -0.8)* -2.7 (-9.1; 3.8)
 Helpfulness information 990 72.2 (1.1) 67.6 (3.6) -4.6 (-11.2; 2.0) 0.4 (-6.4; 7.2)
Satisfaction with care (INPATSAT-32)
 Doctor technical skills 999 79.4 (0.8) 72.1 (2.2) -7.3 (-11.6; -3.0)** -4.4 (-8.9; 0.2)
 Doctor interpersonal skills 1013 76.5 (0.9) 67.0 (2.3) -9.5 (-14.0; -5.0)** -7.7 (-12.4; -2.9)**
 Doctor information provision 1029 77.7 (0.9) 71.4 (2.2) -6.3 (-10.6; -2.0)** -4.0 (-8.5; 0.5)
 Exchange information caregivers 998 66.8 (0.9) 58.2 (2.7) -8.6 (-13.8; -3.4)* -7.5 (-13.1; -1.9)**
 General satisfaction with care 1013 75.8 (0.8) 61.5 (2.8) -14.3 (-19.8; -8.8)** -7.9 (-13.3; -2.4)**
Note: patients were excluded when having a primary progressive cancer (endometrial, N=6; ovarian, N=25).
 aAnalysis was adjusted for time-point (after diagnosis, after 6, 12, and 24 months), age, socio-economic status, cancer type, 
FIGO stage, primary treatment (chemotherapy, radiotherapy), employment status, marital status, and trial allocation (SCP 
care versus usual care). *P<0.05, **P<0.01.
Patients with a recurrence reported significantly lower satisfaction with the interpersonal 
skills of the doctor, exchange of information between caregivers and general satisfaction 
with care compared to patients without a recurrence. Possibly, decreased satisfaction 
with care after diagnosis of a recurrence could be explained by an overall feeling of 
dissatisfaction due to the poor prognosis and more treatments. More effort may be 
needed to improve information exchange between hospitals (’The communication 
between the hospital where I have had surgery and the hospital where I had my follow up 
was very bad. How could it be, that I had to bring the results of the surgery to my doctor 
by myself?’). A trial in patients with recurrent ovarian cancer shows that internet-based 
interventions for symptom management could improve patient-clinician communication 
and increase quality of life. 
Early conversations about goals and planning of care and increased access to early palliative 
care services may be needed to provide necessary support for patients with recurrent 
cancer. A trial in recurrent ovarian cancer demonstrated  that early palliative care is cost-
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effective and cost saving, but effects on patient reported outcomes are understudied.33 
Another trial shows that rehabilitation in a hospice day care unit reduced the unmet 
needs for psychological support for patients with advanced, recurrent or progressive 
cancer. 34 Future intervention studies are needed to investigate the most optimal means 
to improve care for patients with recurrent cancer and to overcome barriers to integration 
of palliative care. 35,36. 
In contrast to earlier studies and to our hypothesis, our study indicated that having a 
recurrence does not change overall satisfaction with information provision. A study 
about experiences of patients with recurrent ovarian cancer described that patients with 
a recurrence felt a change in the attitude of healthcare professionals and they felt that 
communication became strained between themselves and health professionals.20 Patients 
with a recurrence felt that information about treatment options was more difficult to 
obtain after the recurrence was determined than at the time of their initial diagnosis and 
interpreted this change as loss of hope of the care provider.20 However, another qualitative 
study suggests that health care providers aim to tailor their information provision to their 
perception of patients’ needs. 37
Our findings on the impact of recurrence on HRQoL and anxiety and depression are 
similar to previous studies in patients with a recurrence20,38, which also found that patients 
with recurrent cancer have a lower HRQoL and more anxiety. We found that physical 
functioning, role functioning and social functioning were significantly decreased, while 
fatigue, nausea and vomiting, insomnia anxiety and depression were increased in patients 
with a recurrence. While not all of these domains can be improved by treatment, accurate 
detection of these problems and adequate referral to for example psychosocial care is 
important during follow-up. 
An important strength of the current study is our representative sample of endometrial 
and ovarian cancer patients due to the population-based sampling and high response 
rates (73%). The longitudinal design with 2-year follow-up gave the opportunity to 
compare outcome measures before and after recurrent cancer. Due to these strengths, 
the results of this study reflect daily clinical practice. Another strength of this study was 
the possibility to adjust for both socio-demographic and clinical confounders due to the 
complete and thorough data collection. 
A limitation that should be noted is the low number of patients with a recurrence. 
Only a limited number of patients completed a questionnaire after the recurrence was 
determined, resulting in a selective sample of those with lower cancer stages. Due to 
these small numbers, we could not assess the impact of survivorship care plans in patients 
with a recurrence, nor could we stratify the results for endometrial and ovarian cancer. 
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However, our findings were similar in both cancer types. Another limitation is that in the 
longitudinal analyses of patients with and without recurrence separately, we could not 
match for stage, while stage may explain some of our findings. However, in multilevel 
linear mixed models we adjusted for stage as a covariate and results remained similar. 
Future research should study larger groups of patients with recurrent cancer, and different 
cancer types to make results more generalizable.  
Our findings suggest that follow-up care needs to be tailored to the needs of patients 
after diagnosis of a recurrence, since their needs seem to be different from those without a 
recurrence.  More effort may be needed to better communicate the goals and possibilities 
of care and to provide early palliative care in case of cancer recurrence, as a means to 
support patients in the onset of coping with a fatal prognosis.  Possibly, for some patients 
with a recurrence, follow-up care should not only be directed at medical- but also at 
non-medical issues. Other patients with a recurrence may prefer less information, less 
visits and CT scans. Further research is needed to identify what type of patients have what 
type of needs after diagnosis of a recurrence. Our guidelines should provide more room 
for individual patient’s needs and a tailor-made approach. By shared decision making, a 
more tailored treatment and follow-up plan could be designed for patients with recurrent 
disease.  
In conclusion, endometrial and ovarian cancer patients are less satisfied with care after 
diagnosis of recurrent disease. Our results suggest that more attention should be paid 
to the care for patients with a recurrence as their care needs seem to be different from 
patients without a recurrence in routine follow-up care.  
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Chapter 10




The central goal of this thesis was to understand the impact information provision has on 
(gynecological) cancer survivors and to use our findings to inform future survivorship care 
planning. The three overall aims were:
1. To assess the impact of survivorship care plans (SCPs) on patient-reported outcomes 
among ovarian and endometrial cancer survivors in daily clinical practice;
2. To understand the role illness peceptions play in the impact of SCPs;
3. To assess the need for information and care among (gynecological) cancer survivors 
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Figure 1: Conceptual framework of the effects of survivorship care plans and information and care 
needs on patient reported outcomes
 
Part I: the impact of SCPs on patient reported outcomes
As depicted in the conceptual framework presented in figure 1, we first assessed the 
degree of SCP receipt in the intervention arm of the ROGY Care Trial (N=178) and the 
factors associated with receipt of an SCP (Chapter 2). SCPs were generated for 90% 
of the patients in the trial arm, whereas 70% of the patients reported to have received 
one. Patients of an advanced age, patients with ovarian cancer, a distressed (type D) 
personality, and patients who completed the questionnaire a longer time after diagnosis, 
less often reported receipt of an SCP. These findings need to be taken into account when 
evaluating the effectiveness of SCPs on patient reported outcomes.  
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In our evaluation of the impact of SCPs on patient reported outcomes among ovarian 
cancer patients we accounted for receipt of an SCP. We compared all patients in the ‘SCP 
Care’ arm (N=61) to all patients in the ‘Usual Care’ arm (N=113; ‘Intention-to-Treat’ [ITT]). 
Likewise we compared  patients who reported actual receipt of an SCP in the ‘SCP Care’ 
arm (N=40) to all patients in the ‘Usual Care’ arm (N=113; ‘Per Protocol’ [PP]) (Chapter 
3). In both ITT and PP analyses, no beneficial effects of SCPs were found on satisfaction 
with information provision, satisfaction with care or health care use during the 2-year 
follow-up. SCPs did, however, increase threatening illness perceptions: they led to lower 
trust that the treatment would help cure the disease (6.7 vs. 7.5 on a 10-point scale, 
p<0.01). This is in line with previous findings among endometrial cancer patients that 
showed increased threatening illness perceptions: higher perceived impact of the disease, 
more concerns and more symptoms experienced due to the SCP. Therefore, SCPs may 
not be beneficial for all endometrial or ovarian cancer patients. They may, however, be 
beneficial for subgroups of patients.
Because individuals may respond differently to SCPs according to their information 
coping style, we further assessed whether the impact of SCPs differed between patients 
with an information-seeking (‘monitoring’) coping style compared to patients with an 
information-avoiding (‘blunting’) coping style (Chapter 4). Interestingly, patients with a 
monitoring coping style who received an SCP were more satisfied with the information 
received (73.9 vs. 63.9 on a 1-100 scale, p=0.04) and care received (74.5 vs. 69.2, p=0.03), 
while patients with a blunting coping style who received an SCP experienced more 
threatening illness perceptions, including a higher impact of the disease on their life (5.0 
vs. 4.5, p=0.02) and a higher emotional impact of the disease (5.4 vs. 4.2, p=0.01). These 
results suggest that SCPs may be beneficial for subgroups of patients and reflect a need 
for tailored delivery of SCPs.
Part II: the role of illness perceptions
Prior chapters showed that SCPs may increase negative illness perceptions among 
endometrial and ovarian cancer patients, but it remained unclear whether this may 
ultimately be either beneficial or harmful for the patient. We showed that endometrial 
and ovarian cancer patients who experienced more threatening illness perceptions due 
to the SCP, had a lower HRQoL and more anxiety within 12 months after initial treatment 
(Chapter 5). Endometrial cancer patients who experienced more symptoms or concern 
due to the SCP reported worse social functioning (β=-0.82; P=0.01) and more fatigue, 
insomnia, pain and anxiety (β=0.58-0.86, P<0.05) within 12 months after initial treatment. 
Ovarian cancer patients who had lower trust that the treatment would cure their disease 
due to the SCP reported worse emotional functioning 6 months after treatment (β=0.27, 
P=0.02). These results suggest that SCPs may be harmful for patients at risk of developing 
threatening illness perceptions due to the SCP. Therefore, we should be aware of the 
potential negative consequences of SCPs. 
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The potential harm of threatening illness perceptions is further confirmed in a large sample 
of cancer survivors with various cancer diagnoses (Chapter 6). Survivors were categorized 
into a) illness perceptions consistent with prognosis (‘realistic’), b) less threatening illness 
perceptions than expected based on prognosis (‘optimistic’), and c) more threatening 
illness perceptions than expected based on prognosis (‘pessimistic’). Compared to 
survivors with realistic illness perceptions, those with optimistic illness perceptions had 
a better HRQoL (p<0.01 on all EORTC QLQ-C30 scales) and lower mortality (HR=0.72, 
p<0.01), while those with pessimistic illness perceptions had a worse HRQoL (p<0.01 on all 
EORTC QLQ-C30 scales) and higher mortality (HR=1.52, p<0.01). These findings suggest 
that less threatening illness perceptions are most beneficial. However, illness perceptions 
may accurately reflect disease status regardless of prognosis, reflecting that additional 
support is needed for survivors with pessimistic illness perceptions. 
Part III: information and care needs
In order to improve future survivorship care planning, we further sought to assess the 
information and care needs of cancer survivors across the cancer care continuum. With 
regard to survivorship care planning for patients recently diagnosed with a gynecological 
cancer at an American Medical Center, we assessed the perspectives of patients, 
caregivers and health care providers in a qualitative study (N=30) (Chapter 7). Almost all 
participants (95%) reported a desire for more information on how to address survivorship 
needs, specifically as they related to side effects (59%), follow-up schedule (32%), and 
psychological assistance (23%). Preferences for survivorship care planning largely differed 
across individuals and gynecological cancer types, with respect to content of the SCP, 
timing and mode of delivery. Hence, patients, caregivers and health care providers each 
expressed a need for survivorship care resources tailored to gynecological cancers, which 
requires multi-faceted, individualized survivorship care planning. 
The need for individualized care for cancer survivors was further emphasized through 
a cluster analysis of survivorship care needs in a sample of American cancer survivors 
with various cancer types (N=292) (Chapter 8). We demonstrated that these needs 
can be broken down into 1) low needs (42%), 2) mainly physical needs (16%), 3) mainly 
psychological needs (20%) and 4) both physical and psychological needs (23%). Compared 
to cluster 1, patients in clusters 2, 3, and 4 were younger (P<0.03); those in clusters 3 
and 4 had higher levels of psychological distress (P<0.05); and those in clusters 2 and 4 
reported higher levels of fatigue (P<0.05). These findings show that needs among cancer 
survivors are prevalent, but a substantial group report low or no healthcare needs. This 
underscores the importance of both tailored information provision and accounting for 
differences in needs when testing interventions in survivorship care research.  
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As needs for survivorship care planning may change after recurrent disease, we additionally 
assessed the longitudinal impact of recurrent gynecological cancer on satisfaction with 
information provision and care. Therefore, we used data from the ROGY Care Trial as a 
prospective cohort (Chapter 9). During a 2-year follow-up, 25 patients with endometrial 
cancer (12%) and 64 patients with ovarian cancer (43%) had recurrent disease, of whom 
9 endometrial and 26 ovarian cancer patients completed at least one questionnaire after 
their recurrence was determined. We showed that patients with recurrent endometrial or 
ovarian cancer were less satisfied with the interpersonal skills of the doctors, the exchange 
of information between caregivers, and care in general after diagnosis of a recurrence 
compared to before diagnosis of a recurrence as well as compared to patients without 
recurrent disease. Our findings reflect that patients with recurrent gynecological cancer 
are in need of care that is better tailored to their needs, suggesting a need for increased 




As a result of an ageing population, earlier diagnosis and improved treatment options, 
an increasing number of individuals worldwide live with or beyond a cancer diagnosis.1-3 
This growing group of cancer survivors faces difficulties in life after treatment, due to a 
host of physical and psychological effects of the cancer or cancer treatment.4-6 In order 
to support cancer survivors to deal with issues related to survivorship, the American 
Institute of Medicine (IOM) recommended in 2006 that all cancer survivors should receive 
a survivorship care plan (SCP). This SCP should contain at least a treatment summary and 
a follow-up care plan that includes information about the long-term and late effects of 
the treatments received.7 Although this recommendation was not evidence-based back 
in 2006, it has been widely supported and echoed outside of the United States, including 
the Netherlands.8 However, the implementation and dissemination of SCPs has been 
slow and inconsistent.9,10 Further, more than a decade after the IOM’s recommendation, 
the evidence-base for the effectiveness of SCPs on patient reported outcomes is still 
inconclusive.
This thesis aimed to inform future survivorship care planning, by increasing the 
understanding of the impact of SCPs, the role of illness perceptions, as well as the need 
for information and care among (gynecological) cancer survivors. 
MAIN FINDINGS
Receipt of survivorship care plans depends on patient characteristics
In the pragmatic ROGY Care Trial, oncology providers were free to choose who was 
providing the SCP (i.e. gynecologist, gynecologic oncologist or oncology nurse) and how 
much time was dedicated to counseling.11 As a consequence of this pragmatic approach, 
a group of patients in the ‘SCP Care’ arm did not receive an SCP at all. More importantly, 
certain patients were less likely to report receipt of an SCP in the ‘SCP Care’ arm, including 
older patients, patients with ovarian cancer (as compared to endometrial cancer), a 
distressed (type D) personality and those who completed the questionnaire a longer 
time after diagnosis. For some patients, we are not sure if they really did not receive an 
SCP or forgot that they had received one, but we do know that SCPs were less often 
generated for patients with ovarian cancer compared with endometrial cancer. Thus, 
even in a trial, SCP delivery was inconsistent and dependent on patient characteristics. 
Although the potentially harmful effects of SCPs were unknown at the time of the trial, 
oncology providers may have - either intentionally or unintentionally – avoided  providing 
SCPs to patients that might be at risk of harmful effects of SCPs. For instance, patients 
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with a distressed (type D) personality, who typically experience negative emotions and 
avoid social interactions12, may be more likely to become worried by the information 
provided in the SCP. Therefore, oncology providers may have individualized information 
provision according to a patient’s personality by choosing to provide or not to provide 
an SCP. Similarly, oncology providers may have avoided providing SCPs to older patients, 
because they generally have less need for information.13,14 Yet, another explanation of 
the low self-reported SCP receipt in older patients  or patients with a type D personality 
may be that they simply underreported the receipt, perhaps because of avoidance of the 
information,15 dissatisfaction with information in general15 or inaccurate recall.
Survivorship care plans may heal some, but hurt others
A main finding from the ROGY Care Trial reported in this thesis was that SCPs were - 
overall - not beneficial for ovarian cancer patients in terms of satisfaction with information 
provision and care, or health care use. These findings are in line with a previous publication 
from the ROGY Care Trial among endometrial cancer patients16 and other trials that 
did not identify beneficial effects of SCPs on quality of life, psychological distress, or 
patient satisfaction with information and care, in various patient populations including 
breast17-19, gynecological20, colorectal21 and prostate22 cancer. However, a trial in a selected 
population of low-income breast cancer survivors did show increased implementation 
of recommended survivorship care.23 Further, two trials combining SCPs with additional 
information packages or extensive counseling showed some improvements in perceived 
quality of care21 and quality of life.24  
Unlike other trials, we found that SCPs may be even harmful, by inducing threatening 
illness perceptions such as lower trust that the treatment would help cure the cancer. 
This in turn was associated with a decreased health-related quality of life (HRQoL) and 
increased anxiety within 12 months after diagnosis. Conversely, SCPs have earlier been 
found to decrease health worry in breast cancer survivors after 3 months, although this 
effect did not persist after 6 months.19 However, the SCP provided in the latter trial was 
very concise and only summarized the key points, while our SCP was a rather extensive 
document that additionally contained explicit information about the chance of recurrence. 
Differences between SCP trials are important in the evaluation of the impact of SCPs and 
are therefore discussed in more detail under ‘Methodological Considerations’.  
Although SCPs do not seem beneficial in patient populations as a whole in current trials,17-22 
they may be valuable for subgroups of patients, such as patients with a monitoring 
coping style. However, SCPs seem to increase threatening illness perceptions in other 
patients such as those with a blunting coping style, which may result in decreased HRQoL 
and more anxiety. The harmful effects of threatening illness perceptions were further 
confirmed in this thesis by showing that threatening illness perceptions among cancer 
Chapter 10
194
survivors were associated with worse outcomes, even if they may seem ‘realistic’ with 
respect to a particular survivor’s prognosis. Hence, ‘realistic’ illness perceptions, that may 
be obtained through explicit information about the disease and prognosis, may do more 
harm than good for some patients. It is a rather ethical question whether all survivors 
should be aware of all details of  their disease, including all potential long-term and late 
effects and prognosis. On the contrary, our findings suggest that too much information 
may be detrimental for survivors’ HRQoL. This may be particularly applicable to patients 
with a blunting coping style, who generally have lower levels of distress25 that may be 
increased through extensive and explicit disease-related information such as SCPs. On 
the other hand, patients with a monitoring coping style generally have higher levels of 
distress, which  may be decreased by  adequate information about the disease,25 while 
concise SCPs may leave them distressed and dissatisfied. Therefore, patients with a 
monitoring coping style may be in need of a more extensive SCP, like the one provided in 
our trial, while patients with a blunting coping style may prefer a more concise SCP that 
only summarizes the key points. 
Stratification by information coping style is just an example of how delivery of SCPs could 
be tailored according to individual patients’ needs. There are possibly many more patient 
characteristics that determine information needs and subsequently influence the need for 
and impact of an SCP. A previous publication from our trial showed that SCPs are also 
helpful for endometrial cancer patients who do not use the internet to look up medical 
information.26 Further, a trial among low-income breast cancer survivors identified 
improvements in care delivery due to SCPs,23 suggesting that socio-economic status may 
be another moderating factor of the impact of SCPs. 
There is a wide variation in information and care needs
It is not completely surprising that SCPs have different effects on different patients, when 
we look further into their need for information and survivorship care services. This thesis 
showed that information and care needs largely differ across individuals, and also across 
the cancer care trajectory (i.e. before versus after diagnosis of a recurrence). A remarkable 
finding was that a considerable proportion of American cancer survivors (42%) had low or 
no information or care needs. Although a large part of current studies focused on distinct 
individual needs among cancer survivors27-29, one other study using a similar cluster analysis 
identified an even larger cluster of breast cancer patients (63%) with little survivorship care 
needs.30 The finding that not all survivors are in need of additional information or care was 
also described in our qualitative study among gynecological cancer survivors, and further 
aligns with the divergent responses to information among monitors and blunters in the 
ROGY Care Trial. Notably, these findings may explain why survivorship care interventions, 
such as SCPs, were not beneficial in unselected survivor populations.17-22 Outcomes in 
these studies are inevitably diluted by the subgroup of patients that have very limited 
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needs and, subsequently, very little room for improvement. Therefore, we may need to 
focus on those individuals that do have remaining survivorship needs, when we want to 
improve survivors’ outcomes.  
 
Furthermore, survivors that do have unmet needs may not all have the same type of 
needs. Previous studies found that, overall, needs were highest with regard to physical 
symptoms and side-effects, practical assistance in daily living, and help with psychosocial 
problems such as anxiety and fear of recurrence.27-29  This thesis showed that information 
and care needs are not universal across survivors and that subgroups of survivors can 
be identified that share similar needs, including those with physical needs, psychological 
needs, or both physical and psychological needs. Similar patterns of needs could be 
observed in our qualitative study among gynecological cancer patients within a year after 
treatment. Although these studies were in American patients of relatively high socio-
economic status and few ethnic minorities, we expect that a certain extent of variation in 
survivorship care needs is generalizable to other populations. Unfortunately, we could not 
confirm whether information and care needs influence the impact of SCPs, because no 
baseline survivorship care needs assessment was included in our trial. If they do, we would 
need to tailor SCPs not only to the volume or detail of information that fit the information 
coping style, but also by the type of information that fits the type of the needs. 
Another notable finding was that ovarian and endometrial cancer patients in the ROGY Trial 
were less satisfied with care after diagnosis of recurrent gynecological cancer compared 
with before their recurrence was diagnosed, as well as compared with patients without a 
recurrence. Patients with recurrent cancer were also less satisfied with information about the 
treatments and other services after their recurrence was diagnosed compared to before. 
Although the observed dissatisfaction may be explained by an overall disappointment 
about the disease outcome and additional hospital visits, it may alternatively suggest that 
the information and care for these patients is suboptimal. What type of information and 
care is needed for this population is yet unclear. Possibly, early palliative care, including 
early conversations about the goals and planning of care, support with coping such as 
redirecting hope, and assistance with management of symptoms, may meet the needs 
of patients with recurrent or progressive disease.31 Thus, updated SCPs as provided in the 
ROGY Care Trial11 may not sufficiently address the needs of patients with progressive or 
recurrent disease. Therefore, efforts are needed to improve the ongoing information and 
care for survivors when changes in disease status occur. More research in these patient 




The ROGY Care Plan differs from other survivorship care plans
When comparing results of the ROGY Care Trial to that of other SCP trials, it is important to 
consider any differences between the trials. An overview of the most relevant differences of 
current SCP trials is presented in Table 1. Most trials utilized SCP templates from the IOM,32 
American Society of Clinical Oncology (ASCO),33 LIVESTRONG34 or Journey Forward.35 
The latter one facilitates automatically generated SCPs using data from electronic patient 
charts similar to the ROGY Care plan, as used by Maly et al.23 Although all SCP templates 
contain the elements recommended by the IOM7, they considerably differ with respect 
to amount and detail of information. In the ROGY Care Trial, we provided a relatively 
extensive SCP that was up to 25 pages, depending on the treatments received. We 
included detailed information about potential long-term and late effects and, unlike other 
trials, elaborated on recurrence and survival rates. This may explain the negative effects 
we found on illness perceptions, quality of life and anxiety. Interestingly, Brothers et al. 
found that concise SCPs using ASCO’s template of 1-3 pages decreased health worry after 
3 months, although the effects did not persist after 6 months.20 Hence, SCPs containing 
less detail and no prognostic information may be less harmful. Furthermore, Jefford et al. 
found that an SCP in combination with an additional information package containing a 
booklet and a DVD focusing on patient experiences may improve satisfaction with care21, 
while Emery et al. did not find improved outcomes after providing additional information 
on tumor specific issues.22 Perhaps the type of information (i.e. descriptions of patient 
experiences rather than factual information) plays an important role in the benefit for 
patients.
Another difference between the trials worth noting is the additional counseling that 
accompanied  the SCP. Most trials scheduled an additional 30-60 minute consult to discuss 
the SCP, led by a nurse17,18,21 or nurse and nutritionist.19 Kvale et al. included even more 
extensive counseling using motivational interviewing techniques to develop a patient-
owned SCP that contained strategies for follow-up, surveillance, symptom management 
and health goals.24 In contrast, due to its pragmatic character in the ROGY Care Trial 
SCPs were discussed during a regularly scheduled consult, mostly when the results of 
initial surgery and the adjuvant treatment plan were discussed. Self-reported evaluation 
by the oncology providers in our trial showed that on average only 7 minutes were spent 
on discussing the SCP.36 Thus, compared to other trials, the time for discussion in our 
trial was limited while the SCP was relatively extensive. Possibly, the harmful effects we 
found in our trial could be reduced by additional counseling, as this may help the patient 
to maintain hope and optimism while it also prepares for potential long-term and late 
effects.37,38 However, whether SCPs accompanied with extensive counseling are beneficial 
for all patients remains yet unclear.  
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Importantly, detailed descriptions of the SCPs and counseling provided in current SCP 
trials were often lacking, which limits the possibility to compare research findings across 
trials. Therefore, future SCP trials should publish accurate protocol papers to enhance 
transparency and subsequently improve decision making based on trial outcomes.39
The inconsistent implementation reflects real-life clinical practice 
An advantage of our pragmatic design was that implementation of SCPs in the intervention 
arm reflected ‘real-life’ clinical practice. Oncology providers were free to choose how the 
SCP was implemented, fitting in with the individual practice. They could choose who was 
providing the SCP (i.e. gynecologist, gynecologic oncologist or oncology nurse) and how 
much time was dedicated to counseling, provided that a minimum list of elements of the 
SCP was discussed. Further, our cluster-design allowed oncology providers to provide 
the same type of care to all patients in their practice (either ‘SCP care’ or ‘Usual care’), 
which facilitated consistent implementation of SCPs for all patients in the ‘SCP care’ arm. 
Implementation was further facilitated by the ROGY system that supported automatically 
generated SCPs, which substantially limited the time needed to create an SCP and 
therefore helped to overcome one of the main barriers of implementation.40,41 Despite 
these advantages, there were considerable differences in implementation across oncology 
providers. They were instructed to provide the SCP after initial surgery (6-8 weeks after 
diagnosis), but in some cases the SCP was provided after adjuvant treatment was finished 
(2-3 months after diagnosis). Further, some SCPs were rather extensively discussed with 
the patient, while in other cases SCPs were only sent by email and remaining questions 
could be answered by phone. We also showed in this thesis that between 10 and 30% of 
the patients reported not having received an SCP at all. Similarly, the trial from Jefford et 
al. reported that 24% of the patients did not receive counseling according to protocol, 
although all patients did receive an SCP.21 
Whereas these inconsistencies may be interpreted as trial failure, they do reflect daily 
clinical practice, in which implementation of SCPs would likely be at least as inconsistent.9,42 
Therefore, evaluations of our pragmatic ‘effectiveness’ trial reflect the impact of SCPs 
when implemented in ‘real-life’ clinical practice. In contrast, in ‘efficacy’ trials where 
implementation is highly controlled, results may not be generalizable to the real world, 
such as when the SCP guideline is implemented.43 However, more efforts may be needed 
towards implementation to optimize effectiveness in the real world.44 Thus, our trial results 
do not fully show the potential benefit of SCPs when implementation were optimized. 
SCPs might possibly increase satisfaction if every patient  received for example 30 minutes 
of counseling. Unfortunately, we did not assess all the parameters of the implementation 
process that may have influenced the effectiveness of SCPs, such as the time spent on 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Outcome measures may be too insensitive or distal
Current trials evaluating the effectiveness of SCPs on PROs used various outcome 
measures, including patient satisfaction, psychological distress and HRQoL (Table 
1). Similar to other trials17-20,22 except for Jefford et al.21, we did not find overall effects 
on satisfaction with information and care, which may be explained by insensitivity of 
the outcome measures. Patient satisfaction ratings are in large part influenced by the 
patient’s personal preferences and expectations of care.45 As a result, patient satisfaction 
measures are able to detect substantial discrepancies between patients’ expectations and 
actual experience, for instance when care was extremely bad, but does not easily pick up 
changes when information or care is more or less in line with expectations.45 Hence, in 
places where information and care provision is not extremely bad, it is hard to improve 
patient satisfaction ratings. This may explain the null findings on patient satisfaction in 
SCP trials, but may also explain why we did find improvements in satisfaction among 
patients with a monitoring coping style. Monitors typically have high expectations of 
information and care, resulting in a large discrepancy between expectations and actual 
experience. This suggests that patient satisfaction measures are useful in evaluations of 
SCPs among patients that have high expectations of care, but may be less likely to detect 
improvements among patients that are already relatively satisfied.
Further, most trials, including ours17,20-22,24 except for Kvale et al.24, did not find direct 
effects of SCPs on HRQoL. Interestingly, a recent qualitative study found that patients 
and oncology providers do not have expectations of SCPs to improve HRQoL.46 Perhaps, 
HRQoL is a too distal outcome for effectiveness of SCPs. More proximal outcomes, 
such as the understanding of survivorship care issues47 and care provider roles47, self-
management46 and sense of control46 may be more relevant in evaluations of SCPs. This 
may explain why we did find direct effects of SCPs on our most proximal outcome: illness 
perceptions. However, we also consider satisfaction with information and care as proximal 
outcome measures, which, in contrast, were not directly impacted by SCPs. As described 
earlier, this may be due to insensitivity of these outcome measures. The usefulness of 
alternative outcome measures in SCP trials, such as personal goal-setting24 requires 
further research. 
Some patient traits may be underrepresented
Selection bias is a common problem in trials and patient reported outcome research. 
Previous work showed that patients not participating in survey research are more likely to 
have a worse health status48, age of either of both extremes49 and a lower socio-economic 
status (SES)49-51. In the ROGY Care Trial, non-participating endometrial cancer patients had 
a lower SES, and ovarian cancer patients with higher cancer stages were more likely to be 
lost to follow-up, mostly due to death or ill-health, and were therefore underrepresented 
in our longitudinal analyses. Moreover, we showed that patients at an advanced age, 
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patients with ovarian cancer and a distressed (type D) personality less often reported 
receipt of an SCP, indicating that these patients are underrepresented in our evaluation 
of the effectiveness of SCPs. Particularly the underrepresentation of patients with a type 
D personality may have implications for our findings, as these patients may be more 
prone to distress due to the SCP.15,52 Similarly, patients who avoid medical information 
(blunters) may be less likely to have participated in our trial because they do not want to 
be reminded of their cancer53, while we demonstrate that these patients experience more 
threatening illness perceptions due to the SCP. Therefore, we may have underestimated 
the harmful effects of SCPs as a whole. The same reasoning may apply to the other studies 
included in this thesis. Considering that the unhealthy and distressed/vulnerable survivors 
may be underrepresented, we may provide a too optimistic perspective of the needs 
and outcomes of cancer survivors. As such, the proportion of survivors with information 
and care needs may be underestimated in our studies, and the poor health outcomes of 
survivors with pessimistic illness perceptions may be underestimated. 
International differences impede the generalizability of results
This thesis includes studies that were conducted in the Netherlands as well as in the United 
States. Although challenges in survivorship care planning are reported worldwide, specific 
issues may depend on the national health care system and availability of survivorship care 
resources. In most European countries, and also in Canada and Australia, social health 
insurance is compulsory and managed by private health insurance companies, providing 
access to comprehensive cancer care for all citizens.54 In contrast, in the United States 
there is no nation-wide health-care coverage, and not all aspects of cancer care are 
reimbursed by privately financed insurance companies or by the federally run Medicare 
program.54 Particularly post-treatment cancer care lacks appropriate coordination across 
health care providers and payers.55 Subsequently, there is a large variation in delivery 
of information and care to survivors across the United States. Therefore, particularly in 
American community practices where current information provision and survivorship care 
may be insufficient at some places, SCPs may have a greater impact on PROs. Maly et al. 
showed improvements in delivery of care in American community clinics serving Latina 
patients of low SES.23 In contrast, in the ROGY Care Trial there was probably less room 
for improvement because existing information provision was already reasonably good 
at the time of the trial (inclusion years 2011-2014). However, a study conducted in 2008 
among Dutch endometrial cancer patients diagnosed between 1999 and 2007 showed 
that 42% of the sample was dissatisfied with information provision.56 Hence, information 
provision may have already improved during the past decade due to an increased focus 
on survivorship care. Notably, the two American studies included in this thesis were 
conducted at a large Academic Hospital with relatively high quality of care, perhaps already 
meeting a large part of survivors’ needs. Thus, our finding that a substantial proportion of 
survivors has few unmet survivorship care needs may not be fully generalizable to other 
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clinical practices in the United States, but may be generalizable to other countries with 
similar quality of survivorship care. 
FUTURE DIRECTIONS
There is a need for tailored delivery of survivorship care plans
We demonstrated in this thesis that there is a wide variation in information and care needs 
among (gynecological) cancer survivors, and that the impact of SCPs differs according 
to information coping style, suggesting a need for tailored delivery of survivorship care 
plans. The amount and detail (‘intensity’) of information provided in the SCP may need 
to be tailored according to the information coping style. Patients with an information-
seeking coping style (monitors) have high information needs and may benefit from 
extensive SCPs, perhaps including explicit prognostic information, while patients with 
an information-avoiding coping style (blunters) may benefit from brief SCPs that only 
summarize the key points. Possibly, a simple set of screening questions could determine 
the need for extensive or concise information and triage survivors to appropriate SCPs. 
Perhaps, increased access to electronic medical records that include a summary of 
diagnosis and treatments received57, could replace concise SCPs for those with limited 
information needs. However, those with high information needs (monitors) may need 
additional access to  more extensive (web-based) SCPs.
A web-based SCP may be useful to tailor the content of information according to survivors’ 
information and care needs. We showed that these needs may be broken down into 1) low 
needs, 2) physical needs, 3) psychological needs or 4) both physical and psychological 
needs. Providing distinct ‘modules’ of information according to reported needs may be 
a viable strategy to meet those specific needs, and they could be adjusted according to 
(gynecological) cancer type. Further research is required to develop an efficient screening 
tool to identify survivors’ needs and to develop tailored (web-based) SCPs to meet those 
needs. Additionally, the type of information, such as descriptions of patient experiences 
rather than factual information21 may further meet survivors’  needs.
Importantly, a certain degree of counseling may be needed to accompany with the SCP. 
The fact that counseling in our trial was limited36 while our SCPs were extensive and 
included explicit prognostic information, may explain the harmful effects we found on 
illness perceptions, quality of life and anxiety. The few trials that did find beneficial effects 
of SCPs included an additional nurse- or coach-led consult to discuss the content of the 
SCP.21,23,24 This consult can even be used to develop a patient-owned SCP as demonstrated 
by Kvale et al., focusing on self-management.24 Therefore, even if the SCP is provided 
online, additional oral information may be required when the SCP is accessed for the first 
time. 
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Further, according to the preferences of most patients and caregivers in our qualitative 
study, tailored SCPs should be provided after the conclusion of treatment. In the ROGY 
Care Trial, however, patients received the SCP after initial surgery, but before the start of 
adjuvant treatment. The IOM originally recommended that the SCP should be a two-part 
tool, in which the treatment plan is provided right after diagnosis, while the follow-up care 
plan is provided after treatment.32 Although the SCP in our trial could be updated when 
changes in disease status, treatments or oncology providers occurred, this may not have 
been sufficient to address changing needs over time. We demonstrated that satisfaction 
with information and care changed after diagnosis of a recurrence, suggesting that 
additional support is required when changes in diagnosis or treatments occur. A dynamic 
web-based SCP could provide additional modules of information that specifically address 
issues related to recurrent or progressive disease.
More intensive interventions may benefit survivors with highest needs
We suggested that the wide variation in information and care needs among cancer 
survivors could be addressed by tailoring the ‘intensity’ of the information: patients with 
higher needs may require a higher ‘intensity’ of information and support (i.e. extensive 
SCPs), while those with lower needs may require less (concise SCPs). Herein SCPs could 
be part of a ‘stepped-care’ approach, which starts with a low intensity intervention, while 
only the patients with remaining needs are referred to the next step offering a more 
intensive intervention.58 For example, as a first step, all cancer survivors could be provided 
with concise SCPs or access to treatment summaries in electronic medical record systems, 
accompanied by a (nurse-led) consult assessing the need for further information and 
support. Currently, in the Netherlands, a distress thermometer is used as a screening tool 
for psychological needs59, which could be used as a starting point for further development 
of a more comprehensive needs assessment tool. As a second step in the ‘stepped-care’ 
model, only those patients with remaining information or care needs could be provided 
with more extensive, tailored web-based SCPs and additional counseling if needed. As 
a third step, the individuals with remaining needs could be provided with more intensive 
support such as psychological therapy or medication.
Alternatively, as a second step, web-based self-management tools could be provided 
such as the Kanker Nazorg Wijzer (Cancer Aftercare Guide; KNW) or the breast cancer 
e-health intervention (BREATH). The KNW provides personalized information and support 
on psychosocial and lifestyle issues, based on responses to a screening questionnaire, 
and further serves as a needs assessment for more intensive care as the next step in 
the stepped-care model.60 The KNW improved HRQoL at 6 months from baseline, but 
the participation rate was relatively low (40%), suggesting that non-participants did not 
have a need for such an extensive online management tool.61 However, another web-
based self-management tool (BREATH) had high participation rates (89%) and helped 
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to reduce distress among breast cancer survivors.62 Possibly, the combination of less 
intensive interventions such as brief SCPs for all cancer survivors and more intensive 
e-health interventions for selected survivors with remaining needs, could be an efficient 
means to address the needs of cancer survivors. In this respect, information provision and 
support for survivors could be based on risk stratification according to needs, similar to 
the method applied in individualized follow-up.63 However, face-to-face counseling may 
be required for all survivors as a means to screen for information and care needs. Further 
research on this topic is warranted.
Our results may also apply to other types of information provision
A disturbing finding reported in this thesis is that, in some patients, SCPs increased 
threatening illness perceptions, resulting in a lower health-related quality of life and 
more anxiety. These illness perceptions, including a higher impact of the disease on 
life, more concerns about the disease, more symptoms experienced and lower trust in 
the treatment, may be explained by the detailed list of long-term and late effects and 
explicit prognostic information included in the SCP, and limited counseling to discuss this 
information. Importantly, our findings suggest that we should be careful in providing such 
explicit information that may be perceived as threatening, which may also apply to other 
types of information provision. For example, (web-based) tools to estimate individual 
patients’ recurrence risk or survival based on cancer registry data (nomogram)64,65 may 
increase worry when they are accessible to patients and no appropriate counseling is 
provided. Therefore, these tools may require careful evaluation of the potentially harmful 
effects before they are made widely available to patients. On the other hand, such 
information provision tools may be mostly used by a self-selected group of patients with 
an information-seeking coping style and high information needs, which would limit the 
harmful effects. 
The translation from research findings to practical guidelines is slow
Since the recommendation of the IOM to provide SCPs to all cancer survivors in 2006, 
a large number of studies sought to evaluate the benefits of SCPs. Although RCTs were 
scarce in the first years after the recommendation, they evolved when SCPs became a 
care standard in the American Commission of Cancer (CoC) affiliated centers (70% of all 
U.S. cancer centers) in 2015.66 The CoC aimed for  a 10% SCP receipt in that year, and 
25%, 50% and 75% in the following years respectively. However, results of emerging trials 
and non-randomized studies evaluating the impact of SCPs on PROs and health care 
delivery do not fully support this guideline, as summarized in a recently published review 
by Jacobsen et al.47 Although methodological limitations and inconsistencies in current 
SCP trials limit the possibility to draw definite conclusions about the effectiveness of SCPs, 
current evidence does not provide convincing support for the benefit of SCPs either. 
Despite the many null findings to date, the CoC does not want to abandon their care 
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standard, mainly because it helped cancer programs to get survivorship on the radar.66 
Also the IOM, ASCO and the American Cancer Society keep supporting SCPs to date.66 
Similarly, in the Netherlands, the guideline for implementation of SCPs was published in 
2011 (Richtlijn Herstel na Kanker)67 and has not been changed since. Changes in current 
SCP guidelines, such as tailored delivery of SCPs based on needs assessments during a 
consult, would likely receive more support among stakeholders than abolishment of the 
entire guideline. Future research is required to explore efficient and effective means to 
tailor SCPs to survivors’ information and care needs in order to achieve improvements in 
current SCP guidelines.
CONCLUDING REMARKS
More than a decade after the recommendation of the IOM to implement SCPs for all 
cancer survivors,32 the evidence for the effectiveness in unselected patient populations is 
still limited.68 However, (extensive) SCPs may be beneficial for subgroups of survivors, such 
as those with an information-seeking coping style, while they may be less beneficial and 
perhaps even harmful for those with an information-avoiding coping style, suggesting 
a need for tailored delivery of SCPs. More comprehensive (nurse-led) counseling may 
be needed to discuss the information provided in the SCP, to support patients’ self-
management skills and to screen for remaining information and care needs. Further 
research is needed to develop (web-based) tools to tailor information provision to 
survivors’ needs with respect to the level of detail, content and type of information, in 
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Het aantal mensen dat kanker heeft of heeft gehad neemt wereldwijd toe, door vergrijzing 
van de bevolking, vroegere opsporing en betere behandelingen.1-3 In 2017 waren er in 
Nederland al bijna 800 duizend (ex-)patiënten met kanker en er wordt verwacht dat 
dit aantal al in 2025 is gestegen naar één miljoen.3,4 Deze (ex-)patiënten krijgen vaak 
te maken met verschillende lichamelijke en psychologische gevolgen van de kanker of 
de behandelingen die zij hebben gehad. Veelvoorkomende problemen zijn (ernstige) 
vermoeidheid, slaapproblemen, cognitieve beperkingen, seksuele problemen, angst voor 
terugkeer van de kanker en depressie.5,6 
Pas sinds de laatste decennia is er wereldwijd meer aandacht voor de problemen van 
mensen die kanker hebben of hebben gehad. Zo heeft het Amerikaanse Instituut voor 
Geneeskunde (Institute of Medicine, IOM) in 2006 het advies uitgebracht om alle patiënten 
na de kankerbehandeling te voorzien van een ‘zorgplan’.7 Dit zorgplan bevat schriftelijke 
informatie over de diagnose van de patiënt, de behandelingen die hij of zij heeft ondergaan, 
mogelijke korte- en langetermijngevolgen van de behandelingen en leefstijladviezen.7 
Sinds 2007 adviseert ook de Nederlandse Gezondheidsraad zorgplannen voor iedereen 
die in Nederland voor kanker is behandeld. 8 Ten tijde van dit advies was er nog nauwelijks 
wetenschappelijk onderzoek gedaan naar de effectiviteit van zorgplannen, bijvoorbeeld 
naar de tevredenheid onder patiënten en zorgverleners. Inmiddels, meer dan 10 jaar 
later, zijn er wereldwijd een beperkt aantal gerandomiseerde studies gedaan en die laten 
weinig overtuigend bewijs zien van de baten van het zorgplan.9
In 2011 is in Nederland de ROGY Care Studie uitgevoerd om te onderzoeken wat de 
effectiviteit is van zorgplannen bij patiënten met baarmoeder- en eierstokkanker 
gedurende twee jaar na diagnose.10 Twaalf ziekenhuizen in Zuid-Nederland werden 
gerandomiseerd naar het verlenen van zorgplannen óf naar het verlenen van de 
gebruikelijke zorg aan al hun baarmoeder- en eierstokkankerpatiënten. Baarmoeder- 
en eierstokkanker zijn de twee meest voorkomende gynaecologische tumoren. In 
Nederland kregen in 2017 bijna 2.000  vrouwen de diagnose baarmoederkanker en  1.300 
de diagnose eierstokkanker. Eierstokkanker is de meest dodelijke van de twee; slechts 
38% van de eierstokkankerpatiënten is 5 jaar na diagnose nog in leven, terwijl ongeveer 
80% van de baarmoederkankerpatiënten dan nog in leven is. Veelvoorkomende 
problemen die patiënten ervaren na de behandeling van baarmoeder- of eierstokkanker 
zijn pijn, post-menopauzale klachten, seksuele problemen, blaas- en darmproblemen, 
onvruchtbaarheid, neuropathie en vermoeidheid.11-13
Eerdere resultaten van de ROGY Care Studie bij baarmoederkankerpatiënten lieten zien 




en zorg onder de patiënten.14 Verrassend was dat baarmoederkankerpatiënten die een 
zorgplan hadden ontvangen zich juist meer zorgen maakten, meer emotionele gevolgen 
van de ziekte ondervonden en meer lichamelijke klachten. Ook namen ze vaker contact 
op met hun huisarts in verband met deze problemen.14 Het bleef echter nog onduidelijk of 
deze gevolgen van het verstrekken van een zorgplan schadelijk zijn voor deze patiënten 
of misschien juist wel gunstig. Daarnaast bleef onduidelijk wat het effect van zorgplannen 
is bij eierstokkankerpatiënten. 
DOEL VAN DIT PROEFSCHRIFT
De drie overkoepelende doelen van dit proefschrift zijn:
1.  Het onderzoeken van de effecten van zorgplannen op patiënt-gerapporteerde 
uitkomsten bij eierstok- en baarmoederkankerpatiënten in de dagelijkse klinische 
praktijk;
2.  Het begrijpen van de rol die ziektepercepties spelen in de impact van een zorgplan;
3.  Het onderzoeken van de informatie- en zorgbehoeften van mensen die 
een (gynaecologische) kanker hebben, hebben gehad of bij wie de kanker is 
terug gekeerd.
BELANGRIJKSTE BEVINDINGEN
Deel I: de invloed van zorgplannen op patiënt-gerapporteerde uitkomsten
In hoofdstuk 2 van dit proefschrift evalueren we hoeveel eierstok- en baar moeder-
kankerpatiënten in de interventiegroep van de ROGY Care Trial (N=178) een zorgplan 
hebben ontvangen en wie dat waren. We laten zien dat er voor 90% van deze patiënten 
een zorgplan werd gegenereerd in het registratiesysteem ROGY, terwijl maar 70% 
van de patiënten aangeeft daadwerkelijk een zorgplan te hebben ontvangen. Oudere 
Patiënten, patiënten die een negatieve en sociaal geremde (type D) persoonlijkheid 
hebben, en patiënten die de vragenlijst later invulden, rapporteerden vaker dat zij geen 
zorgplan hadden ontvangen. Het is belangrijk om deze bevindingen mee te nemen in de 
interpretatie van de effectiviteit van het zorgplan in de volgende hoofdstukken. 
In hoofdstuk 3 beschrijven we de effecten van zorgplannen op de tevredenheid met 
informatie voorziening en zorg, op ziektepercepties en op zorggebruik  van eierstokkanker-
patiënten gedurende twee jaar na diagnose. Om rekening te houden met het gegeven dat 
niet alle patiënten in de interventiegroep een zorgplan hadden ontvangen, hebben we 
niet alleen de uitkomsten vergeleken van alle patiënten in de interventiegroep (N=61) met 
alle patiënten in de controlegroep (N=113; ‘Intention-to-treat’ [ITT] analyse), maar hebben 
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we ook een vergelijking gemaakt van de patiënten in de interventiegroep die aangaven 
een zorgplan te hebben ontvangen (N=40) met de patiënten in de controlegroep (N=113; 
‘per-protocol-analyse’ [PP]). In beide analyses zagen we dat zorgplannen geen gunstig 
effect hadden op de tevredenheid over informatievoorziening en zorg. We zagen wel 
dat zorgplannen de ziektepercepties verhoogden: patiënten kregen namelijk minder 
vertrouwen in de behandeling door het lezen van het zorgplan (6.7 versus 7.5 op een 
10-puntsschaal, ITT analyse). Deze resultaten zijn vergelijkbaar met eerdere bevindingen 
van de ROGY Care Studie bij baarmoederkankerpatiënten. Blijkbaar hebben niet alle 
baarmoeder- en eierstokkankerpatiënten, maar wellicht wel subgroepen van patiënten, 
baat bij een zorgplan. 
Uit de literatuur blijkt dat mensen verschillend reageren op en omgaan met medische 
informatie; ze hebben verschillende informatie-coping-stijlen. In hoofdstuk 4 evalueren 
we of het effect van zorgplannen verschillend is voor patiënten met een informatie-
zoekende of met een informatie-vermijdende coping-stijl. We laten zien dat patiënten 
met een informatie-zoekende coping-stijl die een zorgplan ontvingen, meer tevreden 
waren met de informatievoorziening (73.9 vs. 63.9, schaal 1-100) en zorg (74.5 vs. 69.2, 
schaal 1-100), terwijl patiënten met een informatie-vermijdende coping-stijl die een 
zorgplan hadden ontvangen, meer bedreigende ziektepercepties ervaarden, zoals de 
invloed van de ziekte op hun leven (5.0 vs. 4.5, schaal 1-10) en de emotionele invloed van 
de ziekte (5.4 vs. 4.2, schaal 1-10), ten opzichte van degenen die geen zorgplan hadden 
ontvangen. Deze resultaten tonen aan dat het samenstellen van een gepersonaliseerd 
zorgplan wellicht uitkomst kan bieden.
Deel II: de rol van ziektepercepties
Eerdere hoofdstukken lieten zien dat zorgplannen de ziektepercepties van baarmoeder- en 
eierstokkankerpatiënten kunnen verhogen. Het bleef echter onduidelijk of deze verhoogde 
ziektepercepties schadelijk zijn voor patiënten of misschien juist wel gunstig op de lange 
termijn. Hoofdstuk 5 laat zien dat patiënten die meer bedreigende ziektepercepties 
ervaarden door het zorgplan, ook een lagere kwaliteit van leven en meer angst ervaarden 
in de eerste twaalf maanden na de behandeling. Baarmoederkankerpatiënten die zich 
meer zorgen maakten over de ziekte of meer klachten hadden, rapporteerden een 
slechter sociaal functioneren, meer vermoeidheid, slapeloosheid, pijn en angst in de 
twaalf maanden na de behandeling. Eierstokkankerpatiënten die door het zorgplan 
minder vertrouwen in de behandeling hadden, rapporteerden een slechter emotioneel 
functioneren in de zes maanden na de behandeling. Deze resultaten laten zien dat 
zorgplannen zelfs schadelijk kunnen zijn voor sommige patiënten en dat we ons bewust 





De mogelijk negatieve gevolgen van bedreigende ziektepercepties worden nader 
beschreven in hoofdstuk 6, in een studie onder mensen met verschillende kankerdiagnoses 
(N=2,457). Deze (ex-)patiënten werden verdeeld in de volgende groepen: zij met a) 
ziektepercepties die in lijn zijn met de prognose (‘realistisch’), b) ziektepercepties die 
minder bedreigend zijn dan verwacht op grond van de prognose (‘optimistisch’) en c) 
ziektepercepties die meer bedreigend zijn dan verwacht op grond van de prognose 
(‘pessimistisch’). In vergelijking met degenen met realistische ziektepercepties, hadden 
degenen met optimistische ziektepercepties een beduidend hogere kwaliteit van 
leven en een betere overleving, terwijl degenen met pessimistische ziektepercepties 
een beduidend lagere kwaliteit van leven hadden en een slechtere overleving. Deze 
resultaten wijzen erop dat pessimistische ziektepercepties het minst gunstig zijn en dat 
passende zorg nodig is om de kwaliteit van leven van (ex-)patiënten met pessimistische 
ziektepercepties te verbeteren.  
Deel III: informatie- en zorgbehoeften
Ten behoeve van de zorg voor (ex-)kankerpatiënten hebben we verder onderzoek gedaan 
naar de informatie- en zorgbehoeften van mensen die kanker hebben, hebben gehad, 
of terugkerende kanker (een recidief) hebben.  Hoofdstuk 7 beschrijft een studie onder 
Amerikaanse patiënten die recent zijn gediagnostiseerd met een gynaecologische kanker 
en de behandeling hebben afgerond, maar ook hun naasten en zorgverleners. In deze 
kwalitatieve studie gaven bijna alle patiënten en naasten aan dat zij behoefte hadden 
aan aanvullende informatie na de behandeling, voornamelijk over bijwerkingen van de 
behandelingen, het nacontroleschema en psychologische hulpverlening. De behoefte 
aan een zorgplan verschilde sterk tussen individuen en naar gelang de gynaecologische 
tumorsoort, met betrekking tot de inhoud van het zorgplan en het moment en de manier 
van verstrekking. Zowel patiënten, naasten als zorgverleners uitten de behoefte aan 
tumor-specifieke en geïndividualiseerde middelen om  de informatievoorziening en zorg 
te verbeteren voor mensen die kanker hebben of hebben gehad, alsook hun naasten.
Ook hoofdstuk 8 benadrukt het belang van  zorg op maat voor kankeroverlevenden. Dit 
hoofdstuk beschrijft een clusteranalyse van nazorgbehoeften onder 292 Amerikanen die 
kanker hebben gehad met verschillende kankerdiagnoses. We laten zien dat de behoeften 
aan nazorg kunnen worden ingedeeld in 1) weinig of geen nazorgbehoeften (42%), 2) 
voornamelijk fysieke behoeften (16%), 3) voornamelijk psychologische behoeften (20%) 
en 4) zowel fysieke als psychologische behoeften (23%). In vergelijking met de eerste 
cluster waren degenen in de andere clusters jonger; degenen in de derde en vierde 
cluster rapporteerden meer psychologische problemen; en degenen in de tweede en 
vierde cluster rapporteerden meer vermoeidheid. Deze bevindingen laten zien dat de 
meerderheid van de mensen die kanker hebben gehad onvervulde behoefte aan nazorg 
heeft, maar dat tegelijkertijd een aanzienlijke groep weinig of geen nazorgbehoeften 
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heeft. Deze grote variatie in nazorgbehoeften toont aan dat het belangrijk is om 
informatievoorziening en zorg op maat aan te bieden. Daarnaast zou er wellicht rekening 
moeten worden gehouden met de nazorgbehoeften wanneer nazorginterventies zoals 
zorgplannen worden geëvalueerd. 
Tot slot worden in hoofdstuk 9 de veranderingen in tevredenheid met de 
informatievoorziening en zorg na terugkeer van kanker beschreven. Hiervoor werd data 
van de ROGY Care Studie gebruikt als prospectieve cohort. Gedurende twee jaar hebben 
25 baarmoederkankerpatiënten (12%) en 64 eierstokkankerpatiënten (43%) een recidief 
gekregen, waarvan 9 baarmoederkanker- en 26 eierstokkankerpatiënten minstens één 
vragenlijst hebben ingevuld na vaststelling van het recidief. We laten zien dat patiënten 
ná vaststelling van een recidief minder tevreden waren over de zorg  dan voordat het 
recidief werd vastgesteld, maar ook minder tevreden dan patiënten zonder recidief. Er 
was ontevredenheid over de sociale vaardigheden van de artsen, de uitwisseling van 
informatie tussen zorgverleners, maar ook de zorg in het algemeen. Deze bevindingen 
laten zien dat patiënten met een recidief behoefte hebben aan betere en passende zorg. 
Wellicht kan vroege palliatieve zorg hierin uitkomst bieden. 
CONCLUSIE
Dit proefschrift laat zien dat zorgplannen waarschijnlijk niet zinvol zijn voor alle eierstok- 
en baarmoederkankerpatiënten, maar wellicht wel voor subgroepen, zoals patiënten die 
behoefte hebben aan een grote hoeveelheid informatie. Zorgplannen lijken daarentegen 
zelfs schadelijk te zijn voor patiënten die liever medische informatie vermijden. Deze 
resultaten wijzen erop dat zorgplannen veel meer afgestemd zouden moeten worden 
op de behoeften van de patiënt. Een aanvullend consult in het ziekenhuis zou, eventueel 
geleid door een verpleegkundig specialist, kunnen dienen om de informatie in het 
zorgplan te bespreken, de patiënt te  ondersteunen in zijn of haar zelfmanagement  en 
om te screenen op verdere informatie- en zorgbehoeften. Toekomstig onderzoek is 
nodig om (online) tools te ontwikkelen, waarmee informatie aangeboden kan worden die 
qua inhoud, type informatie en niveau van detail van de informatie gepersonaliseerd kan 
worden. Hiermee kunnen we de huidige richtlijnen in de kanker(na)zorg, verbeteren, en 
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Uit voorgaand onderzoek is gebleken dat het dankwoord het meest gelezen hoofdstuk 
is van het proefschrift. Daar ga ik dus even goed voor zitten. Tijd om terug te blikken op 
drie bijzonder mooie en leerzame jaren, die nooit zo bijzonder mooi en leerzaam zouden 
zijn geweest zonder een heleboel fijne mensen.
Ruim drie jaar geleden stapte ik bloednerveus het IKNL in Eindhoven binnen voor mijn 
sollicitatiegesprek met Prof. Van de Poll en Dr. Ezendam. Zij bleken uiteindelijk de beste 
promotor en copromotor die ik me had kunnen wensen. Lonneke, je blijft me inspireren 
met je onuitputtelijke enthousiasme en overtuigingskracht. Tijdens onze werkoverleggen 
bedacht je altijd weer geniale oplossingen waarmee ik weer verder kon. Jij weet steeds 
weer het beste uit mensen te halen en de PROFIEL-groep tot een enthousiast en gezellig 
– doch hardwerkend(!) team te maken. Jij bent echt een rolmodel voor mij. Bedankt voor 
je vertrouwen en alle kansen die je me hebt gegeven. Nicole, bedankt voor je luisterend 
oor, je oprechte enthousiasme en je waardevolle input. Ik heb genoten van al onze 
overleggen over nieuwe onderzoeksideeën en de vele nieuwe studies… soms zoveel 
(lees: onderzoeksdesigns, tumorsoorten, vragenlijsten én biomarkers) tegelijk dat het ons 
af en toe begon te duizelen… gelukkig worden we er steeds beter in! Ik ben ontzettend 
blij dat we daar nog even mee door mogen gaan.
In de loop van de jaren zijn de hoofdstukken in dit proefschrift kritisch bekeken en beter 
gemaakt door een groep van gynaecologen, (gynaecologisch) oncologen, verpleegkundig 
specialisten, epidemiologen en psychologen. Kim, jou wil ik in het bijzonder bedanken 
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kunnen doen! Erna, bedankt voor je inzet bij de dataverzameling en het beantwoorden 
van al mijn vragen over de studie. Caroline, jij bent toch wel de meest enthousiaste 
gynaecoloog die ik heb leren kennen, zeker als het gaat om nieuwe onderzoeksideeën of 
gezellige ‘uitjes’ zoals congressen in het buitenland.
De leden van de beoordelingscommissie, Carien Creutzberg, Ad Kaptein, Emiel Krahmer, 
Luc van Lonkhuijzen, Sabine Siesling en Floor Mols, jullie wil ik bedanken voor het lezen 
en beoordelen van mijn proefschrift. Ik kijk ernaar uit om met jullie ‘van gedachten te 
wisselen’ op 20 december. 
Het grootste deel van de werkweek bracht ik door in de kantoortuin van IKNL Eindhoven, 
waar het rustig genoeg was om aan mijn proefschrift te werken, maar ook gezellig genoeg 





lieve (ex-)collega’s. Adri, Annemiek, Britt, Carla, Corina, Debbie, Erica, Erna, Felice, Gijs, 
Janneke, Josianne, Laura F, Laura L, Lindy, Maikel, Margreet, Mies, Merel, Mieke, Maarten, 
Myrte, Nicole, Pauline, Sandra, Rob, Salome en Vera: bedankt voor de gezelligheid tijdens 
de lunchwandelingen, etentjes, (promotie)borrels en sinterklaasvieringen. Lindy, mijn 
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you here, in and outside of the office. I hope our paths will cross again sometime soon 
(preferably in Australia, of course). 
Op donderdagen was ik altijd te vinden op Tilburg University, op de afdeling medische en 
klinische psychologie (MKP). Die dag bestond vooral uit het onderhouden van contacten, 
en dan in het bijzonder met de leukste groep PhD-studenten van de Universiteit, beter 
bekend als MKPartypeople. Annick, Cynthia, Eva, Eveline, Frederique, Ivy, Jori, Laura, Linh, 
Maria, Milou, Paul, Sandra, Stefanie, Tom en Veerle: de donderdaglunches en -borrels, de 
schrijfweek, PhD-trips en stapavondjes in Tilburg waren natuurlijk nooit zo leuk geweest 
zonder jullie. Jullie bewijzen dat ‘in hetzelfde schuitje zitten’ echt verbindend werkt. Met 
mijn kamergenootje Ivy had ik altijd wel iets te delen. Dankzij de gezellige gesprekken 
onder het genot van vele koppen thee vloog de donderdag altijd zo voorbij. Dankjewel 
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An unforgettable three months of my PhD research was spent at Massachusetts General 
Hospital in Boston. Dr. Dizon, Don, thank you for this great opportunity, for showing 
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in our interview study. Dr. Peppercorn, Jeff, thank you for your endless enthusiasm for 
our study and your efforts to improve our manuscript. Dr. Thomas, Teresa, though our 
collaboration has mostly been at long distance, phone and email have been great ways 
for me to learn from your expertise in qualitative research. Thank you. Hanneke, jij hebt 
mijn tijd in Boston een gouden randje gegeven. Dankjewel voor de goede gesprekken en 
de gezellige momenten. 
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